CTAD 2023

Alzheimer

Clinical Trials on Alzheimer's Disease

Final program

In-Person + Remote

October 24-27, 2023
Boston, MA - USA

©Mircea Costina

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15 / San Diego '16
Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21 / San Francisco '22

www.ctad-alzheimer.com
Email: ctad@ant-congres.com

JPAD

SUMMARY

Editorial

CTAD 2023: What is coming next in Alzheimer's Disease clinical research?

The 16th Clinical Trials on Alzheimer's Disease conference (CTAD), is held in Boston, Massachusetts (USA) on October 24-27, 2023.

Last November, in San Francisco, California, CTAD 2022 attracted over 2,800 international leaders to discuss the future of Alzheimer's disease clinical research with pivotal readouts from major pharmaceutical companies and new avenues of treatment beyond Amyloid and Tau.

This year has already seen more breakthrough advances in anti-amyloid treatments, the emergence of diagnostic blood-based biomarkers and encouraging results from other Phase 1 to Phase 3 AD clinical trials.

At CTAD 2023, the scientific program focuses on bringing cutting edge clinical research, thought-provoking roundtable and symposia on the latest advances in AD clinical research. CTAD 2023 brings together leaders from academic research centers, patient advocacy groups, international research coalitions and pharmaceutical companies.

CTAD is also committed to exploring new avenues beyond amyloid-clearing immunotherapy including combination trials of disease-modifying agents, gene therapy, vaccines and multimodal interventions.

The CTAD scientific program is based on a strict peer-review abstract selection process. CTAD 2023 is a great opportunity for clinical and research teams around the world to showcase their work in AD clinical trials.

Boston has long been a hub of laboratory, translational and clinical neuroscience research, and is thrilled to host CTAD this year.

Welcome to Boston!

Reisa Sperling, MD
President of the CTAD23 Scientific Committee

President of the CTAD23 Scientific Committee

Reisa Sperling, MD
Harvard Medical School
and Brigham and Women's Hospital, Boston, MA (USA)

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Gainesville, USA); Michael C DONOHUE (San Diego, USA); Rachelle DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FILLIT (New-York, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T.MIDDLETON* (London, UK); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minnesota, USA); Michael S.RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Hefei, China); Jiong SHI (Hefei, China); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Michael W. WEINER* (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

*Organizing Committee Member

CTAD 2023
Lifetime Achievement Award

Credits: Sid Hastings photographer

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Randall J. Bateman, MD in recognition for his pioneering work in Alzheimer's Disease Research and Plasma Biomarkers in AD diagnostics.

Randall J. Bateman, MD

Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Tracy Family SILQ Center and Bateman Lab for Neurodegenerative Biology, the Dominantly Inherited Alzheimer Network (DIAN), and the Knight Family DIAN Trials Unit (DIAN-TU), Washington University in St. Louis, St. Louis, MO (United States)

Dr. Bateman's research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer's disease. Dr. Bateman's lab accomplishments include pioneering Stable Isotope Labeling Kinetics (SILK), furthering insights of human circadian patterns, and human in vivo control of the processing of amyloid-beta, apolipoprotein E, tau, and neurofilaments. His lab reported a highly accurate amyloid-beta blood test for Alzheimer's disease amyloid plaques and also identified specific tau species in blood for accurate quantitation of amyloid pathology, has described the biology and pathophysiology of tau species in brain, CSF and blood, discovered unique soluble tau species that correlate with tau pathology, and also discovered that tau production is increased in Alzheimer's disease. Dr. Bateman has received awards including the Beeson Award for Aging Research, Alzheimer's Association Zenith Award, Scientific American top innovator, the Glenn Award for Aging Research, the MetLife Foundation Award for Medical Research, the Potamkin Prize, and is a member of the National Academy of Inventors and the National Academy of Medicine.

Keynotes

"Clinical Trials in Alzheimer's Disease Prevention"

Sandrine Andrieu, MD, PhD

Professor of Public Health, Clinical Epidemiology and Public Health Department, Toulouse University Hospital, Toulouse (France)

Dr. Sandrine Andrieu is professor of public health of the clinical epidemiology and public health department at the Toulouse University Hospital (France) and adjunct professor at the University of New Mexico (United States). Since 2009 she has been in charge of the Aging Research team at the Center for Epidemiology and Research in Population Health. She served as the Director of the Research Center for Epidemiology and Research in Population Health (UMR1295 INSERM - University Paul Sabatier) from 2011 to 2020. She has published more than 250 international papers and book chapters in the field of aging. She is involved in large prevention studies in neurodegenerative diseases (GuidAge, MAPT) and in European projects (HATICE study, MIND-AD, PRODEMOS). Her main topic of research is Alzheimer's Disease and prevention of age-related loss of functions and healthy aging. She is the past president of the French National Society of Geriatrics and Gerontology.

"Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer's disease"

Randall J. Bateman, MD

Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Tracy Family SILQ Center and Bateman Lab for Neurodegenerative Biology, the Dominantly Inherited Alzheimer Network (DIAN), and the Knight Family DIAN Trials Unit (DIAN-TU), Washington University in St. Louis, St. Louis, MO (United States)

Dr. Bateman's research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer's disease. Dr. Bateman's lab accomplishments include pioneering Stable Isotope Labeling Kinetics (SILK), furthering insights of human circadian patterns, and human in vivo control of the processing of amyloid-beta, apolipoprotein E, tau, and neurofilaments. His lab reported a highly accurate amyloid-beta blood test for Alzheimer's disease amyloid plaques and also identified specific tau species in blood for accurate quantitation of amyloid pathology, has described the biology and pathophysiology of tau species in brain, CSF and blood, discovered unique soluble tau species that correlate with tau pathology, and also discovered that tau production is increased in Alzheimer's disease. Dr. Bateman has received awards including the Beeson Award for Aging Research, Alzheimer's Association Zenith Award, Scientific American top innovator, the Glenn Award for Aging Research, the MetLife Foundation Award for Medical Research, the Potamkin Prize, and is a member of the National Academy of Inventors and the National Academy of Medicine.

"What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials"

Cynthia A. Lemere, PhD

Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (United States)

Dr. Lemere is a Scientist in the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital (BWH) and an Associate Professor of Neurology at Harvard Medical School in Boston, MA USA. Her research focuses on understanding and using the immune system therapeutically to prevent and treat Alzheimer's disease. Dr. Lemere earned a bachelor's degree in psychology and education from Mount Holyoke College and a master's in neurobiology from SUNY Albany. Dr. Lemere examined Alzheimer's-related brain changes in people with Down syndrome in the Selkoe Laboratory at BWH while pursuing her doctorate in pathology at Boston University School of Medicine. Her current research involves: 1. Non-clinical studies of antibody treatments targeting a pathogenic form of amyloid-beta protein found in plaques in Alzheimer's disease brain; 2. The role of the innate immune system's complement signaling in aging and Alzheimer's disease; and 3. The effects of deep space galactic cosmic radiation on brain aging and the risk of Alzheimer's disease in studies in mouse models and human neural cells in preparation for NASA's upcoming missions to the moon and Mars. Her lab is funded by NIH and NASA. Dr. Lemere serves as an advisor to the Alzheimer's Association, the BrightFocus Foundation, the Cure Alzheimer's Fund, and the AD/PD International Meeting. In addition, she serves as a consultant for several companies.

"Alzheimer's Disease: the Drug Development Pipeline and Emerging Therapies"

Jeffrey Cummings, MD, ScD

Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Las Vegas, NV (United States)

Dr. Cummings is globally known for his contributions to Alzheimer's research, drug development, and clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer's disease through many awards including the Ronald and Nancy Reagan Research Award of the national Alzheimer's Association (2008), Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017), Distinguished Scientist Award of the American Association of Geriatric Psychiatry (2010), Bengt Winblad Lifetime Achievement Award from the national Alzheimer's Association (2019), and the Alzheimer's Drug Discovery Foundation's Melvin R. Goodes Prize. He was featured in the Gentleman's Quarterly (June 2009) as a "Rock Star of Science™." Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London. Dr. Cummings was formerly Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. Dr. Cummings' interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. He has authored or edited 43 books and published over 800 peer-reviewed papers.

Keynotes

"Creating more Equitable and Valid Alzheimer's Clinical Trials for the 21st Century"

Monica Rivera-Mindt, PhD

Professor of Psychology, Latinx Studies, and African & African American Studies, Fordham University and joint appointment in Neurology, Icahn School of Medicine at Mount Sinai, New York, NY (United States)

Dr. Mónica Rivera Mindt, a board-certified neuropsychologist, is Past-President of the Hispanic Neuropsychological Society and a tenured Professor of Psychology, Latinx Studies, and African & African American Studies at Fordham University with a joint appointment in Neurology at the Icahn School of Medicine at Mount Sinai. Her multidisciplinary, community-based research is funded by the NIH/National Institute of Aging (NIA), the Alzheimer's Association, NSF, and Genentech. Her work primarily focuses on the intersection between cultural neuroscience and health inequities in cognitive aging. Her current studies are examining genetic, cerebrovascular, and sociocultural risk factors for cognitive impairment and dementia in ethnoculturally diverse populations, as well as ways to increase diverse representation in cognitive aging and dementia research. She has authored more than 100+ peer-reviewed publications and book chapters. In addition, she is Co-Lead of the NIA-funded Alzheimer's Disease Neuroimaging Initiative's (ADNI) Engagement Core. At the national level, Dr. Rivera Mindt recently served as Chair of NIH/NIA's AGCD-4 Study Section, and is a member of the CDC's BOLD Public Health Center of Excellence on Dementia Risk Reduction Expert Panel, and the CDC/National Alzheimer's Project Act's (NAPA) Physical Activity, Tobacco Use, and Alcohol Workgroup. Locally, she serves as a Board Member for the Alzheimer's Association's NYC Chapter and a Treasurer for the Harlem Community & Academic Partnership (HCAP). As a bilingual (Spanish/English), Afro-Latinx/Indigenous neuroscientist, she brings a unique perspective to her research and is the recipient of several awards for her research, teaching, and contributions to the field, including the 2020 Martha Bernal Award for the Advancement of Diversity Training and Education in Clinical Psychology from the Council of University Directors of Clinical Psychology (CUDCP) and 2019 Hispanic Health Leadership Award from the National Hispanic Medical Association. She is also a Fellow of the American Psychological Association (Division 40, Society for Clinical Neuropsychology), the National Academy of Neuropsychology, and Hispanic Neuropsychological Society.

IN-PERSON PROGRAM

in Boston
Available via livestream
on the CTAD23
digital platform

Program at a glance

● Tuesday, OCTOBER 24

4.00 p.m.	Welcome ceremony and CTAD Lifetime Achievement Award
4.30 p.m.	KEYNOTE 1: Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer's disease
4.55 p.m.	SYMPOSIUM 1: The Effects of Race and Gender on Amyloid Positivity
5.35 p.m.	LATE BREAKING COMMUNICATIONS
6.50 p.m.	CTAD Welcome Reception
7.50 p.m.	End of conference day

● Wednesday, OCTOBER 25

7.30 a.m.	POSTER WALKING TOUR
8.30 a.m.	LATE BREAKING COMMUNICATIONS
9.00 a.m.	KEYNOTE 2: Creating more Equitable and Valid Alzheimer's Clinical Trials for the 21st Century
9.25 a.m.	SYMPOSIUM 2: Donanemab in Early Symptomatic Alzheimer's Disease: Additional Insights from TRAILBLAZER-ALZ 2
10.05 a.m.	Coffee break and poster session
10.35 a.m.	LATE BREAKING COMMUNICATIONS
11.20 a.m.	ORAL COMMUNICATIONS
12.35 p.m.	Lunch and poster sessions
1.40 p.m.	LATE BREAKING SYMPOSIUM 3: Clinical and ATN Biomarker Findings on the Impact of Amyloid Removal in a 10 year prevention trial – the DIAN-TU-001
2.20 p.m.	ORAL COMMUNICATIONS
3.20 p.m.	LATE BREAKING ROUNDTABLE 1: NIA-AA Revised Criteria for Diagnosis and Staging of Alzheimer's disease
3.50 p.m.	Coffee break and poster session
4.20 p.m.	KEYNOTE 3: Alzheimer's Disease: The Drug Development Pipeline and Emerging Therapies
4.55 p.m.	LATE BREAKING COMMUNICATIONS
5.25 p.m.	LATE BREAKING SYMPOSIUM 4: Lecanemab for Early Alzheimer's Disease:Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration
6.05 p.m.	End of conference day

● Thursday, OCTOBER 26

7.30 a.m.	POSTER WALKING TOUR
8.30 a.m.	LATE BREAKING COMMUNICATIONS
9.00 a.m.	ORAL COMMUNICATIONS
10.00 a.m.	LATE BREAKING ORAL COMMUNICATIONS
10.30 a.m.	Coffee break and poster session
11.00 a.m.	KEYNOTE 4: Clinical Trials in Alzheimer's Disease Prevention
11.25 a.m.	SYMPOSIUM 5: What can we LEARN from the A4 Study? Associations among longitudinal cognitive, functional, biomarker and imaging outcomes
12.05 p.m.	Lunch and poster session
1.20 p.m.	ROUNDTABLE 2: Forging the Path Forward: Capitalizing on Recent Alzheimer's Momentum through Strategic Investments in Novel Therapeutics
1.50 p.m.	ORAL COMMUNICATIONS
3.05 p.m.	ROUNDTABLE 3: What is meaningful enough for CMS to cover? – What is reasonable and necessary?
3.35 p.m.	Coffee break and poster session
4.05 p.m.	ORAL COMMUNICATIONS
5.05 p.m.	LATE BREAKING SYMPOSIUM 6: Implementing blood biomarkers in clinical practice and trials
5.45 p.m.	End of conference day

● Friday, OCTOBER 27

7.30 a.m.	POSTER WALKING TOUR
8.30 a.m.	LATE BREAKING COMMUNICATIONS
9.00 a.m.	KEYNOTE 5: What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials
9.25 a.m.	LATE BREAKING SYMPOSIUM 7: INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Aβ oligomers
10.05 a.m.	Coffee break and poster session
10.30 a.m.	ORAL COMMUNICATIONS
12.15 p.m.	Lunch and poster sessions
1.15 p.m.	LATE BREAKING ORAL COMMUNICATIONS
2.15 p.m.	ORAL COMMUNICATIONS' FOCUS SESSION: Phase 1 Clinical Trials
3.05 p.m.	Coffee break and poster session
3.30 p.m.	LATE BREAKING ORAL COMMUNICATIONS
5.00 p.m.	End of the conference

> **Conference Room:** All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> **Overflow room:** Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

4.00 p.m.

Welcome ceremony and CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research

Presented to Randall J. Bateman, MD in recognition for his pioneering work in Alzheimer's Disease Research and Plasma Biomarkers in AD diagnostics

Introduction by Reisa Sperling, President of the CTAD23 Scientific Committee and the CTAD Organizing Committee

4.30 p.m.

KEYNOTE 1

Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer's disease

Introduction by Reisa Sperling, President of the CTAD23 Scientific Committee

Randall J. Bateman, *Washington University School of Medicine, St. Louis, MO (United States)*

4.55 p.m.

SYMPOSIUM 1

The Effects of Race and Gender on Amyloid Positivity

Chair: Suzanne Schindler, Washington University St. Louis, St. Louis, MO (United States)

Introduction : Determining amyloid status in different racial, ethnic, and gender groups

Suzanne Schindler, *Washington University St. Louis, St. Louis, MO (United States)*

Presentation 1: Amyloid PET results from the GAP Bio-Hermes study: initial findings on differences between racial and ethnic groups

Robin Wolz [1], Lynne Hughes [2], Richard Manber [1], Richard Mohs [2], John Dwyer [2], Douglas Beauregard [2]
[1]IXICO - London (United Kingdom), [2]Global Alzheimer's Foundation - Washington (United States)

Presentation 2: Race and Sex Effects on Rates of Amyloid Positivity in Real-World Memory Care: Insights from IDEAS and New IDEAS

Charles Windon [1], Maria Carillo [2], Peggye Dilworth-Anderson [3], Constantine Gatsonis [4], Emily Glavin [5], Lucy Hanna [6], Bruce Hillner [7], Andrew March [5], Sid O'bryant [8], Robert Rissman [9], Barry Siegel [10], Karen Smith [1], Christopher Weber [2], Consuelo Wilkins [11], Gil Rabinovici [1]

[1]Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco - San Francisco (United States), [2]Alzheimer's Association - Chicago (United States), [3]Gillings School of Global Public Health, University of North Carolina-Chapel Hill - Chapel Hill (United States), [4]Department of Epidemiology and Biostatistics, Brown University School of Public Health - Providence (United States), [5]American College of Radiology - Reston (United States), [6]Center for Statistical Sciences, Brown University School of Public Health - Providence (United States), [7]Department of Medicine, Virginia Commonwealth University - Richmond (United States), [8]Institute for Translational Research, University of North Texas Health Science Center at Fort Worth - Fort Worth (United States), [9]Department of Physiology and Neuroscience, Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California - San Diego (United States), [10]Mallinckrodt Institute of Radiology, Washington University in St Louis - St. Louis (United States), [11]Department of Medicine, Division of Geriatric Medicine, Vanderbilt University Medical Center - Nashville (United States)

Questions and Answers

5.35 p.m.

LATE BREAKING COMMUNICATIONS

Moderators: Howard Feldman, University of California San Diego (United States) and Suzanne Schindler, Washington University St. Louis (United States)

5.35 p.m.

LB1 - Baseline levels and longitudinal changes in plasma aβ42/40among self-identified black and white individuals

Chengjie Xiong [1], Jingqin Luo [1], David Wolk [2], Leslie Shaw [2], Erik Roberson [3], Rachel Henson [1], Tammie Benzinger [1], Quoc Bui [1], Folasade Agboola [1], Elizabeth Grant [1], Emily Gremminger [1], Krista Moulder [1], David Holtzman [1], John Morris [1], Suzanne Schindler [1]
[1]Washington University - St. Louis (United States), [2]University of Pennsylvania - Philadelphia (United States), [3]University of Alabama - Birmingham (United States)

5:50 p.m.

LB2 - Plasma MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease

Kanta Horie [1,2,3], Rama Koppisetti [1,2], Shorena Janelidze [4], Erik Stomrud [4,5], Nicolas Barthélemy [1,2], Chihiro Sato [1,2], Tammie Benzinger [6], David Holtzman [2], John Morris [2], Nicklas Mattsson-Carlgren [4,5], Sebastian Palmqvist [4,5], Suzanne Schindler [2], Oskar Hansson [4,5], Randall Bateman [1,2]

[1]Tracy Family SILQ Center, Washington University School of Medicine - St. Louis (United States), [2]Department of Neurology, Washington University School of Medicine - St. Louis (United States), [3]Eisai Inc - Nutley (United States), [4]Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), [5]Memory Clinic, Skåne University Hospital - Malmö (Sweden), [6]Department of Radiology, Washington University School of Medicine - St. Louis (United States)

6:05 p.m.

LB3 - Topline Results From the Phase 2 PIONEER Trial of Oral T3D-959 for the Treatment of Patients Diagnosed With Mild-to-Moderate Alzheimer's Disease

Jessica Stanek [1], Stanley Chamberlain [1], Chris Coutlee [1], Warren Strittmatter [1], Charles Lineberry [1], Blake Swearingen [1], John Didsbury [1]

[1]T3D Therapeutics, Inc. - Research Triangle Park (United States)

6:20 p.m.

LB4 - Safety, immunogenicity, clinical efficacy and biomarkers of ABvac40, an active vaccine anti-Aβ40 in patients with amnestic mild cognitive impairment or very mild Alzheimer's disease: final results of a phase 2 randomized study

Jose Terencio [1,2], María Pascual-Lucas [3], Ana María Lacosta [3], María Montañés [3], Jesús Canudas [3], José Antonio Allué [3], Leticia Sarasa [3], Noelia Fandos [3], Judith Romero [3], Elisabet Molina [3], Manuel Sarasa [3], Merce Boada [4]

[1]Grifols - Barcelona (Spain), [2]Araclon Biotech-Grifols - Zaragoza (Spain), [3]Araclon-Biotech - Zaragoza (Spain), [4]Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya - Barcelona (Spain)

6:35 p.m.

LB5 - Tau vaccine AADvac1 demonstrates clinical and biomarker efficacy on patients with plasma p-tau217 defined Alzheimer's disease in Phase II clinical trial: post hoc analysis

Branislav Kovacech [1], Nicolas Cullen [2], Petr Novak [1], Jozef Hanes [1], Eva Kontsekova [1], Michal Fresser [3], Jeroen Vanbrabant [4], Howard Feldman [5], Bengt Winblad [6], Eric Stoops [4], Eugeen Vanmechelen [4], Norbert Zilka [1]

[1]Axon Neuroscience R&D Services - Bratislava (Slovakia), [2]Department of Clinical Sciences, Lund University - Lund (Sweden), [3]Axon Neuroscience SE - Larnaca (Cyprus), [4]ADx NeuroSciences NV, Technologiepark 94 – Bio Incubator - Gent (Belgium), [5]Department of Neurosciences, University of California San Diego - La Jolla (United States), [6]Karolinska Institutet, Dept NVS, Center for Alzheimer Research, Division of Neurogeriatrics - Solna (Sweden)

6.50 - 7.50 p.m.

CTAD Welcome Reception with the Support of the Alzheimer's Association

Wednesday, OCTOBER 25

> > Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> > Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

7.30 a.m.   **POSTER WALKING TOUR** - Poster Hall

8:30 a.m.   **LATE BREAKING COMMUNICATIONS**
Moderators: Rebecca Amariglio, Harvard Medical School - Boston (United States) and John O'Gorman, Biogen - Cambridge (United States)

8:30 a.m.   **LB6 - Pooled ENGAGE/EMERGE Integrated Placebo-controlled Period and Long-Term Extension (LTE) Topline Results: Slower Clinical Progression at Week 134 in Aducanumab-treated Patients that Became Amyloid PET Negative at Week 78**
John O'Gorman [1], Jennifer Murphy [1], Philip Montenigro [1], Shardae Showell [1], Gersham Dent [1], Carrie Rubel [1], R. Matthew Hutchison [1], Tianle Chen [1], Kumar Kandadi Muralidharan [1], Kate Dawson [1]
[1]Biogen - Cambridge (United States)

8:45 a.m.   **LB7 - PrecivityAD2 blood test: An analytically and clinically validated test combining p-tau217/np-tau217 and Aβ42/40 ratios to identify brain amyloid**
Kristopher Kirmess [1], Matthew Meyer [1], Traci Wente-Roth [1], Faith Irwin [1], Mary Holubasch [1], Stephanie Eastwood [1], Venky Venkatesh [1], Michael Irizarry [2], David Verbel [2], Pallavi Sachdev [2], Satoshi Ito [2], Kevin Yarasheski [1], Joel Braunstein [1], Philip Verghese [1], Tim West [1]
[1]C2N Diagnostics - St. Louis (United States), [2]Eisai Inc. - Nutley (United States)

9.00 a.m.   **KEYNOTE 2**
Creating more Equitable and Valid Alzheimer's Clinical Trials for the 21st Century
Introduction: Mike Weiner, University of California San Francisco (United States)
Monica Rivera-Mindt, *Icahn School of Medicine at Mount Sinai, New York, NY (United States)*

9.25 a.m.   **SYMPOSIUM 2**
Donanemab in Early Symptomatic Alzheimer's Disease: Additional Insights from TRAILBLAZER-ALZ 2
Chair: Takeshi Iwatsubo, The University of Tokyo, Tokyo (Japan)

Presentation 1: Safety Insights from the Donanemab Trials
Steve Greenberg, *Harvard Medical School and Massachusetts General Hospital, Boston, MA (United States)*

Presentation 2: Predicting Efficacy in Donanemab-Treated Participants
Mark Mintun, *Eli Lilly and Company, Indianapolis, IN and Avid Radiopharmaceuticals, Inc. Philadelphia, PA (United States)*

Presentation 3: Clinical Meaningfulness of Donanemab Treatment
Alireza Atri, *Banner Sun Health Research Institute, Sun City, AZ (United States)*

10.05 a.m.   Coffee break and poster session

10.35 a.m.   **LATE BREAKING COMMUNICATIONS**
Moderators: Gad Marshall, Massachusetts General Hospital, Harvard Medical School - Boston (United States), and Catherine Mummery, University College London - London (United Kingdom)

10.35 a.m.   **LB8 - Efficacy of Donanemab by APOE4 Carrier Status in TRAILBLAZER-ALZ 2, a Phase 3 Randomized Clinical Trial in Early Symptomatic Alzheimer's Disease**
Cynthia D. Evans [1], Jennifer A. Zimmer [1], Alette M. Wessels [1], Ming Lu [1], Jondavid Sparks [1], Mark Mintun [1], Dawn A. Brooks [1], John R. Sims [1]
[1]Eli Lilly and Company - Indianapolis (United States)

Wednesday, OCTOBER 25

10.50 a.m. — **LB9 - Exploratory clinical outcomes from BIIB080 (MAPT ASO) phase 1b multiple ascending dose and long-term extension study in mild Alzheimer's disease**

Nick Ziogas [1], Shuang Wu [1], Yumeng Li [1], Lin Lin [1], Amanda Edwards [1], Jessica Collins [1], Irene Tien [1], Catherine Mummery [2], Roger Lane [3], Candice Junge [3], John Beaver [1], Ying Tian [1], Jaren Landen [1], Diana Gallagher [1], Melanie Shulman [1]

[1]Biogen - Cambridge (United States), [2]Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London - London (United Kingdom), [3]Ionis Pharmaceuticals - Carlsbad (United States)

11.05 a.m. — **LB10 - Phase 1 safety, tolerability, and pharmacological results of ALN-APP, the first investigational RNA interference therapeutic in development for early-onset Alzheimer's disease**

Catherine Mummery [1], Simon Ducharme [2], Jared Brosch [3], Everard Vijverberg [4], Liana Apostolova [3], Alexandre Sostelly [5], Sasikiran Goteti [5], Nune Makarova [5], Andreja Avbersek [6], Weinong Guo [5], Bret Bostwick [5], Sharon Cohen [7]

[1]University College London - London (United Kingdom), [2]Douglas Mental Health University Institute, Department of Psychiatry and Montreal Neurological Institute, Department of Neurology & Neurosurgery, McGill University - Montreal, Quebec (Canada), [3]Indiana University School of Medicine - Indianapolis, Indiana (United States), [4]Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC - Amsterdam (Netherlands), [5]Alnylam Pharmaceuticals - Cambridge, Massachusetts (United States), [6]Regeneron Pharmaceuticals, Inc. - Tarrytown, New York (United States), [7]Toronto Memory Program - Toronto, Ontario (Canada)

11.20 a.m. — **ORAL COMMUNICATIONS**
Moderators: Rachelle Doody, Roche - Basel (Switzerland) and Oskar Hansson, Lund University - Lund (Sweden)

11.20 a.m. — **OC1 - Clinical effects of Lewy body pathology in clinically unimpaired and cognitively impaired individuals**

Oskar Hansson [1], Sebastian Palmqvist [1], Piero Parchi [2]

[1]Lund University - Lund (Sweden), [2]University of Bologna - Bologna (Italy)

11.35 a.m. — **OC2 - Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's disease**

Gemma Salvadó [1], Kanta Horie [2, 3, 4], Nicolas R Barthélemy [2, 3], Jacob W Vogel [1, 5], Alexa Pichet Binette [1], Charlie D Chen [6], Brian A Gordon [6], Tammie L S Benzinger [6, 7], David M Holtzman [3, 7], John C Morris [3, 7], Shorena Janelidze [1], Rik Ossenkoppele [1, 8, 9], Suzanne E Schindler [3, 7], Randall J Bateman [2, 3, 7], Oskar Hansson [1, 10]

[1]Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), [2]The Tracy Family SILQ Center, Washington University School of Medicine - St Louis (United States), [3]Department of Neurology, Washington University School of Medicine - St Louis (United States), [4]Eisai Inc. - Nutley (United States), [5]Department of Clinical Science, Malmö, SciLifeLab, Lund University - Lund (Sweden), [6]Department of Radiology, Washington University School of Medicine - St Louis (United States), [7]Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), [8]Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), [9]Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands), [10]Memory Clinic, Skåne University Hospital - Malmö (Sweden)

11.50 a.m. — **OC3 - The anti-amyloid beta "brain shuttle" antibody trontinemab rapidly reduces amyloid plaques in people with Alzheimer's disease**

Luka Kulic [1], Fabien Alcaraz [1], Annamarie Vogt [1], Carsten Hofmann [1], Philip Barrington [2], Maddalena Marchesi [1], Gregory Klein [1], Ruth Croney [3], David Agnew [3], João A. Abrantes [1], Silke Ahlers [4], Paul Delmar [1], Iris Wiesel [1], Hanno Svoboda [1]

[1]Roche - Basel (Switzerland), [2]TranScrip group - Wokingham (United Kingdom), [3]Roche - Welwyn (United Kingdom), [4]Excelya Germany GmbH - Mannheim (Germany)

12.05 p.m. — **OC4 - Rapid detection of the earliest amyloid-related changes in memory consolidation: assessment of learning using daily digital testing**

Kate Papp [1], Roos Jutten [1], Daniel Soberanes [1], Emma Weizenbaum [1], Stephanie Hsieh [1], Cassidy Molinare [1], Rachel Buckley [1], Rebecca Betensky [2], Keith Johnson [1], Dorene Rentz [1], Reisa Sperling [1], Rebecca Amariglio [1]

[1]Harvard Medical School - Boston (United States), [2]New York University - New York (United States)

12.20 p.m. — **OC5 - Clinical Outcomes From a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects With Mild to Moderate Probable Alzheimer's Disease**

Christopher Reading [1], Clarence Ahlem [1], Joseph Palumbo [1], Nily Osman [1], Marcia Testa [2], Donald Simonson [3]

[1]BioVie Inc. - Carson City (United States), [2]Department of Biostatistics, Harvard T.H. Chan School of Public Health - Boston (United States), [3]Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School - Boston (United States)

12.35 p.m. — Lunch break and poster session

Wednesday, OCTOBER 25

1.40 p.m.

LATE BREAKING SYMPOSIUM 3
Clinical and ATN Biomarker Findings on the Impact of Amyloid Removal in a 10 year prevention trial – the DIAN-TU-001
Chairman: Randall Bateman, Washington University School of Medicine - St Louis (United States)

Presentation 1: A comprehensive analysis of CSF tau following amyloid reduction recapitulates the tau-related staging of Alzheimer disease biomarkers.
Eric McDade, *Washington University School of Medicine - St Louis (United States)*

Presentation 2: Examining Amyloid Reduction as A Surrogate Endpoint through Latent Class Analysis Using Clinical Trial Data for Dominantly Inherited Alzheimer's Disease
Guoqiao Wang, *Washington University School of Medicine - St Louis (United States)*

Presentation 3: Top-line results of gantenerumab amyloid removal in the prevention of symptom onset and dementia progression in the DIAN-TU
Randall Bateman, *Washington University School of Medicine - St Louis (United States)*

2.20 p.m.

ORAL COMMUNICATIONS
Moderators: Sandrine Andrieu, Toulouse University Hospital, Toulouse (France) and Ali Rezai, WVU Rockefeller Neuroscience Institute - Morgantown (United States)

2.20 p.m.

OC6 - Plasma P-tau217 facilitates a two-phase screening approach for participant selection into anti-amyloid trials
Niklas Mattsson-Carlgren [1], Lyduine Collij [1,2], Alexa Pichet Binette [1], Rik Ossenkoppele [1,2], Ruben Smith [1], Olof Strandberg [1], Sebastian Palmqvist [1], Erik Stomrud [1], Nicholas Ashton [3], Kaj Blennow [3], Shorena Janelidze [1], Oskar Hansson [1]
[1]Lund University - Lund (Sweden), [2]Amsterdam UMC - Amsterdam (Netherlands), [3]University of Gothenburg - Gothenburg (Sweden)

2.35 p.m.

OC7 - Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Patients with Signs and Symptoms of Cognitive Impairment
Will Canestaro [1], Randall Bateman [2], David Holtzman [2], Mark Monane [3], Joel Braunstein [3]
[1]University of Washington School of Pharmacy - Seattle (United States), [2]Washington University School of Medicine - St Louis (United States), [3]C2N Diagnostics - St Louis (United States)

2.50 p.m.

OC8 - A phase 2b clinical trial of neflamapimod in dementia with Lewy bodies designed to confirm the efficacy results from phase 2a
Niels D. Prins [1], Amanda Gardner [2], Hui-May Chu [3], Kelly Blackburn [2], James E. Galvin [4], John J. Alam [2]
[1]Brain Research Center - Amsterdam (Netherlands), [2]EIP Pharma Inc - Boston (United States), [3]Anoixis Corporation - Natick (United States), [4]University of Miami Miller School of Medicine - Boca Raton (United States)

3.05 p.m.

OC9 - Accelerated β-amyloid plaque reduction in Alzheimer's disease combining aducanumab infusion with focused ultrasound blood-brain barrier opening
Ali Rezai [1], Pierre D'haese [1], Marc Haut [1], Manish Ranjan [1], Jeffrey Carpenter [1], Rashi Mehta [1], Kirk Wilhelmsen [1], Peng Wang [1], Victor Finomore [1], Sally Hodder [1]
[1]WVU Rockefeller Neuroscience Institute - Morgantown (United States)

3.20 p.m.

LATE BREAKING ROUNDTABLE 1
NIA-AA Revised Criteria for Diagnosis and Staging of Alzheimer's disease
Chair: Laurie Ryan, National Institute on aging/NIH - Bethesda (United States)

Panelists: Clifford Jack [1], Reisa Sperling [2,3], Oskar Hansson [4], Heather Snyder [5], Laurie Ryan [6]
[1]Mayo Clinic - Rochester (United States), [2]Brigham and Women's Hospital - Boston (United States), [3]Massachusetts General Hospital - Boston (United States), [4]Lund University - Lund (Sweden), [5]Alzheimer's Association - Chicago (United States), [6]National Institute on aging/NIH - Bethesda (United States)

3.50 p.m.

Coffee break and poster session

Wednesday, OCTOBER 25

> **Conference Room:** All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> **Overflow room:** Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

4.20 p.m.

KEYNOTE 3
Alzheimer's Disease: The Drug Development Pipeline and Emerging Therapies
Introduction: Bruno Vellas, Toulouse University Hospital, Toulouse (France)
Jeffrey Cummings, *University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)*

4.55 p.m.

LATE BREAKING COMMUNICATIONS
Moderators: Yan Li, Washington University St. Louis, St. Louis (United States) and Jeffrey Cummings University of Nevada Las Vegas (UNLV), Las Vegas (United States)

4.55 p.m.

LB11 - Rapid amyloid clearance and efficacy: Results from TRAILBLAZER-ALZ 2, a phase 3 study of donanemab for treatment of early Alzheimer's disease
Sergey Shcherbinin [1], Ming Lu [1], Jian Wang [1], Hong Wang [1], Paula Hauck [1], Ivelina Gueorguieva [1], Dawn Brooks [1], John Sims [1], Mintun Mintun [1], Emily Collins [1]
[1]Eli Lilly and Company - Indianapolis (United States)

5.10 p.m.

LB12 - Reduced caregiver distress associated with neuropsychiatric symptoms in EMERGE, a Phase 3, double-blind clinical trial of aducanumab in participants with early Alzheimer's disease
Jeffrey Cummings [1], Sharon Cohen [2], Jennifer Murphy [3], Ping He [4], Carl De Moor [5], Fiona Forrestal [3], John Harrison [6,7], Judith Jaeger [8,9], Catherine Jane Mummery [10], Anton P. Porsteinsson [11], Michele Potashman [12], Ying Tian [3], Lili Yang [13], John O'gorman [3], Samantha Budd Haeberlein [14]
[1]Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, UNLV - Las Vegas (United States), [2]Toronto Memory Program - Toronto (Canada), [3]Biogen Inc. - Cambridge (United States), [4]Takeda Pharmaceutical Company Limited - Boston (United States), [5]Certara - Princeton (United States), [6]Scottish Brain Sciences - Edinburgh (United Kingdom), [7]Alzheimercentrum of the Amsterdam UMC - Amsterdam (Netherlands), [8]CognitionMetrics, LLC - Stamford (United States), [9]Albert Einstein College of Medicine - New York (United States), [10]Dementia Research Centre, Queen Square Institute of Neurology, University College London - London (United Kingdom), [11]University of Rochester School of Medicine and Dentistry - Rochester (United States), [12]Biohaven Pharmaceuticals Inc - New Haven (United States), [13]Alnylam Pharmaceuticals - Cambridge (United States), [14]Enigma Biomedical USA - Nashville (United States)

5.25 p.m.

LATE BREAKING SYMPOSIUM 4
Lecanemab for Early Alzheimer's Disease:Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration
Chairman: Christopher van Dyck, Yale Alzheimer's Disease Research Center - New Haven (United States)

Presentation 1: Clarity AD: Review of the Mechanism-Based Rationale and Results of the Lecanemab Phase 3 Trial
Christopher van Dyck, *Yale Alzheimer's Disease Research Center - New Haven (United States)*

Presentation 2: Biomarker Assessments from Clarity AD: Downstream Implications of Targeting Protofibrils and Tau as a Predictive Biomarker
Keith Johnson, *Harvard Medical School - Boston (United States)*

Presentation 3: Lecanemab for the Treatment of Early Alzheimer's Disease: The Extension of Efficacy Results from Clarity AD
Reisa Sperling, *Brigham and Women's Hospital Harvard Medical School - Boston (United States)*

Presentation 4: Preliminary Update on Lecanemab Safety in Clarity AD Open-Label Extension, Including Subcutaneous Formulation
Michael Irizarry, *Eisai Inc. - Nutley (United States)*

Panel Discussion and Q&A

6.05 p.m.

End of the Conference Day

Thursday, OCTOBER 26

> > Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> > Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

7.30 a.m.   **POSTER WALKING TOUR** - Poster Hall

8:30 a.m.   **LATE BREAKING COMMUNICATIONS**
Moderators: Rema Raman, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego - San Diego (United States) and Samuel P. Dickson, Pentara Corporation - Salt Lake City (United States)

8:30 a.m.   **LB13 - Time Savings Estimates for Donanemab TRAILBLAZER-ALZ Phase 2 & Phase 3 Studies**
Samuel P. Dickson [1], Suzanne B. Hendrix [1], Lars Lau Raket [2], Saptarshi Chatterjee [2], Joshua Christensen [1], Benjamin Haaland [1], Jondavid Sparks [2], John R. Sims [2], Dawn A. Brooks [2], Mark A. Mintun [2]
[1]Pentara Corporation - Salt Lake City (United States), [2]Eli Lilly and Company - Indianapolis (United States)

8:45 a.m.   **LB14 - Evidence that Lumipulse G pTau217 Plasma measurements have the ability to quantitatively assess Tau stage and burden**
Anthony Bannon [1], Edwin Stage [1], Manu Vandijck [2], Francesca Desimone [2], John Lawson [3], Larry Ward [4], Vincent Doré [5], James Doecke [6], Chris Fowler [4], Jurgen Mejan-Fripp [6], Chris Rowe [4]
[1]AbbVie Inc - North Chicago (United States), [2]Fujirebio - Antwerp (Belgium), [3]Fujirebio - Malvern (United States), [4]The Florey Institute of Neuroscience and Mental Health - Melbourne (Australia), [5]CSIRO - Melbourne (Australia), [6]CSIRO - Brisbane (Australia)

09.00 a.m.   **ORAL COMMUNICATIONS**

9.00 a.m.   **Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease**
Chair and introduction: Howard Fillit, Alzheimer's Drug Discovery Foundation, New York, NY (United States)

9.15 a.m.   **OC10 - Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease (REGEN-BRAIN©)**
Roberta Brinton [1], Gerson Hernandez [1], Claudia Lopez [1], Lon Schneider [2]
[1]University of Arizona - Tucson (United States), [2]University of Southern California - Los Angeles (United States)

9.30 a.m.   **OC11 - Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in an ongoing Phase 1/2 AD study**
Terrence Fisher [1], Elizabeth Evans [1], Megan Boise [1], Vikas Mishra [1], Crystal Mallow [1], John Leonard [1], Eric Siemers [2], Raymond Turner [3], Wendy Bond [4], John Huffaker [4], Maurice Zauderer [1]
[1]Vaccinex, Inc. - Rochester (United States), [2]Siemers Integration LLC - Indianapolis (United States), [3]Re-Cognition Health - Fairfax (United States), [4]Neuropsychiatric Research Center of Southwest Florida - Fort Myers (United States)

9.45 a.m.   **OC12 - Astrocyte reactivity biomarker for the populational enrichment of clinical trials in preclinical Alzheimer's disease**
Bruna Bellaver [1], Guilherme Povala [1], Pamela C.I. Ferreira [1], João Pedro Ferrari-Souza [1], Douglas Teixeira Leffa [1], Firoza Z. Lussier [1], Andrea L. Benedet [2], Nicholas J. Ashton [2], Eduardo R. Zimmer [3], Henrik Zetterberg [2], Kaj Blennow [2], Ann Cohen [1], Thomas K. Karikari [1], Pedro Rosa-Neto [4], Tharick A. Pascoal [1]
[1]University of Pittsburgh - Pittsburgh (United States), [2]University of Gothenburg - Gothenburg (United States), [3]Universidade Federal do Rio Grande do Sul - Porto Alegre (United States), [4]McGill University - Montreal (United States)

10.00 a.m.   **LATE BREAKING ORAL COMMUNICATIONS**
Moderators: Mike Rafii, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego -San Diego (United States) and Sharon Cohen, Toronto Memory Program - Toronto (Canada)

10.00 a.m.   **LB15 - An exploration of amyloid removal measures in relation to clinical benefit: a review and meta-regression of anti-amyloid trials in AD**
Marzia Antonella Scelsi [1], Josie Jackson [1], Matteo Tonietto [2], Gregory Klein [2], Christopher Lane [1], Janice Smith [1], Rachelle Doody [2], Paul Delmar [2]
[1]Roche Products Ltd - Welwyn Garden City (United Kingdom), [2]F. Hoffman-La Roche AG - Basel (Switzerland)

Thursday, OCTOBER 26

> **Conference Room:** All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> **Overflow room:** Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

10.15 a.m.

LB16 - Progression analysis on cognitive, functional, and behavioral endpoints in EMERGE, a Phase 3, double-blind clinical trial of aducanumab in participants with early Alzheimer's disease

Sharon Cohen [1], Jeffrey Cummings [2], Jennifer Murphy [3], Ping He [4], Mihaela Levitchi Benea [5], Fiona Forrestal [3], John Harrison [6, 7], Judith Jaeger [8, 9], Catherine Jane Mummery [10], Anton P. Porsteinsson [11], Michele Potashman [12], Lili Yang [13], Shuang Wu [3], Ying Tian [3], Samantha Budd Haeberlein [14]

[1]Toronto Memory Program - Toronto (Canada), [2]University of Las Vegas - Las Vegas (United States), [3]Biogen Inc. - Cambridge (United States), [4]Takeda Pharmaceutical Company Limited - Boston (United States), [5]Fulcrum Therapeutics - Cambridge (United States), [6]Scottish Brain Sciences - Edinburgh (United Kingdom), [7]Alzheimercentrum of the AUmC - Amsterdam (Netherlands), [8]CognitionMetrics, LLC - Stamford (United States), [9]Albert Einstein College of Medicine - New York (United States), [10]Dementia Research Centre, Queen Square Institute of Neurology, University College London - London (United Kingdom), [11]University of Rochester School of Medicine and Dentistry - Rochester (United States), [12]Biohaven Pharmaceuticals, Inc. - New Haven (United States), [13]Alnylam Pharmaceuticals - Cambridge (United States), [14]Enigma Biomedical USA - Nashville (United States)

10.30 a.m.   Coffee break and poster session

11.00 a.m.

KEYNOTE 4
Clinical Trials in Alzheimer's Disease Prevention
Introduction: Paul Aisen, Alzheimer Therapeutic Research Institute, University of Southern California - San Diego (United States)

Sandrine Andrieu, *Toulouse University Hospital, Toulouse (France)*

11.25 a.m.

SYMPOSIUM 5
What can we LEARN from the A4 Study? Associations among longitudinal cognitive, functional, biomarker and imaging outcomes
Chair: Paul Aisen, Alzheimer Therapeutic Research Institute, University of Southern California - San Diego (United States)

Presentation 1: Plasma phospho-tau217 baseline and longitudinal outcome measures in the A4 Study

Roy Yaari, *Lilly and Co. - Indianapolis (United States)*

Presentation 2: Amyloid and Tau PET in the A4 Study

Keith Johnson, *Massachusetts General Hospital, Harvard Medical School - Boston (United States)*

Presentation 3: Predictors of Cognitive and Functional Decline in the A4 and LEARN Studies

Reisa Sperling, *Brigham and Women's Hospital Harvard Medical School - Boston (United States)*

12.05 p.m.   Lunch and poster session

1.20 p.m.

ROUNDTABLE 2
Forging the Path Forward: Capitalizing on Recent Alzheimer's Momentum through Strategic Investments in Novel Therapeutics
Howard Fillit [1], Philip Scheltens [2], Susan Kohlhaas [3], John Behr [4], Joe Lewcock [5]

[1]Alzheimer's Drug Discovery Foundation - New York City (United States), [2]EQT Life Sciences - Amsterdam (Netherlands), [3]Alzheimer's Research UK - London (United Kingdom), [4]Dementia Discovery Fund - London (United Kingdom), [5]Denali Therapeutics - South San Francisco (United States)

> **Conference Room:** All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> **Overflow room:** Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

1.50 p.m.

ORAL COMMUNICATIONS
Moderators: Nicola Coley, INSERM-University of Toulouse UMR1295, Toulouse (France) and Lars Lannfelt, BioArctic AB - Stockholm (Sweden)

1.50 p.m.

OC15 - Stress Testing the CL concept: Evaluating Centiloid Stability to Tracer, Effective Image Resolution and Quantification Method

Mahnaz Shekari [1,2,3], David Vállez García [4], Lyduine.E Collij [4], Daniel Altomare [5], Fiona Heeman [4], Hugh Pemberton [6,7], Núria Roé Vellvé [8], Santiago Bullich [8], Christopher Buckley [6], Andrew Stephens [8], Gill Farrar [6], Giovanni Frisoni [5], William.e Klunk [9], Frederik Barkhof [4,7], Juan Domingo Gispert [1,2,10]

[1]Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), [2]IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), [3]Universitat Pompeu Fabra - Barcelona (Spain), [4]Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [5]Memory Center, University Hospitals and University of Geneva - Geneva (Switzerland), [6]GE Healthcare Pharmaceutical Diagnostics, UK - Amersham (United Kingdom), [7]University College London - London (United Kingdom), [8]Life Molecular Imaging GmbH - Berlin (Germany), [9]University of Pittsburgh - Pittsburgh (United States), [10]Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN) - Barcelona (Spain)

2.05 p.m.

OC16 - End-to-end automated scoring of speech-based cognitive assessments for Alzheimer's Disease: A comparison with manual scoring in the AMYPRED-US and AMYPRED-UK studies

Jack Weston [1], Udeepa Meepegama [1], Caroline Skirrow [1], Michael Ropacki [2], Emil Fristed [1]

[1]Novoic - London (United Kingdom), [2]Oryzon - Temecula (United States)

2.20 p.m.

OC17 - Characterization of the synaptic blood marker β-synuclein in different stages of Alzheimer´s disease and other dementias

Patrick Oeckl [1], Giovanni Bellomo [2], Lorenzo Barba [3], Daniel Alcolea [4], Anna L. Wojdala [2], Juan Fortea [4], Alberto Lleó [4], Lucilla Parnetti [2], Olivia Belbin [4], Markus Otto [3]

[1]Ulm University Hospital, Department of Neurology and DZNE Ulm - Ulm (Germany), [2]Section of Neurology, Department of Medicine and Surgery, University of Perugia - Perugia (Italy), [3]Department of Neurology, Martin-Luther-University of Halle-Wittenberg - Halle (saale) (Germany), [4]Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain - Barcelona (Spain)

2.35 p.m.

OC18 - Remote detection and characterization of cognitive performance trajectories in mild cognitive impairment and populations at-risk from the INTUITION brain health study

Monroe Butler [2], Roland Brown [1], Andrew Becker [1], Matt Hobbs [1], Paramita Saha-Chaudhuri [1], Joaquín Penalver-Andres [1], Daniel Roggen [1], Alf Scotland [1], Yuval Zabar [1], Richard Hughes [1], Hanson Lenyoun [2], Matt Bianchi [2], Audrey Gabelle [1], Shibeshih Belachew [1], The Intuition Scientific Study Committee [1]

[1]Biogen - Cambridge (United States), [2]Apple - Cupertino (United States)

2.50 p.m.

OC19 - Binding profiles of lecanemab and donanemab to different amyloid-beta species

Lars Lannfelt [1,2], Malin Johannesson [1], Patrik Nygren [1], Adeline Rachalski [1], Emily Button [1], Anne-Sophie Svensson [1], Eleni Gkanatsiou [1], Nicolas Fritz [1], Olof Zachrisson [1], Linda Söderberg [1], Christer Möller [1]

[1]BioArctic AB - Stockholm (Sweden), [2]Department of Public Health/Geriatrics - Uppsala (Sweden)

3.05 p.m.

ROUNDTABLE 3
What is meaningful enough for CMS to cover? – What is reasonable and necessary?
Chair: Lefkos Middleton, Imperial College – London (United Kingdom)
Discussants: Maria Carrillo[1], Ron Petersen[2], Lon Schneider[3]
[1]Alzheimer's Association - Chicago, IL (United States), [2]Mayo Clinic - Rochester, MN (United States), [3]USC - Los Angeles (United States)

3.35 p.m.

Coffee break and poster session

Thursday, OCTOBER 26

> **Conference Room:** All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> **Overflow room:** Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

4.05 p.m.

ORAL COMMUNICATIONS

Moderators: Lon Schneider, Keck School of Medicine of USC - Los Angeles (United States) and Guoqiao Wang, Washington University School of Medicine, St Louis (United States)

4.05 p.m.

OC20 - Estimating Time-Saving Treatment Effects in Alzheimer's Clinical Trials: Exploring Alternative Approaches

Guoqiao Wang [1], Gary Cutter [2], Lon Schneider [3], Whedy Wang [4], Brian Mangal [4], Yijie Liao [5], Yan Li [1], Chenjie Xiong [1], Jorge Llibre-Guerra [1], Eric Mcdade [1], Randall Bateman [1]

[1]Washington University School of Medicine, St. Louis, MO - St Louis (United States), [2]University of Alabama at Birmingham - Birmingham (United States), [3]Keck School of Medicine, University of Southern California - Los Angeles (United States), [4]Alector, Inc - San Francisco (United States), [5]Asher Biotherapeutics - San Francisco (United States)

4.20 p.m.

OC21 - The Potential for Time Savings in Early Alzheimer Clinical Trials

Lon Schneider [1], Guoqiao Wang [2], Richard Kennedy [3], Gary Cutter [3]

[1]Keck School of Medicine of USC - Los Angeles (United States), [2]Washington University - Saint Louis (United States), [3]University of Alabama, Birmingham - Birmingham (United States)

4.35 p.m.

OC22 - Precision medicine analysis of heterogeneity in individual-level treatment response to beta-amyloid removal in early Alzheimer's disease

Menglan Pang [1], Audrey Gabelle [1], Paramita Saha-Chaudhuri [1], Willem Huijbers [1], Arie Gafson [1], Paul Matthews [2], Lu Tian [3], Ivana Rubino [1], Richard Hughes [1], Carl De Moor [1], Shibeshih Belachew [1], Changyu Shen [1]

[1]Biogen - Cambridge (United States), [2]Imperial College London - London (United Kingdom), [3]Stanford University School of Medicine - Stanford (United States)

4.50 p.m.

OC23 - Effects of an 18-month multimodal intervention on cognitive function (J-MINT PRIME Tamba): A randomized controlled trial

Yutaro Oki [1], Tohmi Osaki [2], Ryoko Kumagai [3], Shunsuke Murata [4], Haruhi Encho [3], Hisafumi Yasuda [1], Rei Ono [5], Hisatomo Kowa [3]

[1]Department of Public Health, Kobe University Graduate School of Health Sciences - Kobe (Japan), [2]Department of Occupational Therapy, Faculty of Rehabilitation, Kobe Gakuin University - Kobe (Japan), [3]Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences - Kobe (Japan), [4]Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center Research Institute - Suita (Japan), [5]Department of Physical Activity Research, National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition - Ibaraki (Japan)

5.05 p.m.

LATE BREAKING SYMPOSIUM 6
Implementing blood biomarkers in clinical practice and trials
Chair: Stephen Salloway, Brown University - Providence (United States)

Presentation 1: Defining the minimum acceptable performance of blood-based biomarkers of Alzheimer's disease for clinical use in symptomatic patients

Suzanne Schindler, *Washington University School of Medicine - St. Louis (United States)*

Presentation 2: A highly accurate blood test for Alzheimer's disease pathology has performance equivalent or superior to clinically used cerebrospinal fluid tests

Oskar Hansson, *Lund University – Lund (Sweden)*

Presentation 3: $A\beta 42/A\beta 40$ and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's Disease

Robert Rissman, *Alzheimer, University California San Diego – San Diego (United States)*

5.45 p.m.

End of the Conference Day

Friday,
OCTOBER 27

> > Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> > Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

7.30 a.m. POSTER WALKING TOUR - Poster Hall

8.30 a.m. LATE BREAKING COMMUNICATIONS
Moderators: Merce Boada, Fundacio Ace, Barcelona (Spain) and Christopher Van Dyck, Yale School of Medicine - New Haven (United States)

8.30 a.m. LB17 - Topline results of a Phase II Trial of Edonerpic Maleate in Patients with Early Stage Biomarker-Proven Alzheimer's Disease
Niels Prins[1], Charlotte Teunissen [2], Pieter Van Bokhoven [3], Sietske Sikkes 4, Willem De Haan [4], Tomohiro Okuda [5], Philip Scheltens [6]
[1]Brain Research Center - Amsterdam (Netherlands), [2]Neurochemistry Laboratory, Department of Neurochemistry, Amsterdam UMC - Amsterdam (Netherlands), [3]IXA-Neuroscience, Amsterdam Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), [4]Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location Vumc - Amsterdam (Netherlands), [5]FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), [6]Amsterdam UMC - Amsterdam (Netherlands)

8.45 a.m. LB18 - CT1812 START Study Design: Anti-Aβ Monoclonal Antibodies as Background Therapy
Christopher Van Dyck [1], Rema Raman [2], Michael Donohue [2], Robert Rissman [2], Michael Rafii [2], Mary Hamby [3], Michael Grundman [3], Anthony Caggiano [3], Paul Aisen [2]
[1]Yale School of Medicine - New Haven (United States), [2]Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego - San Diego (United States), [3]Cognition Therapeutics Inc. - Pittsburgh (United States)

9.00 a.m. KEYNOTE 5
What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials
Introduction: Jacques Touchon, Montpellier University, Montpellier (France)
Cynthia A. Lemere, *Brigham and Women's Hospital and Harvard Medical School, Boston, MA (United States)*

9.25 a.m. LATE BREAKING SYMPOSIUM 7
INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Aβ oligomers
Chair: Diana Kerwin, Kerwin Medical Center, Dallas (United States)

Presentation 1: Determination of target engagement at various doses of ACU193 in INTERCEPT-AD
Mirjam Trame, *Certara, Boston (United States)*

Presentation 2: Reduction in amyloid plaque load at higher doses of ACU193 in INTERCEPT-AD
Eric Siemers, *Acumen Pharmaceuticals, Inc, Charlottesville (United States)*

Presentation 3: Characteristics of Participants in INTERCEPT-AD Who Did or Did Not Develop ARIA with ACU193
Stephen Salloway, *Alpert Medical School of Brown University, Providence (United States)*

10.05 a.m. Coffee break and poster session

10.30 a.m. ORAL COMMUNICATIONS
Moderators: Serge Gauthier, McGill University, Montréal (Canada) and Mary Sano, Icahn School of Medicine at Mount Sinai - New York (United States)

10.30 a.m. OC24 - Alzheimer's disease in Down syndrome: Natural History, Biomarkers and Clinical Trials
Michael Rafii [1]
[1]Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (United States)

10.45 a.m. OC25 - Risk of Incident Cognitive Impairment Using Stages of Objective Memory Impairment (SOMI) and Neuroimaging
Kellen Petersen [1], Ali Ezzati [2], Bhargav Nallapu [1], Richard Lipton [1], Reisa Sperling [3], Kathryn Papp [3], Dorene Rentz [3], Ellen Grober [1]
[1]Albert Einstein College of Medicine - Bronx (United States), [2]University of California, Irvine - Irvine (United States), [3]Harvard Medical School - Boston (United States)

Friday, OCTOBER 27

11.00 a.m.

OC26 - Quantitative Amyloid-PET in Real-World Practice: Lessons from the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study

Renaud La Joie [1], Ehud Zeltzer [1], Nidhi Mundada [1], Ganna Blazhenets [1], Jhonny Mejia Perez [1], Daniel Schonhaut [1], Leonardo Iaccarino [2], Maria Carrillo [3], Lucy Hanna [4], Constantine Gatsonis [4], Andrew March [5], Barry Siegel [6], Bruce Hillner [7], Rachel Whitmer [8], Gil Rabinovici [1]

[1]University of California, San Francisco - San Francisco, Ca (United States), [2]Avid Radiopharmaceuticals - Philadelphia, Pa (United States), [3]Alzheimer's Association - Chicago, Il (United States), [4]Brown university - Providence, Ri (United States), [5]American College of Radiology - Philadelphia, Pa (United States), [6]Washington University School of Medicine in St. Louis - St Louis, Mo (United States), [7]Virginia Commonwealth University - Richmond, Va (United States), [8]University of California, Davis - Davis, Ca (United States)

11.15 a.m.

OC27 - Measuring Meaningful Benefit of Disease Modifying Treatment on Health-Related Resource Use

Carolyn Zhu [1], Mary Sano [1]

[1]Icahn School of Medicine at Mount Sinai - New York, NY (United States)

11.30 a.m.

OC28 - Establishing the validity of a novel electronic Clinical Dementia Rating (eCDR)

Rachel Nosheny [1], Daniel Yen [2], Taylor Howell [1], Monica Camacho [3], Krista Moulder [2], Miriam Ashford [3], Ronald Petersen [4], Nikki Stricker [4], Erik Roberson [5], Daniel Marson [5], Walter Kukull [6], Scott Mackin [1], Michael Weiner [1], John Morris [2], Yan Li [2]

[1]UCSF - San Francisco (United States), [2]Washington University - St. Louis (United States), [3]Northern California Institute for Research and Edcuation - San Francisco (United States), [4]Mayo Clinic - Rochester (United States), [5]University of Alabama at Birmingham - Birmingham (United States), [6]University of Washington - Seattle (United States)

11.45 a.m.

OC29 - AI-based enrichment tools substantially increase the efficiency of AD clinical trials

Viswanath Devanarayan [1], Yuanqing Ye [1], Harald Hampel [1], Lynn Kramer [1], Michael Irizarry [1], Shobha Dhadda [1]

[1]Eisai Inc. - Nutley (United States)

12.00 p.m.

OC30 - Timing of Biomarker Changes in Sporadic Alzheimer Disease in Estimated Years from Symptom Onset

Yan Li [1], Daniel Yen [1], Rachel Hendrix [1], Brian Gordon [1], Sibonginkhosi Dlamini [1], Nicolas Barthelemy [1], Andrew Aschenbrenner [1], Rachel Henson [1], Eric Mcdade [1], David Holtzman [1], Tammie Benzinger [1], John Morris [1], Randall Bateman [1], Suzanne Schindler [1]

[1]Washington University in St. Louis - St. Louis (United States)

12.15 p.m.

Lunch break and poster session

1.15 p.m.

LATE BREAKING ORAL COMMUNICATIONS

Moderators: Pierre-Jean Ousset, Toulouse University Hospital, Toulouse (France) and Laia Montoliu-Gaya, University of Gothenburg - Gothenburg (Sweden)

1.15 p.m.

LB19 - Pharmacokinetic-Pharmacodynamic (PK-PD) Relationship Between Aducanumab Exposure and Amyloid PET Over Long-term Treatment Period Including Dosing Gap in the EMBARK Phase 3b Study

Jackson Burton [1], Kowalski Ken [2], Kumar Kandadi Muralidharan [1], R. Matthew Hutchison [1], Philip Montenigro [1], Ivan Nestorov [1]

[1]Biogen - Cambridge (United States), [2]Kowalski PMetrics Consulting LLC - Naples (United States)

1.30 p.m.

LB20 - A mass spectrometric panel of phosphorylated and non-phosphorylated plasma tau species reveals differences in the associations with early and intermediate tau PET in sporadic Alzheimer's disease

Laia Montoliu-Gaya [1], Gemma Salvadó [2], Nicholas J Ashton [1], Shorena Janelidze [2], Johanna Nilsson [3], Niklas Mattsson-Carlgren [2], Sophia Weiner [4], Sebastian Palmqvist [2], Juan Lantero-Rodriguez [3], Gunnar Brinkmalm [4], Erik Stomrud [2], Henrik Zetterberg [3], Johan Gobom [3], Kaj Blennow [3], Oskar Hansson [2]

[1]University of Gothenburg - Gothenburg (Sweden), [2]Lund University - Lund (Sweden), [3]University of Gothenburg - Gothenburg (Sweden) - Gothenburg (Sweden), [4]University of Gothenburg - Gothenburg (Sweden) - Gothenburg (Sweden) - Gothenburg (Sweden)

1.45 p.m.

LB21 - Evaluating the Efficacy of AR1001 on Plasma ptau 181 Levels and ADAS-Cog 13 in Mild to Moderate Alzheimer's Disease: Results from the Phase 2 Trial

Byoung Seok Ye [1], David Greeley [2], Fred Kim [2], Jai Jun Choung [2]

[1]Department of Neurology, Yonsei University College of Medicine - Seoul (Korea, Republic of), [2]AriBio Co., Ltd. - Seongnam (Korea, Republic of)

2.00 p.m.

LB22 - Aducanumab Phase 3b EMBARK Study Interim Analysis: Topline Safety Results

Gioacchino G Curiale [1], Philip Montenigro [1], Kimberly Umans [1], Tao Sun [1], John O'gorman [1], Karen Smirnakis [1]

[1]Biogen - Cambridge (United States)

> **Conference Room:** All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> **Overflow room:** Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

2.15 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION: Phase 1 Clinical Trials**
Moderators: Robert Rissman, Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), and Oliver Peters, Charité - Berlin (Germany)

2.15 p.m. **OC31 - RG6289, a new γ-secretase modulator for the treatment of Alzheimer's disease: Results from a phase I healthy volunteer study**

Stefan Sturm [1], Agnes Portron [1], Annamarie Vogt [2], Agnes Poirier [1], Tianxu Yang [3], Adnan Mohamed Abdi [1], Gwendlyn Kollmorgen [4], Cory Simmons [5], Kalbinder Mahil [6], Lothar Lindemann [2], Karl-Heinz Baumann [2], Thomas Mueggler [2], Taner Vardar [7], Rosanna Tortelli [2], Irene Gerlach [2]

[1]Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), [2]Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), [3]Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Beijing (China), [4]Roche Diagnostics GmbH - Penzberg (Germany), [5]Product Development Data Sciences, F. Hoffmann-La Roche Ltd - Mississauga (Canada), [6]Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Roche Products Limited - Welwyn (United Kingdom), [7]Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Basel (Switzerland)

2.25 p.m. **OC32 - A phase 1a single ascending dose study of the safety, tolerability, and brain receptor occupancy of BMS-984923 in healthy older adults**

Adam P Mecca [1], Elaheh Salardini [1], Jean-Dominique Gallezot [1], Ryan S O'dell [1], Juan Young [1], Emma Cooper [1], Meghan G Donahue [1], Julia L Waszak [1], Jeanine L May [1], Joshua Spurrier [1], Timothy R Siegert [2], Richard E Carson [1], Stephen M Strittmatter [1,2], Christopher H Van Dyck [1]

[1]Yale School of Medicine - New Haven (United States), [2]Allyx Therapeutics, Inc. - New Haven (United States)

2.35 p.m. **OC33 - A Phase 1 Study demonstrating safety, CNS target engagement and PBMC pharmacodynamic response to ASN51, a novel and orally administered O-GlcNAcase inhibitor**

Ryan Schubert [1], Bruno Permanne [1], Rolf Pokorny [1], Pearl Fang [1], Vanessa Teachout [1], Maud Nény [1], Solenne Ousson [1], Ruhi Ahmed [1], Manfred Schneider [1], Anna Quattropani [1], Dirk Beher [1]

[1]Asceneuron - Lausanne (Switzerland)

2.45 p.m. **OC34 - E2511, a Novel TrkA Modulator, Engages its CNS Cholinergic Target in a Phase 1 Clinical Study**

Satya Saxena [1], Yuanqing Ye [1], Kazunari Sasaki [1], Takeo Kamakura [1], Garth Ringheim [1], Luigi Giorgi [1], Natasha Penner [1], Kanta Horie [1], Viswanath Devanarayan [1], Pallavi Sachdev [1]

[1]Eisai Inc. - Nutley (United States)

2.55 p.m. **OC35 - Mode of action, clinical phase Ib data in patients, and the phase II design of the orally available anti-prionic compound PRI-002 that disassembles Aβ oligomers into Aβ monomers**

Dieter Willbold [1], Nicoleta-Carmen Cosma [2], Janine Kutzsche [1], Dagmar Jürgens [3], Gerhard Tischler [3], Oliver Peters [2]

[1]FZ Jülich - Jülich (Germany), [2]Charité - Berlin (Germany), [3]Prinnovation - Leipzig (Germany)

3.05 p.m. Coffee break and poster session

3.30 p.m. **LATE BREAKING ORAL COMMUNICATIONS**
Moderators: Suzanne Hendrix, Pentara Corporation - Millcreek (United States), Susan Landau, UC Berkeley - Berkeley (United States)

3.30 p.m. **LB23 - Results of a Phase 2 randomized withdrawal study of simufilam in mild-to-moderate Alzheimer's Disease**

Ian Cohen [1], Shishuka Malhotra [1], Paayal Patel [2], Suzanne Hendrix [3], Craig Mallinckrodt [3], Ben Murray [4], Leslie Jones [4], Antonio Hernandez [4], Emmalee Crow [4], Melissa Snyder [4], Lindsay Burns [4], James Kupiec [4], Nadav Friedmann [4]

[1]Toronto Memory Program - Toronto (Canada), [2]Brain Matters Research - Delray Beach (United States), [3]Pentara Corporation - Millcreek (United States), [4]Cassava Sciences, Inc. - Austin (United States)

Friday,
OCTOBER 27

3.45 p.m.

LB24 - Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-beta pathology

Przemysław Kac [1], Armand González-Escalante [2,3,4], Marta Milà-Alomà [2,5], Nicholas Ashton [1,6,7,8], Mahnaz Shekari [2,3,4,5], Paula Ortiz-Romero [2,3], Henrik Zetterberg [1,6,9,10], Juan Domingo Gispert [2,3,5,11], Kaj Blennow [1,12], Marc Suárez-Calvet [2,3,11,13], Thomas Karikari [1,14]

[1]Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), [2]Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), [3]Hospital del Mar Research Institute - Barcelona (Spain), [4]Universitat Pompeu Fabra - Barcelona (Spain), [5]Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain), [6]Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London - London (United Kingdom), [7]NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation - London (United Kingdom), [8]Centre for Age-Related Medicine, Stavanger University Hospital - Stavanger (Norway), [9]Hong Kong Center for Neurodegenerative Diseases, HKCeND - Hong Kong (China), [10]School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), [11]Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina - Madrid (Spain), [12]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), [13]Servei de Neurologia, Hospital del Mar - Barcelona (Spain), [14]Department of Psychiatry, School of Medicine, University of Pittsburgh - Pittsburgh (United States)

4.00 p.m.

LB25 - Elevated amyloid and tau are not associated with cognition in a diverse clinical trial cohort

Susan Landau[1], Theresa Harrison[1], Tyler Ward[1], Prashanthi Vemuri[2], Samuel Lockhart[3], Robert Koeppe[4], Danielle Harvey[5], Laura Lovato[3], Arthur Toga[6], Sarah Tomaszewski Farias[5], Kathryn Papp[7], Heather Snyder[8], Charles Decarli[5], William Jagust[1], Laura Baker[3]

[1]UC Berkeley - Berkeley (United States), [2]Mayo Clinic - Rochester (United States), [3]Wake Forest School of Medicine - Winston-Salem (United States), [4]University of Michigan - Ann Arbor (United States), [5]UC Davis - Davis (United States), [6]University of Southern California - Los Angeles (United States), [7]Harvard University - Boston (United States), [8]Alzheimer's Association - Chicago (United States)

4.15 p.m.

LB26 - Feasibility of remote blood collection and plasma biomarker analyses to assess eligibility for Alzheimer's disease preclinical clinical trials - The AlzMatch Study

Rema Raman [1], Sarah Walter [1], Gustavo A. Jimenez-Maggiora [1], Robert Rissman [1], Alireza Atri [2], Dana Goldman [3], Joshua Grill [4], Gad A. Marshall [5], Gregory Jicha [6], Michael Racke [7], Raymond Turner [8], Christopher H. Van Dyck [9], Venky Venkatesh [10], Reisa Sperling [5], Paul Aisen [1]

[1]Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), [2]Banner Sun Health Research Institute and Banner Alzheimer's Institute, Banner Health, Brigham And Women's Hospital - Sun City And Phoenix, Boston (United States), [3]Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California - Los Angeles (United States), [4]Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), [5]Massachusetts General Hospital, Harvard Medical School - Boston (United States), [6]University of Kentucky - Lexington (United States), [7]Quest Diagnostics - Secaucus (United States), [8]Georgetown University - Washington Dc (United States), [9]Yale College of Medicine - New Haven (United States), [10]C2N Diagnostics - St. Louis (United States)

4.30 p.m.

LB27 - Twelve-month results in FTD-C9orf72 participants from INFRONT-2: a phase 2 study of latozinemab (AL001) in FTD

Lawrence Carter [1], Peter Ljubenkov [2], Harro Seelaar [3], Olga Kahn [1], Lori Long [1], Grace Chao [1], James Okoronkwo [1], Megan Smithey [1], Julie Huang [1], Whedy Wang [1], Gary Romano [1], Albert Ludolph [4]

[1]Alector - South San Francisco (United States), [2]University of California San Francisco - San Francisco (United States), [3]Erasmus University Medical Center - Rotterdam (Netherlands), [4]University of Ulm and DZNE - Ulm (Germany)

4.45 p.m.

LB28 - Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology

Benjamin Wolozin [1], Peter Ash [1], Amit Berson [1], Caroline Murphy [1], Nick Fredette [1], Ben Moore [1], Joe Vacca [1], Robert Schaub [1], Glenn Larsen [1] - [1]Aquinnah Pharmaceuticals Inc. - Cambridge (United States)

5.00 p.m.   End of the conference

POSTER PRESENTATIONS
presented in Boston
and available on the CTAD23
digital platform

Listing of CTAD23 POSTERS

All posters are available in Pdf format
at all times on the CTAD23 digital platform.

Posters presented remotely
are indicated with this icon :

THEME: Clinical Trials: Methodology	P001 to P030 & LP001 to LP016
THEME: Clinical Trials: Results	P031 to P045 & LP017 to LP034
THEME: Clinical Trials: Imaging	P046 to P063 & LP035 to LP042
THEME: Clinical Trials: Biomarkers including plasma	P064 to P097 & LP043 to LP060
THEME: Clinical Trials: Cognitive and Functional Endpoints	P098 to P117 & LP062 to LP069
THEME: Cognitive assessment and clinical trials	P118 to P137 & LP070 to LP080 & LP121 to LP123
THEME: Behavioral disorders and clinical trials	P138 to P140 & LP124 to LP126
THEME: Health economics and clinical trials	P141 to P143
THEME: Epidemiology and clinical trials	P144 to P150 & LP082 to LP083 & LP127 to LP128
THEME: Animal Model	P151 to P152 & LP084 to LP089
THEME: New Therapies and Clinical Trials	P153 to P158 & LP090 to LP097 & LP129 to LP130
THEME: Proof of Concept/Translational research	P159 to P178 & LP098 to LP108
THEME: Digital health/E-trials	P179 to P192 & LP109 to LP117 & LP131 to LP133
THEME: Beyond Amyloid and Tau	P193 to P204 & LP118 to LP120

POSTER PRESENTATIONS

THEME: Clinical Trials: Methodology

P001 Variation in the mini-mental state examination in subjects with suspected mild to moderate Alzheimer's disease: Implications for clinical trial designs
James Rock [1], Jessie Nicodemus-Johnson [2], Holly Wood [2], Fred Kim [1], Jongkyi Kim [3], Yoon-Seok Chun [3], Suzanne Hendrix [2]
[1]AriBio - San Diego (United States), [2]Pentara - Mill Creek (United States), [3]AriBNC - Gyeonggi-Do (United States)

P002 Communicating Topline Trial Results to Participants and Study Partners in a Preclinical Alzheimer's Disease Study
Taylor Clanton [1], Joshua D. Grill [2], Jason Karlawish [3], Karen Chilcott Holdridge [4], Roy Yaari [4], Rema Raman [1], Sarah Walter [1], Elizabeth Shaffer [1], Paula J. G. Cohen [1], Paul S. Aisen [1], Reisa A. Sperling [5]
[1]Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), [2]UC Irvine - Irvine (United States), [3]University of Pennsylvania - Philadelphia (United States), [4]Eli Lilly and Company - Indianapolis (United States), [5]Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital - Boston (United States)

P003 Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer's disease
Robyn Moxon [1], Todd Feaster [1], Gopalan Sethuraman [1], Alyssa Carroll [1], Siew Tin Gan [1], Shane Ziemba [1], Kimber Price [1], Vladimir Skljarevski [1], Karen Sundell [1], Janice Hitchcock [1], Eric Siemers [1]
[1]Acumen Pharmaceuticals - Charlottesville (United States)

P004 Investigating Treatment Effect Heterogeneity in Data-Driven Subgroups of TOMMORROW
Cameron Shand [1], Neil Oxtoby [1]
[1]University College London - London (United Kingdom)

P005 How should the next generation of Alzheimer's Disease clinical trials be analyzed in the estimands framework? The GRADUATE I & II experience
Rachid Abbas [1], Nicola Voyle [2], Giuseppe Palermo [1], Geoff Kerchner [1], Christopher Lane [2], Angeliki Thanasopoulou [1], Janice Smith [2], Rachelle Doody [1, 3], Paul Delmar [1]
[1]F. Hoffmann-La Roche Ltd - Basel (Switzerland), [2]Roche Products Ltd - Welwyn Garden City (United Kingdom), [3]Genentech, Inc. - South San Francisco (United States)

P006 Factors Influencing Older Adults' Intention to Participate in a Secondary Prevention Trial in Alzheimer's Disease
Emily Largent [1], Joshua Grill [2], Jason Karlawish [1], Amy Bleakley [3]
[1]University of Pennsylvania - Philadelphia (United States), [2]University of California, Irvine - Irvine (United States), [3]University of Delaware - Newark (United States)

P007 Evaluation of machine learning models that predict Alzheimer's disease progression in observational studies and randomized clinical trials
Sofia Broomé [1], Shibeshih Belachew [2], Bastien Caba [2], Enrica Cavedo [1], Jonathan Dubois [2], Audrey Gabelle [2], Refaat Gabr [2], Arie Gafson [2], Despoina Ioannidou [1], Xiaotong Jiang [2], Yan Jin [2], Neil Oxtoby [3], Menglan Pang [2], Nikos Paragios [1], Willem Huijbers [2]
[1]TheraPanacea - Paris (France), [2]Biogen - Cambridge (United States), [3]Toybox Science - Mildenhall (United Kingdom)

P008 Study Design of POLARIS-AD, AR1001 Phase 3 Study in Early Alzheimer's Disease
Sharon Sha [1], SangYun Kim [2, 3], Jeffrey Cummings [4], Charlotte Teunissen [5], David Greeley [6], Monica Kim [6], James Rock [6], Fred Kim [6], Jai Jun Choung [6]
[1]Stanford University - Palo Alto (United States), [2]Seoul National University College of Medicine - Seoul (Korea, Republic of), [3]Seoul National University Bundang Hospital - Seoul (Korea, Republic of), [4]University of Nevada, Las Vega - Las Vegas (United States), [5]Amsterdam University Medical Centers - Amsterdam (Netherlands), [6]AriBio Co., Ltd - Seongnam (Korea, Republic of)

P009 Enrichment for clinical trial of early AD using combination of PHS and plasma p-tau181 as screening instruments
Xin Wang [1], Xinran Wang [1], Steven Edland [1], Iris Broce [1], Sarah Banks [1]
[1]University of California, San Diego - La Jolla (United States)

P010 Validating an automatic phone-based speech biomarker measuring cognition SB-C against PACC5 and MoCA in the Swedish H70 epidemiological cohort
Johannes Tröger [1], Fredrik Öhman [2], Elisa Mallick [1], Alexandra König [1], Johan Skoog [2], Anna Zettergren [2], Silke Kern [2], Simona Sacuiu [2], Michael Schöll [2], Nicklas Linz [1], Ingmar Skoog [2]
[1]ki elements GmbH - Saarbrücken (Germany), [2]Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden)

P011 A systematic review and meta-analysis of agitation trials in individuals with dementia: Are cognitive measures needed?
Heather Belanger [1], Kavita Gohil [1], Jeffrey Finman [1], Gary Kay [1]
[1]Cognitive Research Corporation (CRC), University of South Florida - St Petersburg (United States)

P012 Effects of Informant Replacement in Alzheimer's Disease Clinical Trials
Mikaela Nishida [1], Michelle Nuno [2], Joshua Grill [1], Daniel Gillen [1]
[1]University of California, Irvine - Irvine (United States), [2]University of Southern California - Los Angeles (United States)

P013 Harnessing the power of continuous time: Learnings from recent large clinical trial data
Paul Delmar [1], Lars Lau Raket [2], John O'gorman [3], Guoqiao Wang [4], Michael Donohue [5]
[1]F.Hoffmann-La Roche Ltd. - Basel (Switzerland), [2]Eli Lilly and Company, Indianapolis, USA - Indianapolis (United States), [3]Biogen - Cambridge (United States), [4]Washington University School of Medicine, - Saint Louis (United States), [5]University of Southern California - San Diego (United States)

P014 Internet-based insomnia intervention to prevent cognitive decline: Use of Internet-based recruitment, intervention, and assessment methods
Meghan Mattos [1], Carol Manning [1], Wen You [1], Kirsten Macdonnell [1], Lee Ritterband [1]
[1]University of Virginia - Charlottesville (United States)

POSTER PRESENTATIONS

P015 Exploring the Impact of Baseline Discordance Between Functional Scales in Early AD Clinical Trials

Alan Kott [1], Xingmei Wang [2], David Miller [2]
[1]Signant Health - Prague (Czech Republic), [2]Signant Health - Blue Bell (United States)

P016 A pragmatic, investigator-driven process for disclosure of amyloid PET scan results to ADNI4 research participants

Claire Erickson [1], Jason Karlawish [1], Joshua Grill [2], Kristin Harkins [1], Susan Landau [3], Ronald Petersen [4], Paul Aisen [5], Michael Weiner [6], Emily Largent [1]
[1]University of Pennsylvania - Philadelphia (United States), [2]University of California Irvine - Irvine (United States), [3]University of California Berkley - Berkley (United States), [4]Mayo Clinic - Rochester (United States), [5]University of Southern California - San Diego (United States), [6]University of California San Francisco - San Francisco (United States)

P017 RG6289, a new γ-secretase modulator for the treatment of Alzheimer's disease: Dose selection for a phase II trial based on population PK/PD modeling

Dominik Lott [1], Agnes Portron [1], Mizan Alam [1], Carina Cantrill [1], Ruth Croney [2], Fabien Alcaraz [3], Rosa Maria Rodríguez Sarmiento [4], Lothar Lindemann [3], Lutz Mueller [1], Thomas Mueggler [3], Taner Vardar [5], Rosanna Tortelli [3], Stefan Sturm [1], Irene Gerlach [3]
[1]Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), [2]Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Roche Products Limited - Welwyn (United Kingdom), [3]Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), [4]Medicinal Chemistry, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), [5]Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Basel (Switzerland)

P018 Recruitment Source, Eligibility, and Reason for Prescreen-Fail across Sex, Race & Ethnicity: A Preliminary Analysis of Prescreening Data from the AHEAD Study

Dylan Kirn [1,2], Shunran Wang [3], Joshua D. Grill [4], Karin Ernstrom [3], Akpevweoghene Ikoba [2], Emily Sprague [1], Gustavo Jimenez-Maggiora [3], Elizabeth Shaffer [3], Reisa Sperling [1,5], Rema Raman [3]
[1]Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), [2]Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Charlestown (United States), [3]Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), [4]Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), [5]Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)

P019 Impact of recruitment methods on racial and ethnic diversity: results from the Davis Memory and Aging Cohort at Mass General Brigham

Stephanie Moreno [1], Akpevweoghene Ikoba [1], Caitlyn Christiano [1], Juliana Aya Ussui Anzai [1], Andrea Roman [1], Dylan Kirn [2], Lenore Jackson-Pope [1], Martha Cecilia Muniz [1], Jasmeer P. Chhatwal [3], Seth A. Gale [4], Gad A. Marshall [4], Reisa A. Sperling [4], Hyun-Sik Yang [5], Dennis J. Selkoe [4], Dorene M. Rentz [6]
[1]Center for Alzheimer Research and Treatment, Brigham and Women's Hospital - Boston (United States), [2]Department of Neurology, Brigham and Women's Hospital - Boston (United States), [3]Department of Neurology, Mass General Hospital - Boston (United States), [4]Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), [5]Department of Neurology, Brigham and Women's Hospital - Boston (United States), [6]Center for Alzheimer Research and Treatment, Brigham and Women's Hospital - Boston (United States) - Boston (United States)

P020 Improving Diverse Recruitment in an Early Phase Therapeutic AD trial through a Pre-screening Study, Apheleia-001

Dawn Batchuluun [1], Katy Smith [1], Tamiko Magee-Rodgers [1], Leigh Zisko [1], John Dwyer [1], Jason Bork [1], Richard Mohs [1], Julie Schwartzbard [2], Anthony Bannon [3], Shau Yu Lynch [3], Christa Lee [3], Danielle Mcgeeney [3]
[1]Global Alzheimer's Platform Foundation - Washington (United States), [2]Aventura Hospital and Medical Center - Aventura (United States), [3]AbbVie, Inc. - North Chicago (United States)

P021 On Adaptive Randomization in Time-to-Event Alzheimer's Disease Clinical Trials

Navneet Hakhu [1], Joshua Grill [1], Daniel Gillen [1]
[1]University of California, Irvine - Irvine (United States)

P022 Views and perceptions of amyloid imaging among racial and ethnic groups in a preclinical Alzheimer's disease trial

Christina M. Magana-Ramirez [1], Gimarie Irizarry [2], Daniel L. Gillen [1,3], Joshua D. Grill [2,3,4]
[1]Department of Statistics, University of California, Irvine, California - Irvine (United States), [2]Department of Neurobiology and Behavior, University of California, Irvine, California - Irvine (United States), [3]Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California - Irvine (United States), [4]Department of Psychiatry and Human Behavior, University of California, Irvine, California - Irvine (United States)

P023 Application of the personalized medicine approach to a behavioral intervention study: the Internet-based Conversational Engagement Clinical Trial (I-CONECT)

Chao-Yi Wu [1], Kexin Yu [2], Steven Arnold [1], Sudeshna Das [1], Hiroko Dodge [1]
[1]Neurology, Massachusetts General Hospital, Harvard Medical School - Charlestown (United States), [2]Neurology, Oregon Health & Science University - Portland (United States)

P024 Understanding Non-progressors in Alzheimer's Disease Clinical Trials

Shuang Wu [1], Jennifer Murphy [1], Wei Feng [2], Philip Montenigro [1], Ying Tian [1]
[1]Biogen - Cambridge (United States), [2]Keros Therapeutics - Lexington (United States)

P025 A Phase 2 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Confirm Safety and Efficacy of NA-831 in Combination with Aducanumab in Subjects with Early Alzheimer's Disease

Lloyd Tran [1], Fern Vu [1], Markku Kurkinen [1]
[1]Biomed Industries, Inc. - San Jose

P025B A Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Confirm Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease

Lloyd Tran [1], Fern Vu [1], Markku Kurkinen [1]
[1]Biomed Industries, Inc. - San Jose (United States)

P026 Simulating Covariate-Adaptive Randomization Strategies in Alzheimer's Disease Clinical Trials
Charlene Flournoy [1], Rema Raman [1], Paul Aisen [1], Michael Donohue [1]
[1]USC Alzheimer's Therapeutic Research Institute - San Diego (United States)

P027 Persistence Pays - The Relationship Between Repeated Reschedule Attempts and Eventual Attendance and Screening Rates
Sarah Starling [1], Gabriela Munoz [1], Paul Sablone [1], Miriam Evans [1], Stephanie Rutrick [1]
[1]Adams Clinical - Watertown (United States)

P028 Methodologies that Support the Identification of Disease Modifying Therapies Which Are a Radical Shift from Short Acting Symptomatic Treatments: Owning Instead of Renting Our Treatment Effects
Suzanne Hendrix [1], Craig Mallinckrodt [1], Samuel Dickson [1]
[1]Pentara - Salt Lake City (United States)

P029 The time machine: how converting treatment effects to time savings will change the world
Samuel P. Dickson [1], Benjamin A. Haaland [1], Joshua Christensen [1], Matthew Morgan [1], Craig H. Mallinckrodt [1], Suzanne B. Hendrix [1]
[1]Pentara Corporation - Salt Lake City (United States)

P030 Why your AD clinical trial might succeed (the right reasons and the wrong ones)
Kent Hendrix [1], Suzanne Hendrix [1], Samuel Dickson [1]
[1]Pentara - Salt Lake City (United States)

LP001 Phase 3 POLARIS-AD: AR1001 study design in early Alzheimer's disease
Sharon Sha [1], Sangyun Kim [2], Jeffrey Cummings [3], Charlotte Teunissen [4], David Greeley [5], James Rock [5], Matthew Choung [5]
[1]Stanford University - Palo Alto (United States); [2]Seoul National University College of Medicine - Seoul (Korea, Republic of); [3]University of Las Vegas - Las Vegas (United States); [4]Amsterdam UMC - Amsterdam (Netherlands); [5]AriBio Co LTD - San Diego (United States)

LP002 Negative Amyloid biomarkers Following Treatment (NAFT): a call for harmonization and future investigations
Claire Sexton [1], Jeffrey Cummings [2], Douglas Galasko [3], Milos Ikonomovic [4], Susan Landau [5], Jorge Llibre-Guerra [6], Catherine Mummery [7], Rik Ossenkoppele [8, 9], Julie Price [10], Shannon Risacher [11], Ruben Smith [9], Christopher Van Dyck [12], Maria Carrillo [1], Renaud La Joie [13, 14]
[1]Alzheimer's Association - Chicago (United States); [2]University of Nevada Las Vegas - Las Vegas (United States); [3]University of California, San Diego - San Diego (United States); [4]VA Pittsburgh Healthcare System - Pittsburgh (United States); [5]University of California, Berkeley - Berkeley (United States); [6]Washington University School of Medicine in St Louis - St Louis (United States); [7]University College London - London (United Kingdom); [8]Amsterdam University Medical Center - Amsterdam (Netherlands); [9]Lund University - Lund (Sweden); [10]Massachusetts General Hospital - Boston (United States); [11]Indiana University School of Medicine - Indianapolis (United States); [12]Yale School of Medicine - New Haven (United States); [13]University of California, San Francisco - San Francisco (United States); [14]University of Pittsburgh School of Medicine - Pittsburgh (United States)

LP003 Implications of Missing Data and Dropouts in Randomized Clinical Trials in Early Alzheimer's Disease
Donald Berry [1]
[1]Berry Consultants - Austin (United States)

LP004 Determinants of Individual Differences in the Efficacy of Aerobic Exercise to Improve Brain Health and Reduce Alzheimer's Disease Risk in Older African Americans
Bernadette Fausto [1], Steven Malin [2], Paul Duberstein [3], Kirk Erickson [4], Liangyuan Hu [5], Mark Gluck [1]
[1]Center for Molecular and Behavioral Neuroscience, Rutgers, The State University of New Jersey–Newark - Newark, New Jersey (United States); [2]Department of Kinesiology and Health, Rutgers University - New Brunswick, New Jersey (United States); [3]Department of Health Behavior, Society and Policy, Rutgers School of Public Health - Piscataway, New Jersey (United States); [4]AdventHealth Research Institute - Orlando, Florida (United States); [5]Department of Biostatistics and Epidemiology, Rutgers School of Public Health - Piscataway, New Jersey (United States)

LP005 Investigating partially discordant results in aducanumab ENGAGE and EMERGE trials using Subtype and Stage Inference machine learning
Neil Oxtoby [1], Cameron Shand [1], Frederik Barkhof [1, 2, 3]
[1]UCL Centre for Medical Image Computing, Department of Computer Science, University College London - London (United Kingdom); [2]UCL Queen Square Institute of Neurology, University College London - London (United Kingdom); [3]Department of Radiology & Nuclear Medicine, Amsterdam University Medical Center - Amsterdam (Netherlands)

LP006 Confirmatory but not independent? Implications of using early phase results as confirmatory evidence in AD registration trials
Daniel Gillen [1], Joshua Grill [1], Sarah Schlund [1], Scott Emerson [2]
[1]University of California, Irvine - Irvine (United States); [2]University of Washington - Seattle (United States)

LP007 Optimizing Alzheimer's Disease Clinical Trial Data for Facilitating Scientific Discovery
Kathleen A. Welsh-Bohmer [1], Stephen Haneline [2], Rebecca Wilgus [1], Jack Shostak [1], Haotian Zou [3], Sheng Luo [1], Michael Lutz [4], Brenda Plassman [4], Daniel K. Burns [2], Rebecca Li [5], Frank Rockhold [1], Matthew Clement [6], Tetsuyuki Maruyama [6]
[1]Duke Clinical Research Institute (DCRI) - Durham (United States); [2]Zinfandel - Chapel Hill (United States); [3]UNC-Chapel Hill - Chapel Hill (United States); [4]Duke University - Durham (United States); [5]Vivli - Cambridge (United States); [6]Alzheimer's Disease Data Initiative (ADDI) - Kirkland (United States)

LP008 Incorporating the Study Participant's Voice into Early Development of ACU193 for Early Alzheimer's Disease: A Qualitative Interview Study Following Participation in the INTERCEPT-AD Study
Kelly Johnston [1], Victoria Brown [1], Carrie Presnall [1], Elizabeth Merikle [1], Stephanie Cline [2], Todd Feaster [2]
[1]Fortrea, Inc. - Durham (United States); [2]Acumen Pharmaceuticals - Charlottesville (United States)

POSTER PRESENTATIONS

LP009 Reducing screen failure rates due to biomarker cut-offs in early Alzheimer's disease trials using a prognostic model

Angela Tam [1], César Laurent [1], Christian Dansereau [1]
[1]Perceiv AI - Montreal (Canada)

LP010 Rationale and design of a Phase 2b trial to evaluate the efficacy of a specific inhibitor of 11β-HSD1, Xanamem®, in mild and moderate AD

Dana Hilt [1], Jack Taylor [1], Tamara Miller [1], John Harrison [2, 3, 4], Christopher Chen [5], Craig Ritchie [2]
[1]Actinogen Medical - Sydney (Australia), [2]Scottish Brain Sciences - Edinburgh (United Kingdom), [3]King's College - London (United Kingdom), [4]Alzheimercentrum, AUmc - Amsterdam (Netherlands), [5]Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore)

LP011 Impact of a Site Supplemental Funding Program to Alleviate Recruitment Burden: Experiences in the Preclinical Alzheimer's Disease AHEAD Study

Leona K Shum [1], Rema Raman [1], Oliver Langford [1], Victoria Salcedo [1], Andy Liu [1], Reisa Sperling [2, 3], Joshua D Grill [4], Crystal M Glover [5, 6, 7], Paul Aisen [1], Keith Johnson [2, 3], Shobha Dhadda [8], Michael Irizarry [8], Doris Molina-Henry [1]
[1]Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), [2]Brigham and Women's Hospital, Harvard Medical School - Boston, Ma (United States), [3]Massachusetts General Hospital, Harvard Medical School - Boston, Ma (United States), [4]University of California, Irvine - Irvine, Ca (United States), [5]Department of Neurological Sciences, Rush Medical College - Chicago, Il (United States), [6]Department of Psychiatry and Behavioral Sciences, Rush Medical College - Chicago, Il (United States), [7]Rush Alzheimer's Disease Center - Chicago, Il (United States), [8]Eisai Inc. - Nutley, Nj (United States)

LP012 Establishing an evidence-based patient recruitment strategy through a site recruitment needs assessment for a hospice-eligible population with dementia

Karla López Aguiñiga [1], Arianne Zokas Fritts [2], Jacobo Mintzer [2], Brigid Reynolds [3], Melanie Chadwick [3], Olga Brawman-Mintzer [4], Gregory Jicha [5], Mark Kindy [6], Branko Huisa-Garate [7], Jeffrey Keller [8], Taylor Clanton [1], Brendon Smith [1], Joshua D. Grill [9], Paul Aisen [1], Rema Raman [1]
[1]Alzheimer's Therapeutic Research Institute (ATRI) - San Diego (United States), [2]Medical University of South Carolina - Charleston (United States), [3]Georgetown University - District Of Columbia (United States), [4]Ralph H. Johnson Veteran Affairs Medical Center - Charleston (United States), [5]University of Kentucky - Lexington (United States), [6]University of South Florida - Tampa (United States), [7]The Neuron Clinic - San Marcos (United States), [8]Pennington Biomedical Research Center - Baton Rouge (United States), [9]University of California, Irvine - San Diego (United States)

LP013 Inviting Diverse Communities to Clinical Research Participation through Medical Record Retrieval and Review

Katie King [1], Erin Beck [2]
[1]Biogen - Wilmington (United States minor outlying islands), [2]SiteRx - New York (United States minor outlying islands)

LP014 Addressing Representative Alzheimer's Disease Enrollment in Clinical Research via Real-World Conversion Analysis across the Recruitment Funnel

Michael Stalder [1]
[1]SiteRx - New York (United States)

LP015 Examining the role of community engagement in enhancing the participation of minoritized communities in Alzheimer's disease clinical trials; a rapid review

Sanaz Dabiri [1], Doris Molina-Henry [1]
[1]Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

LP016 Developing a Screening Platform for Early-Phase Clinical Trials to Prevent AD (The EPIICH Platform)

Gene Bowman [1], Hira Shrestha [1], Hiroko Dodge [2], Jody-Lynn Lupo [3], Jeremiah Momper [4], James Silverman [3], Carolyn Revta [3], Kevin Rynearson [5], Steven Edland [5], Jonathan Rosand [6], Steven Arnold [2], Howard Feldman [7], Rudolph Tanzi [1]
[1]McCance Center for Brain Health, Clinical Trials Unit and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - Boston (United States), [2]Interdisciplinary Brain Center, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - Boston (United States), [3]Alzheimer's Disease Cooperative Study, University of California San Diego - San Diego (United States), [4]Department of Pharmacology, University of California San Diego - San Diego (United States), [5]Department of Neurosciences, University of California San Diego - San Diego (United States), [6]McCance Center for Brain Health, Clinical Trials Unit, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - San Diego (United States), [7]Alzheimer's Disease Cooperative Study and Department of Neurosciences, University of California San Diego - San Diego (United States)

THEME: Clinical Trials: Results

P031 Combined exercise and cognitive interventions for adults with mild cognitive impairment and dementia: A systematic review and network meta-analysis

Dandan Xue [1], Polly W.c. Li [1], Doris S.f. Yu [1], Rose S.y. Lin [2], Yuewen Lao [3]
[1]School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong - Hong Kong (Hong Kong), [2]University of Rochester School of Nursing, New York, USA - New York (United States), [3]Sir Run Run Shaw Hospital, Zhejiang University School of Medicine - Hangzhou (China)

P032 Planning the next generation of Alzheimer's Disease clinical trials using diverse patient-level database from the Critical Path for Alzheimer's Disease (CPAD) Consortium

Sudhir Sivakumaran [1], Nicholas Cullen [1], Eileen Priest [1], Corissa Lau [1], Hazel White [1], Michael Irizarry [2], Klaus Romero [1], Yashmin Karten [1]
[1]Critical Path Institute - Tucson (United States), [2]Eisai Inc. - Nutley (United States)

POSTER PRESENTATIONS

P033   **Critical Path for Alzheimer's Disease (CPAD) Consortium: Data-Driven Solutions for Clinical Trial Design and Informed Decision Making**

Sudhir Sivakumaran [1], Nicholas Cullen [1], Corissa Lau [1], Eileen Priest [1], Hazel White [1], Michael Irizarry [2], Gregory Klein [3], Klaus Romero [1], Antoine Leuzy [1, 4, 5], Yashmin Karten [1]
[1]Critical Path Institute - Tucson (United States), [2]Eisai Inc. - Nutley (United States), [3]F. Hoffmann-La Roche Ltd - Basel (Switzerland), [4]Lund University - Malmo (Sweden), [5]Enigma Biomedical USA - Knoxville (United States)

P034   **Combination Treatment of a Novel β2 Adrenoceptor Agonist, CST-2032, and Nadolol Improves Cognitive. Measures in Patients with Alzheimer's Disease**

John Harrison [1], Renee Martin [2], Peter Butera [2], Judy Reynolds [2], Anthony Ford [2], Gabriel Vargas [2]
[1]Institute of Psychiatry, Psychology & Neuroscience King's College London - London (United Kingdom), [2]CuraSen Therapeutics - San Carlos (United States)

P035   **Safety and Feasibility Trial of Dapagliflozin in Early Alzheimer's Disease**

Jeffrey Burns [1], Jill Morris [1], Eric Vidoni [1], Heather Wilkins [1], In-Young Choi [1], Phil Lee [1], Suzanne Hunt [1], Jonathan Mahnken [1], William Brooks [1], Rebecca Lepping [1], Peter Adany [1], Aditi Gupta [1], Russell Swerdlow [1]
[1]University Of Kansas Alzheimer's Disease Center - Kansas City (United States)

P036   **Phase 3 Clinical Studies in Alzheimer's and Parkinson's disease; Interim Analysis and FDA guidance for both indications**

Cheng Fang [1], Eve Damiano [1], Melissa Gaines [1], Michele Shaffer [2], Anne-Marie Nagy [3], Laurie Sanders [4], Maria Maccecchini [1]
[1]Annovis Bio - Berwyn (United States), [2]Wuxi - Austin (United States), [3]TFS - Lund (Sweden), [4]DCRI - Durham (United States)

🖥 **P037**   **Safety, tolerability, and pharmacokinetics findings in a Phase 1 single dose study of donanemab in healthy Chinese participants**

Yimin Cui [1], Rihan Wu [2], Ivelina Gueorguieva [3], Chenxi Qian [2], Junyu Xu [1]
[1]Peking University First Hospital - Beijing (China), [2]Eli Lilly and Company - Shanghai (China), [3]Eli Lilly and Company - Bracknell (United Kingdom)

P038   **Safety of higher doses of gantenerumab in the open-label extension of the dominantly inherited Alzheimer's Network trials unit (DIAN–TU-001 trial)**

Jorge Llibre-Guerra [1], Nelly Joseph-Mathurin [1], Yan Li [1], Guoqiao Wang [1], Andrew Aschenbrenner [1], Xiong Chengjie [1], Brian Gordon [1], Janice Hitchcock [2], Richard Perrin [1], Carsten Hofmann [3], Jakub Wojtowicz [4], Atri Alireza [5], Eric Mcdade [1], Randall Bateman [1], David Clifford [1]
[1]Washington University School Of Medicine In St.louis - St. Louis (United States), [2]Hitchcock Regulatory Consulting, Inc - St. Louis (United States), [3]Roche Innovation Center Basel - Basel (Switzerland), [4]F. Hoffmann-La Roche Ltd - Basel (Switzerland), [5]Banner Sun Health Research Institute - Sun, Arizona (United States)

P039   **A Single Ascending Dose Study of ABBV-916, an Anti-Amyloid Antibody, in Healthy Volunteers**

Sagar Bachhav [1], Hana Florian [2], Joey Boiser [3], Yamin Wang [4], Dee-Dee Shiller [1], Shau Yu Lynch [2], Ole Graff [2], Hao Xiong [1]
[1]Clinical Pharmacology, AbbVie Inc - North Chicago (United States), [2]Neuroscience Clinical Development, AbbVie Inc - North Chicago (United States), [3]Pharmacovigilance and Patient Safety, AbbVie Inc - North Chicago (United States), [4]Statistics, AbbVie Inc - North Chicago (United States)

🖥 **P040**   **Efficacy of anti-amyloid-ß monoclonal antibody therapy in prodromal versus mild dementia due to Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials**

Julyana Dantas [1], Pedro Romeiro [2], Caroline Dagostin [3], Nicole Felix [4], Denilsa Navalha [5], Antonio Mutarelli [6], Paulo Caramelli [7], Sávio Batista [8], Larissa Teixeira [9]
[1]Federal University of Rio Grande do Norte - Natal (Brazil), [2]University Center Tiradentes - Maceió (Brazil), [3]University of the Extreme South of Santa Catarina - Criciúma (Brazil), [4]Federal University of Campina Grande - Campina Grande (Brazil), [5]Eduardo Mondlane University - Maputo (Mozambique), [6]Federal University of Minas Gerais - Belo Horizonte (Brazil), [7]Behavioral and Cognitive Neurology Unit, Federal University of Minas Gerais - Belo Horizonte (Brazil), [8]Universidade Federal do Rio de Janeiro, - Rio de Janeiro (Brazil), [9]Universidade Federal de Campina Grande - Campina Grande (Brazil)

P041   **High adherence and tolerability of a sensory stimulation system in a 6-month sham-controlled clinical trial in Alzheimer's disease**

Chandran V Seshagiri [1], Zach Malchano [1], Alyssa Boasso [1], Mihály Hajós [1], Evan Hempel [1], Kahlil G Saikali [1], Brent Vaughan [1], Ralph Kern [1]
[1]Cognito Therapeutics - Cambridge (United States)

P043   **Effect of ALZ-801 (Valiltramiprosate), an Oral Inhibitor of Amyloid Oligomer Formation, on Plasma Biomarkers, Volumetric Brain Imaging Biomarkers, and Clinical Outcomes of Alzheimer's Disease: 12-Month Results of Phase 2 Biomarker Study in Early AD APOE4 Carrier Subjects**

John Hey [1], Susan Abushakra [1], Philip Scheltens [2], Jakub Hort [3], Katerina Sheardova [4,5], Ladislav Pazdera [6], Niels Prins [7], Sterre Rutgers [7], Paul Dautzenberg [7], Jeremy Yu [1], Patrick Kesslak [1], Luc Bracoud [8], Aidan Power [1], Joyce Suhy [8], Martin Tolar [1]
[1]Alzheon - Framingham (United States), [2]Amsterdam University Medical Centers, Alzheimer Center - Amsterdam (Netherlands), [3]Charles University Department of Neurology - Brno (Czech Republic), [4]Memory Center, St. Anne University Hospital - Brno (Czech Republic), [5]International Clinical Research Center - Brno (Czech Republic), [6]Vestra Research Clinics - Rychnov And Knĕžnou (Czech Republic), [7]Brain Research Center - Den Bosch (Netherlands), [8]Clario, Inc. - San Mateo (United States)

P044   **Safety and pharmacokinetics of multiple ascending doses of E2511, a novel TrkA allosteric modulator, in healthy volunteers**

Natasha Penner [1], Nancy Hall [1], Cuiyuan Cai [2], Masaki Mikamoto [2], Jagadeesh Aluri [1], Takuya Yagi [1], Julia Chang [1], Ali Ardati [1], Steve Hersch [1], Luigi Giorgi [3], Larisa Reyderman [1]
[1]Eisai - Nutley (United States), [2]Eisai - Tsukuba (Japan), [3]Eisai - Hatfield (United Kingdom)

POSTER PRESENTATIONS

PO45   **ARIA by Clinical Subgroup and Baseline Amyloid PET Centiloid Levels from the Lecanemab Clarity AD Study**

Marwan Sabbagh [1], David Li [2], Shobha Dhadda [2], Michael Irizarry [2], Steve Hersch [2], Luigi Giorgi [2], Andre Matta [3], Lynn Kramer [2]
[1]Barrow Neurological Institute - Phoenix (United States), [2]Eisai Inc - Nutley (United States), [3]Eisai Co., Inc - Hatfield (United Kingdom)

LP017   **A Phase 1b Double Blind Multiple Ascending Dose Study of the Safety and Pharmacokinetics of NTRX-07 in Normal Volunteers and Patients with Mild Cognitive Impairment or Early Alzheimer's Disease**

Joseph Foss [1], Tony Giordano [1], Mariana Kiraly [1]
[1]NeuroTherapia, Inc. - Cleveland (United States)

LP018   **Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer's disease**

Philip Scheltens [1], Alireza Atri [2,3,4], Howard H. Feldman [5], Oskar Hansson [6,7], Filip K. Knop [8,9,10,11], Mary Sano [12,13], Claus Dethlefsen [14], Peter Johannsen [14], Teresa León Colombo [15], Charlotte T. Hansen [14], Jeffrey Cummings [16]
[1]Alzheimer Centre, VU University Medical Center Amsterdam - Amsterdam (Netherlands), [2]Banner Sun Health Research Institute - Sun City, Az (United States), [3]Banner Alzheimer's Institute - Phoenix, Az (United States), [4]Brigham and Women's Hospital, Harvard Medical School - Boston, Ma (United States), [5]Alzheimer's Disease Cooperative Study, Department of Neurosciences University of California San Diego - La Jolla, Ca (United States), [6]Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), [7]Memory Clinic, Skåne University Hospital - Malmö (Sweden), [8]Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen - Hellerup (Denmark), [9]Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), [10]Steno Diabetes Center Copenhagen - Herlev (Denmark), [11]Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), [12]Icahn School of Medicine at Mount Sinai - New York, Ny (United States), [13]James J Peters VAMC - Bronx Ny (United States), [14]Novo Nordisk A/S - Søborg (Denmark), [15]Novo Nordisk A/S - Madrid (Spain), [16]University of Nevada - Las Vegas, Nv (United States)

LP019   **The Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (BRAVE) Study**

Carol Van Hulle [1], Hanna Zylstra [1], Kate Cronin [1], Aleshia Cole [1], Elena Beckman [1], Allison Eierman [2], Madeleine Blazel [3], Karen Lazar [1], Kevin Johnson [1], Leonardo Rivera [1], Carey Gleason [1], Henrik Zetterberg [4], Sterling Johnson [1], Cynthia Carlsson [1]
[1]University of Wisconsin-Madison - Madison (United States), [2]Medical College of Wisconsin-Green Bay - Green By (United States), [3]Case Western Reserve University School of Medicine - Cleveland Ohio (United States), [4]Sahlgrenska Academy - Moldal (Sweden)

LP020   **Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease and Major Depressive Disorder**

Lloyd Tran [1], Zung Tran [1]
[1]Biomed Industries, Inc. - San Jose (United States)

LP022   **RetiSpec's AI-based retinal test: Results of a multi-site, prospective, validation study to predict brain Aβ pathology in a diverse population of adults with Preclinical, MCI, and Probable Alzheimer's disease**

Alon Hazan [1], Catherine Bornbaum [1], Eliav Shaked [1], Jennifer Giordano [1], Yochai Edlitz [2,3], David He [4], Diana Kerwin [5]
[1]RetiSpec - Toronto (Canada), [2]Weizmann Institute of Science - Rehovot (Israel), [3]MLAIA Data Science - Tel Aviv (Israel), [4]Analytical Solutions Group, Inc. - North Pontomac (United States), [5]Kerwin Medical Center - Dallas (United States)

LP023   **Dopaminergic Therapy for Frontotemporal Dementia Patients: preliminary results from a phase 2 multi-site, Randomized Clinical Trial**

Martina Assogna [1,2], Francesco Di Lorenzo [1], Sonia Bonnì [1], ALPerto Benussi [3], Ilaria Borghi [1], Emanuele Cerulli Irelli [4], Enrico Premi [3], Valentina Cantoni [3], Valentina Pezzopane [1], Lucia Mencarelli [1], Caterina Motta [2], Clarissa Ferrari [5], Martorana Alessandro [2], Giacomo Koch [1,6]
[1]Department of Clinical and Behavioural Neurology,Santa Lucia Foundation - Rome (Italy), [2]Memory Clinic, Department of Systems Medicine, University of Tor Vergata, - Rome (Italy), [3]Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, - Brescia (Italy), [4]Department of Human Neurosciences, Sapienza, University of Rome - Rome (Italy), [5]Office of Research and Clinical Trials, Fondazione Poliambulanza Istituto Ospedaliero, - Brescia (Italy), [6]Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT), - Ferrara (Italy)

LP024   **RESULTS FROM: A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimer's Disease**

Willem De Haan [1,2], Anthony Caggiano [3], Philip Scheltens [4], Michael Grundman [5], Elliz Scheijbeler [1,2], Mary Hamby [3], Everard Vijverberg [1]
[1]Department of Clinical Neurophysiology and MEG Center, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [2]Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), [3]Cognition Therapeutics - Purchase (United States), [4]EQT Group - Amsterdam (Netherlands), [5]Global R&D Partners and Department of Neurosciences, University of California - San Diego (United States)

LP025   **Palmitoylethanolamide Combined with Luteoline in Frontotemporal Dementia patients (PEA-FTD): A phase 2 Randomized Clinical Trial**

Martina Assogna [1], Francesco Di Lorenzo [1], Sonia Bonnì [1], Ilaria Borghi [1], Emanuele Cerulli Irelli [2], Lucia Mencarelli [1], Michele Maiella [1], Elias Paolo Casula [1], Valentina Pezzopane [1], Caterina Motta [3], Clarissa Ferrari [4], Carlo Caltagirone [1], Martorana Alessandro [5], Giacomo Koch [1,6]
[1]Department of Clinical and Behavioural Neurology,Santa Lucia Foundation - Rome (Italy), [2]Department of Human Neurosciences, Sapienza, University of Rome - Rome (Italy), [3]Memory Clinic,University of Tor Vergata, - Rome (Italy), [4]Office of Research and Clinical Trials, Fondazione Poliambulanza Istituto Ospedaliero, - Brescia (Italy), [5]Memory Clinic, Department of Systems Medicine, University of Tor Vergata - Rome (Italy), [6]Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT), - Ferrara (Italy)

LP026 OVERTURE Open-Label Extension Data Confirms Safety, Adherence and Durability of Treatment Benefits over 18 Months
Ralph Kern [1], Colin Kuang [1], Mihaly Hajos [1], Alex Konisky [1], Alyssa Boasso [1], Evan Hempel [1], Brent Vaughan [1], Chandran Seshagiri [1], Zach Malchano [1], Suzanne Hendrix [2], Khalil Saikali [1]
[1]Cognito Therapeutics - Cambridge (United States), [2]Pentara Corporation - Salt Lake City (United States)

LP027 Baseline risk factors for ARIA-E in the GRADUATE I and II studies of gantenerumab
Paul Delmar [1], Nicola Voyle [2], Michael Grundman [3], Stephen Salloway [4], Jakub Wojtowicz [1], Marco Lyons [2], Christopher Lane [2], Angeliki Thanasopoulou [1], Simona Rossomanno [1], Szofia Bullain [1], Gregory Klein [1], Tobias Bittner [5], Andres Schneider [1], Janice Smith [2], Rachelle Doody [5]
[1]F. Hoffmann-La Roche Ltd - Basel (Switzerland), [2]Roche Products Ltd - Welwyn Garden City (United Kingdom), [3]Global R&D Partners, LLC and Dept. of Neurosciences, University of California - San Diego (United States), [4]Butler Hospital and Warren Alpert Medical School of Brown University - Providence (United States), [5]F. Hoffmann-La Roche Ltd and Genentech, Inc. - Basel (Switzerland)

LP028 Donanemab: Characterization of immunogenicity from the TRAILBLAZER-ALZ & TRAILBLAZER-ALZ 2 trials
Garrett Mullins [1], Paul Ardayfio [1], Ivelina Gueorguieva [1], Greg Anglin [1], Jason Bailey [1], Laiyi Chua [1], Jennifer Zimmer [1], Cynthia Evans [1], Emel Nery [1], Hong Wang [1], Rashna Khanna [1], Dawn Brooks [1], John Sims [1]
[1]Eli Lilly and Company - Indianapolis (United States)

LP029 Donanemab: Characterizing infusion-related reactions from TRAILBLAZER-ALZ & TRAILBLAZER-ALZ 2
Paul Ardayfio [1], Garrett Mullins [1], Jennifer Zimmer [1], Cynthia Evans [1], Greg Anglin [1], Ivelina Gueorguieva [1], Emel Nery [1], Hong Wang [1], Rashna Khanna [1], Dawn Brooks [1], John Sims [1]
[1]Eli Lilly and Company - Indianapolis (United States)

LP030 Cerebral Amyloid Angiopathy and Comorbid Cardiovascular Risk Factors in APOE4/4 Homozygotes with Early Alzheimer's Disease: Baseline Results from APOLLOE4 Phase 3 Trial of Oral Anti-Amyloid Agent ALZ-801
Rosalind Mclaine [1], Earvin Liang [1], Susan Abushakra [1], David Watson [2], Merce Boada [3], Sharon Cohen [4], Marwan Sabbagh [5], Aidan Power [1], Susan Flint [1], Winnie Pak [1], John Hey [1], Martin Tolar [1]
[1]Alzheon, Inc. - Framingham (United States), [2]Alzheimer's Research and Treatment Center - Wellington (United States), [3]Ace Alzheimer's Center - Barcelona (Spain), [4]Toronto Memory Program - Toronto (Canada), [5]Barrow Neurolgical Institute - Phoenix (United States)

LP031 ACI-35.030 anti-phospho-Tau active immunotherapy for the treatment of early Alzheimer's Disease (AD): Update from the Phase 1b/2a study data and perspectives.
Olivier Sol [1], Johannes Streffer [2], Julien Mermoud [1], Marija Vukicevic [1], Eva Gollwitzer [1], David Hickman [1], Valérie Hliva [1], Julian Gray [1], Lennert Steukers [3], Lingjue Li [4], Andrea Pfeifer [1], Marie Kosco-ViLPois [1], Philip Scheltens [5]
[1]AC Immune SA - Lausanne (Switzerland), [2]University of Antwerp - Antwerp (Belgium), [3]Janssen - Beerse (Belgium), [4]Janssen - New Jersey (United States), [5]Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, VUmc - Amsterdam (Netherlands)

LP033 ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive Assay of Target Engagement for the sAβO-Selective Antibody ACU193 in INTERCEPT-AD
Erika Cline [1], Jerome Moore [1], Hao Zhang [1], Gopalan Sethuraman [1], Eric Siemers [1], Robert Dean [1], Jasna Jerecic [1]
[1]Acumen Pharmaceuticals - Charlottesville (United States)

LP034 INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer's disease
Hao Zhang [1], Jerome Moore [1,2], Erika Cline [1], Mahsan Rafizadeh [1], Eric Siemers [1], Robert Dean [1,3], Jasna Jerecic [1]
[1]Acumen Pharmaceuticals - Charlottesville (United States), [2]Pacific BioDevelopment - Davis (United States), [3]Department of Pathology & Laboratory Medicine, Indiana University School of Medicine - Indianapolis (United States)

THEME: Clinical Trials: Imaging

P046 Brain structure-allelic associations and networks in Alzheimer's disease
Seokwoo Moon [1]
[1]Konkuk University Chungju Hospital - Chungju (Korea, Republic of)

P047 Impact of anodal transcranial direct current stimulation on white matter microstructure integrity in mild cognitive impairment patients according to effect modifiers as risk factors for Alzheimer's disease
Dong Woo Kang [1]
[1]Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)

POSTER PRESENTATIONS

P048   Measuring changes in longitudinal Tau-PET with [18F]MK-6240: group-level vs individualized ROIs definition

Nick Sidorenko [1], Matteo Tonietto [1], Antoine Leuzy [2], Gregory Klein [1]

[1]Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), [2]Clinical Memory Research Unit, Department of Clinical Sciences, Lund University - Malmö (Sweden)

P049   Regional Aβ-tau interactions can predict individual-level time periods of the optimal therapeutic window for amyloid-lowering treatments

Gilhwan Lim [1], Hanna Cho [2], Chul Hyoung Lyoo [2], Joon-Kyung Seong [1, 3, 4, 5], Wha Jin Lee [1], ADNI: Alzheimer's Disease Neuroimaging Initiative [6]

[1]NeuroXT - Seoul (Korea, Republic of), [2]Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), [3]School of Biomedical Engineering, Korea University - Seoul (Korea, Republic of), [4]Department of Artificial Intelligence, Korea University - Seoul (Korea, Republic of), [5]Interdisciplinary Program in Precision Public Health, Korea University - Seoul (Korea, Republic of), [6]Alzheimer's Disease Neuroimaging Initiative - Los Angeles (United States)

P050   Utility of [18F]PI-2620 PET in clinical trials: insights into tau pathology deposition in Down Syndrome

Isabel Barroeta [1], Jordi Pegueroles [1], Victor Montal [1], Mateus Rozalem [1], Alejandra Morcillo [1], Sara Zsadanyi [1], Lidia Vaque [1], Bessy Benejam [1], Laura Videla [1], Maria Carmona-Iraqui [1], Alexandre Bejanin [1], Valle Camacho [2], Albert Flotats [2], Alberto Lleo [1], Juan Fortea [1]

[1]Unidad de Memoria, Servicio de Neurología, Institut d'Investigacions Biomèdiques Sant Pau, Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona, Barcelona - Barcelona (Spain), [2]Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain - Barcelona (Spain)

P051   Automated brain MRI segmentation using a novel AI-based method

Thomas Cajgfinger [1], Joël Schaerer [1], Po-Han Chen [2], Chris Conklin [3], Madhura Ingalhalikar [3], David Scott [4], Joyce Suhy [4], Luc Bracoud [1]

[1]Clario - Lyon (France), [2]Clario - Estenfeld (Germany), [3]Clario - Philadelphia (United States), [4]Clario - San Mateo (United States)

P052   Assessing the Relationship Between Central Cholinergic Integrity and Amyloid Accumulation in Individuals with Down Syndrome Using [18F]-FEOBV and [11C]-PiB PET: Preliminary Data

Jason K. Russell [1], Alexander C. Conley [1], Brian D. Boyd [1], Rachel Schlossberg [1], Adam J. Rosenberg [2], Lealani Mae Y. Acosta [1], Michael S. Rafii [3], Sepideh Shokouhi [1], Paul A. Newhouse [1, 4]

[1]Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center - Nashville (United States), [2]Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center - Nashville (United States), [3]Alzheimer's Therapeutic Research Institute and Department of Neurology, Keck School of Medicine, University of Southern California - San Diego (United States), [4]Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System - Nashville (United States)

P053   Minimizing sample sizes for trials using MK-6240: impact of reference and target tissues

John Becker [1], Cristina Lois [1], Emma Thibault [1], Grace Del Carmen Montenegro [1], Justin Sanchez [2], Brian Healy [3], Fang Fu [1], Julie Price [1], Georges El Fakhri [1], Keith Johnson [1]

[1]Massachusetts General Hospital - Boston (United States), [2]Washington University School of Medicine - St. Louis (United States), [3]Harvard T.H. Chan School of Public Health - Boston (United States)

P054   Cerebral Amyloid Angiopathy in APOE4/4 Homozygotes with Alzheimer's Disease: Baseline Characteristics of Subjects Enrolled in APOLLOE4 Phase 3 Trial of Oral ALZ-801 in Early AD

Rosalind Mclaine [1], Susan Abushakra [1], Earvin Liang [1], Jerome Barakos [2], Aidan Power [1], David Watson [3], Emer Macsweeney [4], Anton Porsteinsson [5], Joyce Suhy [6], John Hey [1], Martin Tolar [1]

[1]Alzheon, Inc. - Framingham (United States), [2]California Pacific Medical Center & Clario - San Francisco (United States), [3]Alzheimer's Research and Treatment Center - Wellington (United States), [4]Re:Cognition Health - London (United Kingdom), [5]University of Rochester School of Medicine and Dentistry - Rochester (United States), [6]Clario - San Mateo (United States)

P055   Changes in cortical microstructure in brain regions associated with cognitive status and disease duration after short-term treatment with XPro1595 for Alzheimer's disease

Parris Pope [1], Christopher Barnum [1], Raymond Tesi [1], Tom Soeder [2]

[1]INmune Bio, Inc. - Boca Raton (United States), [2]Allucent - Cary (United States)

P056   Association of cholinergic integrity to age, amyloid, cortical volume and cognitive performance in healthy postmenopausal women using [18F]-FEOBV PET

Alexander Conley [1], Jason Russell [1], Brian Boyd [1], Tonnar Castellano [1], Adam Rosenberg [2], Brittany Bosko [1], Julie Dumas [3], Paul Newhouse [1, 4]

[1]Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center - Nashville (United States), [2]Department of Radiology, Vanderbilt University Medical Center - Nashbille (United States), [3]Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont Larner College of Medicine - Burlington (United States), [4]Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System - Nashville (United States)

P057   Real-world implementation of patient stratification with faster cognitive decline using MRI-based prediction of regional tau positivity

Yeong-Hun Song [1], Wha Jin Lee [2], Joon-Kyung Seong [1]

[1]Korea University - Seoul (Korea, Republic of), [2]NeuroXT - Seoul (Korea, Republic of)

P058

Association of amyloid PET burden with longitudinal cognitive decline in a heterogeneous alzheimer's disease research cohort

Emily Johns [1], Kyan Younes [1], Shubhabrata Mukherjee [2], Christina B. Young [1], Jesse Mez [3], Timothy J. Hohman [4], Duygu Tosun [5], Sarah Biber [6], Walter A. Kukull [6], Paul Crane [2], Elizabeth C. Mormino [1]

[1]Department of Neurology and Neurological Sciences, Stanford University - Palo Alto (United States), [2]Department of Medicine, The University of Washington - Seattle (United States), [3]Department of Neurology, Boston University - Boston (United States), [4]Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center - Nashville (United States), [5]Department of Radiology and Biomedical Imaging, University of California, San Francisco - San Francisco (United States), [6]Department of Epidemiology, National Alzheimer's Coordinating Center, University of Washington - Seattle (United States)

P059

Stress-Testing the Centiloid Concept: Validation of the Between-Tracer Accuracy of the Centiloid Method in an Independent Cohort

Juan Domingo Gispert [1,2,3], David Vállez García [4], Lyduine.e Collij [4], Mahnaz Shekari [1,2,5], Lucca Presotto [6,7], Richard Manber [7], Robin Wolz [7,8], Henrik Zetterberg [9,10,11,12], Kaj Blennow [13,14], Andrew Stephens [15], Gill Farrar [16], Pieter-Jelle Visser [17,18,19], Craig Ritchie [20], Frederik Barkhof [4,21]

[1]Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation. Barcelona, Spain - Barcelona (Spain), [2]IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain - Barcelona (Spain), [3]Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, Spain - Barcelona (Spain), [4]Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117, Amsterdam, Netherlands & - Amsterdam (Netherlands), [5]Universitat Pompeu Fabra, Barcelona, Spain - Barcelona (Spain), [6]University of Milano-Bicocca - Milan (Italy), [7]IXICO, London, UK - London (United Kingdom), [8]Imperial College, London, UK - London (United Kingdom), [9]Dementia Research Institute, University College London, London, UK. - London (United Kingdom), [10]Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK. - London (United Kingdom), [11]Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China. - Hong Kong (China), [12]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. - Gothenburg (Sweden), [13]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden. - Gothenburg (Sweden), [14]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. - Mölndal (Sweden), [15]Life Molecular Imaging GmbH, Berlin, Germany - Berlin (Germany), [16]GE Healthcare Pharmaceutical Diagnostics, UK - Amersham (United Kingdom), [17]Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, Netherlands. - Maastricht (Netherlands), [18]Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam University Medical Center, VU Medical Center, Amsterdam, Netherlands. - Amsterdam (Netherlands), [19]Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden. - Stockholm (Sweden), [20]Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. - Edinbrugh (United Kingdom), [21]Institute of Neurology and Centre for Medical Image Computing, University College London, UK - London (United Kingdom)

P060

Estimating the time between Amyloid- and tau-PET positivity: Implications for Alzheimer's Disease Prevention trials

Alexis Moscoso [1], Fiona Heeman [1], Tora Dunås [1], Michael Schöll [1]

[1]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden)

P061

A Novel Tau Staging Scheme Using [18F]MK-6240 PET Visual Read Extent Scores

Eddie Stage [1], Dustin Wooten [1], John Seibyl [2], Nicholas Seneca [1], Anthony Bannon [1], Hana Florian [1], Robert Comley [1], Qi Guo [1]

[1]AbbVie - North Chicago (United States), [2]Institute for Neurodegenerative Disorders - New Haven (United States)

P062

Cortical microstructural changes associated with RBANS scores in cognitively unimpaired and MCI in the European Prevention of Alzheimer's Dementia (EPAD) study

Mario Torso [1], Ged Ridgway [1], Michele Valotti [1], Ian Hardingham [1], Steven Chance [1,2]

[1]Oxford Brain Diagnostics - Oxford (United Kingdom), [2]for the European Prevention of Alzheimer's Dementia (EPAD) Consortium

P063

Amyloid PET Scan Reads in IDEAS – Comparison of Local Clinician and Expert Reads

Charles Windon [1], Barry Siegel [2], Maria Carrillo [3], Constantine Gatsonis [4], Lucy Hanna [5], Bruce Hillner [6], Andrew March [7], Rachel Whitmer [8], Anupa Arora [9], Santiago Bullich [10], Christopher Buckley [11], Paul Sherwin [11], Gil Rabinovici [1]

[1]Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco - San Francisco (United States), [2]Mallinckrodt Institute of Radiology, Washington University in St Louis - St. Louis (United States), [3]Alzheimer's Association - Chicago (United States), [4]Department of Epidemiology and Biostatistics, Brown University School of Public Health - Providence (United States), [5]Center for Statistical Sciences, Brown University School of Public Health - Providence (United States), [6]Department of Medicine, Virginia Commonwealth University - Richmond (United States), [7]American College of Radiology - Reston (United States), [8]Department of Public Health Sciences, University of California, Davis - Davis (United States), [9]Avid Radiopharmaceuticals - Philadelphia (United States), [10]Life Molecular Imaging GmbH - Berlin (Germany), [11]GEHC - Massachusetts (United States)

LP035

Baseline Regional Flortaucipir Profiles in Preclinical Alzheimer's Disease

Vikas Kotari [1], Michael Case [1], Karen Holdridge [1], Roy Yaari [1], Aaron Schultz [2], Keith Johnson [3], Paul Aisen [4], Reisa Sperling [2], John Sims [1], Sergey Shcherbinin [1]

[1]Eli Lilly and Company - Indianapolis (United States), [2]Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), [3]Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), [4]Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - San Diego (United States)

LP036

Interim MRI safety analysis from a 76-week Phase 3 clinical trial of simufilam in Alzheimer's Disease

James Kupiec [1], Luc Bracoud [2], Joyce Suhy [3], Laura Rodriguez [1], Lindsay Burns [1]

[1]Cassava Sciences - Austin (United States), [2]Clario - Lyon (France), [3]Clario - San Mateo (United States)

LP037

Advancing Practicality for the Real-World Anti-Amyloid Treatment: Application of Solitaire T2-Fluid-Attenuated Inversion Recovery-Based Brain Volumetric Analysis Model

Hye Weon Kim [1], Zunhyan Rieu [1], Hyunji Lee [1], Min-Woo Lee [1], Jimin Kang [2], Won-Jin Moon [3]

[1]Research Institute, Neurophet Inc. - Seoul (Korea, Republic of), [2]Research Institute of Medical Science, Konkuk University of Medicine - Seoul (Korea, Republic of), [3]Department of Radiology, Konkuk University Medical Center - Seoul (Korea, Republic of)

POSTER PRESENTATIONS

LP038 Longitudinal Tau PET analysis pipeline with consistent progression measures across tracers and diagnoses in commonly used as well as subject-specific AD Regions of Interest

Ziad Saad [1], David Henley [2,3], Ritobrato Datta [1], Christopher Rowe [4], Hartmuth KoLP [1]
[1]Neuroscience Biomarkers and Global Imaging, Janssen R&D, Johnson & Johsnon - San Diego (United States), [2]Neuroscience Clinical Development, Janssen R&D, Johnson & Johsnon - San Diego (United States), [3]Indiana University School of Medicine, [4]Austin Health and University of MeLPourne - San Diego (United States)

LP039 The utility of [18F]FDG brain uptake to predict disease progression and estimations of sample and effect size compared to clinical scales to help guide clinical trial development plans

Nicholas Seneca [1], Eddie Stage [1], Sjoerd Finnema [1], Scott Gladstein [1]
[1]Abbvie - North Chicago (United States)

LP040 Stress Testing the CL concept: Validation of Generalizable Centiloid Cut-off Values in Two Large, Independent and Representative Clinical Alzheimer Cohorts

Juan Domingo Gispert [1,2,3], Christopher Buckley [4], Santiago Bullich [5], Daniele Altomare [6], Mahnaz Shekari [7,2,3], Lyduine Collij [8,9], David Vállez-García [8], Andrew Stephens [5], Gill Farrar [4], Andrew March [10], Renaud La Joie [11], Gil Rabinovici [11], Giovanni Frisoni [6], Frederik Barkhof [8]
[1]Barcelonaⓑeta Brain Research Center (BBRC), Pasqual Maragall Foundation. Barcelona, Spain - Barcelona (Spain), [2]IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), [3]Universitat Pompeu Fabra - Barcelona (Spain), [4]GE Healthcare Pharmaceutical Diagnostics - Amersham (United Kingdom), [5]Life Molecular Imaging GmbH - Berlin (Germany), [6]Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva - Geneva (Switzerland), [7]Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva - Barcelona (Spain), [8]Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117 - Amsterdam (Netherlands), [9] Clinical Memory Research, Lund University - Lund (Sweden), [10]American College of Radiology - Washington (United States), [11]Department of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco - San Francisco (United States)

LP041 Improved Differential Diagnosis of Hydrocephalus Ex Vacuo and Idiopathic Normal Pressure Hydrocephalus by Integrating Radscale and Dilatation of Perihippocampal Fissure

Jung-In Lim [1], Soyeong Lee [1], Minkyung Kim [2], Sun-Won Park [3], Jun-Young Lee [1], Jung-Hyo Rhim [2], Jee-Young Lee [4], Yu Kyeong Kim [5], Sang-Hyung Lee [6]
[1]Department of Psychiatry, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), [2]Seoul National University College of Medicine - Seoul (Korea, Republic of), [3]Department of Radiology, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), [4]Department of Neurology, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), [5]Department of Nuclear Medicine, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), [6]Department of Neurosurgery, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of)

LP042 Characterization of distortion correction on DTI measurements in a large multi-center clinical trial

Chris Conklin [1], Stefan Radonjic [1], Luc Bracoud [1], Madhura Ingalhalikar [1], Saima Rathore [2], Diana Otero Svaldi [2], Adam Fleisher [2], Dave Scott [1]
[1]Clario - Philadelphia (United States), [2]Eli Lilly and Company - Indianapolis (United States)

THEME: Clinical Trials: Biomarkers including plasma

P064 The ViewMind AI Solution (VIMAS) detects and characterises neurocognitive decline along the Alzheimer's disease continuum

Mario A. Parra [1], Francisco Lopera Restrepo [2], Gerardo Fernandez [3], Danilo Verge [4]
[1]University of Strathclyde - Glasgow (United Kingdom), [2]Grupo de Neurociencias - Antioquia (Colombia), [3]ViewMind - Bahia Blanca (Argentina), [4]ViewMind - West Chester (United States)

P065 Predicting cognitive stage transition using p-tau181, Centiloid, and other measures

Seong-Ho Koh [1], Hyuk Sung Kwon [1], Yongkyung Lee [1], Hyun-Jeung Yu [2], Seong Hye Choi [2], Hongil Kim [1]
[1]Hanyang University Guri Hospital - Guri (Korea, Republic of), [2]Bundang Jesaeng Hospital - Seongnam (Korea, Republic of)

P066 Relationship between brain amyloid deposition and regional electroencephalogram abnormalities in older adults

Woo Jung Kim [1], Jaesub Park [2]
[1]Yonsei University College of Medicine - Yongin-Si, Gyeonggi-Do (Korea, Republic of), [2]National Health Insurance Service Ilsan Hospital - Goyang-Si, Gyeonggi-Do (Korea, Republic of)

P067 Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults

Seong-Ho Koh [1], Hyun-Jeung Yu [2], Kee Hyung Park [3], Seong Hye Choi [4]
[1]Department of Neurology, College of Medicine, Hanyang University - Guri (Korea, Republic of), [2]Bundang Jesaeng Hospital - Seongnam (Korea, Republic of), [3]Department of Neurology, College of Medicine, Gachon University Gil Medical Center - Incheon (Korea, Republic of), [4]Department of Neurology, College of Medicine, Inha University Medical Center - Incheon (Korea, Republic of)

P068 Direct Comparison of Four Blood Plasma-Based Biomarkers in Preclinical Alzheimer's Disease

Peter Snyder [1], Jessica Alber [1], Andreas Jeromin [2], Lauren Chaby [2], Stuart Portbury [2], Louisa Thompson [3], Jennifer Strenger [4], Ashley Price [1]
[1]The University of Rhode Island - Kingston (United States), [2]ALZpath, Inc. - Carlsbad (United States), [3]Alpert Medical School of Brown University - Providence (United States), [4]Butler Hospital - Providence (United States)

P069 Blood RNAs as fluid biomarkers for the differentiation between Alzheimer's disease and dementia with Lewy bodies

Katrin Beyer [1], Jorge Mena [1], David Adamuz [1], Dolores Vilas [2], Ispierto Lourdes [2], Álvarez Ramiro [2], Pastor Pau [2]
[1]Research Institute Germans Trias i Pujol - Badalona (Spain), [2]Hospital Germans Trias i Pujol - Badalona (Spain)

POSTER PRESENTATIONS

P070 Systematic literature review of the clinical and non-clinical value of imaging and fluid biomarker testing to diagnose, identify and monitor patients with Alzheimer's Disease

Salwa Masud [1], Helen Hu [2], Sreeranjani Menon [1], Miya Strait [1], Christian Siegfried [1], Elizabeth Somers [2], Catheline Plaideau [1]
[1]Veranex - Boston (United States), [2]Eisai Inc. - Nutley (United States)

P071 Serum Tau-A and Tau-C levels and their association with cognitive impairment and dementia progression in a memory clinic derived cohort

Tobias Melton Axelsen [1,2,3], Peter Høgh [4,5], Asger Bihlet [6], Morten Asser Karsdal [2], Kim Henriksen [2], Steen Gregers Hasselbalch [7], Anja Hviid Simonsen [7,5]
[1]Department of Biomedical Sciences, University of Copenhagen - Copenhagen (Denmark), [2]Nordic Bioscience - Herlev (Denmark), [3]Sanos Clinic, Herlev, Denmark - Herlev (Denmark), [4]Regional Dementia Research Centre, Department of Neurology, Zealand University Hospital - Roskilde (Denmark), [5]Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), [6]NBCD - Søborg (Denmark), [7]Danish Dementia Research Centre (DDRC), Department of Neurology, Rigshospitalet - Copenhagen (Denmark)

P072 Biomarker responses to gamma sensory stimulation in Alzheimer's disease patients assessed in HOPE clinical trial

Mihaly Hajos [1], Monika Shpokayte [1], Celine Houser [1], Evan Hempel [1], Chandran Seshagiri [1], Alyssa Galley [1], Zach Malchano [1], Ralph Kern [1]
[1]Cognito Therapeutics - Cambridge (United States)

P073 A robust and specific ELISA for N-acetylated VAMP-2, a novel synaptic biomarker for Alzheimer's disease in CSF

Charlotte De Rocker [1], Julie Goossens [1], Alba Cervantes Gonzalez [2], Alberto Lleo [2], Olivia Belbin [2], Eugeen Vanmechelen [1]
[1]ADx NeuroSciences - Gent(-Zwijnaarde) (Belgium), [2]CIBERNED - Madrid (Spain)

P074 Alzheimer's disease and microbiota: the MICMALZ cohort

Germain Ulysse Busto [1,2], Linda-Nora Mekki [3], Sylvaine Artero [3], Yves Dauvilliers [4,2], Audrey Gabelle [1], Karim Bennys [1,2], Sylvie Claeysen [1]
[1]Resource and Research Memory Center (CMRR), Department of Neurology, Montpellier University Hospital - Montpellier (France), [2]University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), - Montpellier (France), [3]The Institute of Functional Genomics (IGF), University of Montpellier, CNRS, INSERM, Montpellier, France - Montpellier (France), [4]Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital - Montpellier (France)

P075 Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer's Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812

Britney Lizama [1], Eunah Cho [1], Duc Duong [2], Kiran Pandey [3], Claire Williams [1], Anthony Caggiano [1], Nicholas Seyfried [2], Valentina Di Caro [1], Mary Hamby [1]
[1]Cognition Therapeutics, Inc - Pittsburgh (United States), [2]Emory University School of Medicine - Atlanta (United States), [3]Emtherapro, Inc. - Atlanta (United States)

P076 Associations between the NIH Toolbox Emotion Battery and Tau Pathology in Preclinical Alzheimer's Disease: Analysis of data from the multi-site ARMADA study

Kexin Yu [1], Jennifer Gatchel [2], Emily Ho [3], Steven Arnold [4], Hiroko Dodge [4]
[1]Layton Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health & Science University - Portland (United States), [2]Department of Psychiatry, Massachusetts General Hospital/McLean Hospital, Harvard Medical School - Boston (United States), [3]Department of Medical Social Sciences, Northwestern University - Evanston (United States), [4]Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)

P077 Plasma protein markers to screen for blood-brain barrier dysfunction in Alzheimer's disease.

Betty Tijms [1]
[1]Amsterdam UMC - Amsterdam (Netherlands)

P078 A novel plasma CNS-derived tTau assay for detection of amyloid positivity in Alzheimer's Disease

Gallen Triana-Baltzer [1], Antonella Scaglione [1], Setareh Moughadam [1], Kristof Van Kolen [2], Vanessa Raymont [3], Mark Woolrich [3], James Rowe [4], Hartmuth KoLP [1]
[1]Janssen R&D - San Diego (United States), [2]Janssen R&D - Beerse (Belgium), [3]University of Oxford - Oxford (United Kingdom), [4]University of Cambridge - Cambridge (United Kingdom)

P079 Pharmacodynamic Effects of Semorinemab on Biomarkers of Tau, Synaptic Function, and Gliosis in a Phase 2 Trial of Mild-to-Moderate Alzheimer's Disease (Lauriet)

Stephen Schauer [1], Balaz Toth [1], Julie Lee [1], Veronica Anania [1], Lee Honigberg [1], Kristin Wildsmith [1], Vidya Ramakrishnan [1], Felix Yeh [1], Michael Dolton [1], Sandra Sanabria Bohorquez [1], Edmond Teng [1], Cecilia Monteiro [1]
[1]Genentech - South San Francisco (United States)

P080 CSF proteomic insights into the mechanism of action of gamma sensory stimulation in Alzheimer's Disease

Kiran Pandey [1], Annabelle Singer [2], Duc Duong [3], James Lah [3], Allan Levey [3], Nicholas Seyfriend [3], Monika Spokayte [4], Zach Malchano [4], Mihaly Hajos [4]
[1]Emtherapro. Inc. - Atlanta (United States), [2]Georgia Tech - Atlanta (United States), [3]Emory University - Atlanta (United States), [4]Cognito Therapeutics - Cambridge (United States)

P081 Changes in the neurology related CSF proteome after short-term treatment with XPro1595 for Alzheimer's disease

Parris Pope [1], Christopher Barnum [1], Raymond Tesi [1]
[1]INmune Bio, Inc. - Boca Raton (United States)

POSTER PRESENTATIONS

P082 A biomarker to aid Alzheimer's disease staging: sTREM2 is decreased in Amyloid positive/Tau negative, yet increased once Tau aggregates leading to increased cognitive decline

Rodrigo Canovas [1], Christopher J. Fowler [2], Stephanie Rainey-Smith [3, 4, 5, 6], Margherita Carboni [7], Ivonne Suridjan [7], Gwendlyn Kollmorgen [8], Chad Logan [9], Vincent Dore [1, 10], Jurgen Fripp [11], Colin L. Masters [2], Qiao-Xin Li [2], Steven J. Collins [12], Paul Maruff [13], James D. Doecke [11]

[1]Australian E-Health Research Centre, CSIRO, Parkville-Melbourne, Vic (Australia), [2]The University of Melbourne, The Florey Institute-Melbourne, Vic (Australia), [3]Centre for Healthy Ageing, Murdoch University - Murdoch, Wa (Australia), [4]Australian Alzheimer's Research Foundation, - Perth, Wa (Australia), [5]University of Western Australia - Perth, Wa (Australia), [6]Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care-Joondalup, Wa (Australia), [7]Roche Diagnostics International Ltd-Rotkreuz (Switzerland), [8]Roche Diagnostics GmbH - Penzberg (Germany), [9]Centralised & Point of Care Solutions, Roche Diagnostics GmbH-Penzberg (Germany), [10]Department of Molecular Imaging & Therapy Austin Health-Melbourne, Vic (Australia), [11]Australian E-Health Research Centre, CSIRO-Brisbane, Qld (Australia), [12]Department of Medicine & The Florey Institute, The University of Melbourne, Parkville-Melbourne, Vic (Australia), [13]Cogstate Ltd-Melbourne, Vic (Australia)

P083 Sex Differences in Amyloid PET: A Secondary Analysis of the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) Study

Maison Abu Raya [1], Ehud Zeltzer [1], Isabel Elaine Allen [1], Maria Carrillo [2], Constantine Gatsonis [3], Lucy Hanna [4], Bruce E Hillner [5], Leonardo Iaccarino [1], Andrew March [6], Nidhi Mundada [1], Jhony Mejia Perez [1], Barry A Siegel [7], Rachel A Whitmer [8], Renaud La Joie [1], Gil Rabinovici [1]

[1]University of California San Francisco - San Francisco (United States), [2]Alzheimer Association - Usa (United States), [3]Brown University - Providence, Rhode Island (United States), [4]Brown University - Providence,rhode Island (United States), [5]VCU Health - Virginia (United States), [6]American College of Radiology - Philadelphia (United States), [7]Washington University in St. Louis - St. Louis (United States), [8]UCDAVIS - Davis (United States)

P084 The mastermind of the Alzheimer's blood-based biomarkers: development of cutoffs and a visualization tool for use in clinical dementia practice

Charlotte Teunissen [1], Inge M.W. Verberk, [1], Jolien Jutte [1, 2], Maurice Y. Kingma [1, 2], Argonde C. Van Harten [1, 3], Anouk Den Braber [1, 3], Sinthujah Vigneswaran [1, 4], Mariam Gouda [3], Marie-Paule Van Engelen [3], Afina W. Lemstra [3], Yolande A.L. Pijnenburg [3], Wiesje M. Van Der Flier [3, 5], Martijn Schut [2], David Wilson [6]

[1]Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [2]Translational Artificial Intelligence laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [3]Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, - Amsterdam (Netherlands), [4]Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, - Amsterdam (Pays-Bas) - Asmterdam (Netherlands), [5]Amsterdam Public Health, Methodology & Digital Health - Amsterdam (Netherlands), [6]Quanterix - Billerica (United States)

P085 AD risk genes for blood-brain barrier dysfunction

Pieter Jelle Visser [1,2,3], Sven Van Der Lee [1], Charlotte Teunissen [1], Wiesje Vander Flier [1], Frode Berven [4], Betty Tijms [1]

[1]Amsterdam UMC - Amsterdam (Netherlands), [2]Maastricht University - Maastricht (Netherlands), [3]Karolinska Institute - Stockholm (Sweden), [4]University of Bergen - Norway (Netherlands)

P086 MIP-1α serum levels correlate alongside positive outcome of clinical endpoints in Alzheimer's Disease patients receiving plasma exchange with albumin replacement

Carla Minguet [1], Ricardo Gonzalo [1], Ana Ortiz [1], Isabel Bravo [1], Laura Núñez [1], Agustin Ruiz [2, 3], Óscar López [4], Mercè Boada [2, 3], Antonio Páez [1], Montserrat Costa [1]

[1]Grifols - Barcelona (Spain), [2]Universitat Internacional de Catalunya, Ace Alzheimer Centre Barcelona - Barcelona (Spain), [3]Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) - Madrid (Spain), [4]University of Pittsburgh School of Medicine - Pittsburg (United States)

P087 Proteomic Analyses in the 24-Week PEGASUS Trial Using the Olink Platform: Providing Insight Into the Biologic Activity of Sodium Phenylbutyrate and Taurursodiol in Alzheimer's Disease

Nicholas Cullen [1], Ryan Miller [2], Marcelo Gutierrez [2], Rudolph E. Tanzi [3], Lahar Mehta [2]

[1]BioFINDER Group, Department of Clinical Sciences, Lund University - Lund (Sweden), [2]Amylyx Pharmaceuticals, Inc. - Cambridge (United States), [3]Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University - Boston (United States)

P088 Statistical considerations for assessing the relationship between disease progression biomarkers and clinical endpoints in alzheimer's disease

Tianle Chen [1], R.matthew Hutchison [1], Carrie Rubel [1], Jennifer Murphy [1], Jing Xie [1], Philip Montenigro [1], Wenting Cheng [1], Kyle Fraser [1], Gersham Dent [1], John O'gorman [1], Suzanne Hendrix [2], Oskar Hansson [3], Paul Aisen [4], Ying Tian [1]

[1]Biogen - Cambridge, Ma (United States), [2]Pentara Corporation - Millcreek, Ut (United States), [3]Lund University - Malmö (Sweden), [4]University of Southern California - San Diego, Ca (United States)

P089 Validation of clinical cutoffs for the beta-amyloid (Abeta42), p-Tau181 and p-Tau181/Abeta42 Roche Elecsys Generation 2 assays

Joshua Bornhorst [1], Rebecca Deters [1], Jp Theobald [1], Alicia Algeciras-Schimnich [1]

[1]Mayo Clinic - Rochester (United States)

P090 Structural and functional DMN preservation after 24 weeks of rTMS in Alzheimer's disease patients

Giacomo Koch [1], Lucia Mencarelli [1], Mario Torso [2], Martina Assogna [1], Federico Giove [1], Emiliano Santarnecchi [3]

[1]Santa Lucia Foundation IRCCS - Rome (Italy), [2]Oxford Diagnostics - Oxford (United Kingdom), [3]MGH - Boston (United States)

P092   **Associations Between Blood-Based Biomarkers and Amyloid PET measurements in Cognitively Unimpaired Presenilin 1 E280A Mutation and Non-Mutation Carriers from the API Autosomal Dominant Alzheimer's Disease Colombia Prevention Trial**

Vedanshi Bhargava*[1], Mike Malek-Ahmadi*[2,3,4], Francisco Lopera*[5], Silvia Rios-Romenets[5], Eugenia Cardona[5], Yakeel T Quiroz-Gaviria[6], Jessica Langabaum[2], Pierre Tariot[2], Robert Alexander[2], Yi Su[2,1,7], Kewei Chen[2,3], Tobias Bittner[8], David Clayton[8], Rachelle Doody[8], Eric Reiman[2,9,10,1]
[1]University of Arizona College of Medicine Phoenix - Phoenix (United States), [2]Banner Alzheimer's Institute - Phoenix (United States), [3]University of Arizona College of Medicine Phoenix - Phoenix (United States), [4]Arizona Alzheimer's Consortium - Phoenix (United States), [5]Neurosciences Group of Antioquia, Universidad de Antioquia - Medellin (Colombia), [6]Massachusetts General Hospital and Harvard Medical School - Boston (United States), [7]Arizona Alzheimer's Consortium - Phoenix (United States), [8]Genentech - San Francisco (United States), [9]Translational Genomics Research Institute - Phoenix (United States), [10]Arizona Alzheimer's Consortium - Phoenix (United States)

P093   **Plasma p-tau217 as a cost-effective surrogate biomarker for clinical trials across the AD continuum**

Pamela C Lukasewicz Ferreira[1], Bruna Bellaver[1], Guilherme Povala[1], Joao Pedro Ferrari-Souza[1], Firoza Z. Lussier[1], Douglas T. Leffa[1], Helmet Karim[1], Chang Hyung Hong[2], Hyun Woong Rho[2], Dana L. Tudorascu[1], Thomas K. Karikari[1], Beth E. Snitz[3], Sang Joon Son[2], Tharick A Pascoal[1]
[1]Department of Psychiatry, School of medicine, University of Pittsburgh - Pittsburgh (United States), [2]Department of Psychiatry, Ajou University School of Medicine - Sowon (Korea, Republic of), [3]Department of Neurology, School of Medicine, University of Pittsburgh - Pittsburgh (United States)

P094   **Plasma biomarkers and longitudinal cognitive decline in non-demented Alzheimer's disease**

Karly Cody[1], Rebecca Langhough[1], Lianlian Du[1], Erin Jonaitis[1], Nathaniel Chin[1], Beckie Jeffers[1], Monica Vandenlangenberg[1], Sanjay Asthana[1], Kris Kirmess[2], Matthew Meyer[2], Kevin Yarasheski[2], Tim West[2], Tobey Betthauser[1], Sterling Johnson[1]
[1]Wisconsin Alzheimer's Disease Research Center, University of Wisconsin - Madison (United States), [2]C2N Diagnostics - St. Louis (United States)

P095   **Cerebrospinal fluid cellular transcriptomics as biomarkers of central nervous system drug-target engagement of a peripherally administered vaccine in older adults with and without cognitive impairment (BCG-AD)**

Marc Weinberg[1,2], Mahesh Kodali[1,2], Rojashree Jayakumar[1], Denise L. Faustman[1], Sudeshna Das[1,2], Steven Arnold[1,2]
[1]Mass General Hospital - Boston, MA (United States), [2]Harvard Medical School - Cambridge, Ma (United States)

P096   **Bio-Hermes study topline results: Aβ 42/40 and p-Tau 181/217 blood-based biomarkers compared to amyloid PET and CSF in a diverse, community-based population**

Douglas Beauregard[1], Richard Mohs[1], John Dwyer[1], Sarah Hollingshead[1], Jennifer Gaudioso[1], Jason Bork[1], Diana Kerwin[2]
[1]Global Alzheimer's Platform Foundation - Washington, Dc (United States), [2]Kerwin Medical Center - Dallas (United States)

LP043   **Novel diagnostic platform enabling protein specific biomarker signature for the diagnosis of AD**

Marion San Nicolo[1], Oliver Peters[2], Hilary Wunderlich[1], Timo Grimmer[3], Lutz Frölich[4], Arno Schaepe[1], Richard Metzler[1], Sabine Mertzig[1], Klaus Hallermayer[5], Harald Waltenberger[6], Thomas Heydler[1], Mareike Haack[1]
[1]Noselab GmbH - Munich (Germany), [2]Charite - Berlin (Germany), [3]TUM - Munich (Germany), [4]ZI Mannheim - Mannheim (Germany), [5]GMX - Munich (Germany), [6]Microcoat - Munich (Germany)

LP044   **A Cross-Sectional Study of Plasma Aβ42/40 ratio, p-Tau217, p-Tau181, GFAP and Nf-L in a Clinical Cohort Characterized by CNS Amyloid PET Imaging**

Ahmed Chenna[1], Youssouf Badal[1], Mintzu Lo[1], Brandon Yee[1], Bryan Lim[1], Christopher Fowler[2], Robert Martone[3], Christos Petropoulos[1], John Winslow[1]
[1]Labcorp-Monogram Biosciences - South San Francisco, Ca (United States), [2]The Florey Institute of Neuroscience and Mental Health - Parkville, VIC (Australia), [3]Labcorp Drug Development - Indianapolis, IN (United States)

LP046   **Analytical Validation and Initial Clinical Evaluation of a New Blood-Based Diagnostic Test for Alzheimer's Disease**

Andrew Schade[1], Adam Abel[1], Antonio Chambers[1], Jeff Fill[1], Heinz Reiske[1], Ming Lu[1], Amanda Morris[1], Michael Pontecorvo[1], Emily Collins[1], Mark Mintun[1], Michael Hodsdon[1]
[1]Eli Lilly and Company - Indianapolis (United States)

LP047   **Analytical and Clinical Validation of β-Amyloid 1-40, 1-42, and the 1-42/1-40 Ratio using a Clinical Autoanalyzer**

Ayla Harris[1], Tien Le[1], Bradley Collier[1], Matthew Chappell[1], Deborah Boles[1], Russell Grant[1]
[1]Labcorp - Burlington (United States)

LP048   **The Alzheimer's Association Global Biomarker Standardisation Consortium (GBSC) plasma phospho-tau Round Robin study**

Nicholas Ashton[1], Ashvini Keshavan[2], Lana Grötschel[1], Les Shaw[3], Kaj Blennow[4], Jonathan Schott[5], Henrik Zetterberg[6]
[1]University of Gothenburg - Göteborg (Sweden) - Göteborg (Sweden), [2]University College London - London (United Kingdom) - London (United Kingdom), [3]University of Pennsylvania - Philadelphia (United States) - Philadelphia (United States), [4]University of Pennsylvania - Philadelphia (United States), [5]University College London - London (United Kingdom), [6]University of Gothenburg - Göteborg (Sweden)

LP049   **Gene Expression Profile of Synchronized Cells Identifies Alzheimer's Disease in Autopsy Validated Skin and Blood Samples**

Florin Chirila[1,2], Macturk William[1], Wallace Jack[1], Xu Guang[1], Alkon Daniel[1]
[1]Synaps Dx - Rockville (United States), [2]Spot Dx - Morgantown (United States)

POSTER PRESENTATIONS

LP051 Investigating Sex-Specific Blood Biomarkers Associated with Memory Changes in Middle-Aged Adults: Insights from the Framingham Heart Study

Huitong Ding [1], Chunyu Liu [2], Yi Li [2], Ting Fang Alvin Ang [1], Sherral Devine [1], Yulin Liu [1], Rhoda Au [1], P. Murali Doraiswamy [3]
[1]Boston University Chobanian & Avedisian School of Medicine - Boston (United States), [2]Boston University School of Public Health - Boston (United States), [3]Duke University School of Medicine - Boston (United States)

LP052 Validation of an Ultra-Sensitive Method for Phospho-Tau 217 (pTau-217) Quantitation in Human Plasma, Serum, and CSF

Hongming Zhang [1], Jialu Liu [1], Nan Zhang [1], Zhongping John Lin [1]
[1]Frontage Laboratories Inc. - Exton (United States)

LP053 Prediction of Amyloid PET positivity from blood-based biomarkers and clinical data using AI-based Digital Twins

Wenjun Zhu [1], So-Youn Shin [1], Jeanne Latourelle [1]
[1]Aitia - Somerville (United States)

LP054 Changes of CSF and plasma biomarkers during 18-month period in a phase II clinical trial with biomarker proven Alzheimer's disease patients

Charlotte Teunissen [1], Marleen Koel-Simmelink [1], Marlies Oosthoek [1], Niels Prins [2], Pieter Van Bokhoven [3], Tomohiro Okuda [4], Philip Scheltens [5]
[1]Neurochemistry Laboratory, Department of Neurochemistry, Amsterdam UMC - Amsterdam (Netherlands), [2]Brain Research Center - Amsterdam (Netherlands), [3]IXA-Neuroscience, Amsterdam Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), [4]FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), [5]Amsterdam UMC - Amsterdam (Netherlands)

LP055 Analytical and clinical validation of the Simoa Janssen plasma p217+ Tau as a CLIA lab developed test (LDT) for clinical use

David Wilson [1], Gallen Triana-Baltzer [2], Ann-Jeanette Vasko [1], Karen Copeland [3], Lyndal Hesterberg [4], Meenakshi Khare [1], Michele Wolfe [1], Patrick Sheehy [1], Zachary Fernandes [1], Hartmuth KoLP [2], Mark Roskey [1], Mark Miller [1]
[1]Quanterix - Billerica (United States), [2]Janssen R&D - La Jolla (United States), [3]Boulder Statistics - Steamboat Springs (United States), [4]HCS, Inc - Denver (United States)

LP056 The role of neuroinflammation in Alzheimer's disease: A systematic literature review

Michael T. Heneka [1], Serge Gauthier [2], Chandekar Anil Sagar [3], Julie Hahn-Pedersen Hviid [3], Marie Bentsen [3], Henrik Zetterberg [4]
[1]Luxembourg Centre for Systems Biomedicine, Université du Luxembourg - Belvaux (Luxembourg), [2]AD and Related Disorders Research Unit, McGill Center for Studies in Aging, Departments of Neurology & Neurosurgery, Psychiatry, and Medicine at McGill - Montreal (Canada), [3]Novo Nordisk A/S - Søborg (Denmark), [4]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden)

LP057 Proteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer's Disease Patients

Valentina Di Caro [1], Kiran Pandey [2], Britney Lizama [1], Eunah Cho [1], Duc Duong [3, 4], Willem De Haan [5, 6], Michael Grundman [7], Nicholas Seyfried [4], Anthony Caggiano [1], Everard Vijverberg [6], Mary Hamby [1]
[1]Cognition Therapeutics, Inc. - Pittsburgh (United States), [2]Emtherapro Inc, Systems Biology. - Atlanta (United States), [3]Emtherapro Inc, Systems Biology - Atlanta (United States), [4]Emory University School of Medicine, Biochemistry - Atlanta (United States), [5]Department of Clinical Neurophysiology and MEG Center, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [6]Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), [7]Global R&D Partners, LLC and Dept of Neurosciences University of California - San Diego (United States)

LP058 Changes in EEG theta/alpha ratio during an 18-month period in a phase II clinical trial with biomarker-confirmed Alzheimer's disease patients

Willem De Haan [1], Niels Prins [2], Pieter Van Bokhoven [3], Tomohiro Okuda [4], Philip Scheltens [5]
[1]Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location Vumc - Amsterdam (Netherlands), [2]Brain Research Center - Amsterdam (Netherlands), [3]IXA-Neuroscience, Amsterdam Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), [4]FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), [5]Amsterdam UMC - Amsterdam (Netherlands)

LP059 Assessment of plasma biomarkers combined with clinical measures in mild cognitive impairment, AD dementia, and normal aging

Marwan Sabbagh [1], Megan Thomas [1], Jeffrey Wilson [2], Giovanni Malaty [1], Boris Decourt [3]
[1]Barrow Neurological Institute - Phoenix (United States), [2]Arizona State University - Tempe (United States), [3]Texas Tech University - Lubbock (United States)

LP060 Multiomic Blood-Based Biomarkers Exhibit High Specificity in Predicting Alzheimer's Disease from Predementia

Benoit Souchet [1], Alkeos Michail [1], Maud Heuillet [2], Aude Dupuy-Gayral [2], Eloi Haudebourg [2], Catherine Pech [2], Antoine Berthemy [2], François Autelitano [2], Baptiste Billoir [1], Kimiko Domoto-Reilly [3], Christopher Fowler [4], Thomas Grabowski [3], Suman Jayadev [3], Colin L. Masters [4], Jerome Braudeau [1]
[1]AgenT - Paris (France), [2]Evotec - Toulouse (France), [3]University of Washington - Seattle (United States), [4]University of MeLPourne - Victoria (Australia)

THEME: Clinical Trials: Cognitive and functional endpoints

P098 Between-Country Comparisons of Quality of Life and Activities of Daily Living in Multinational Alzheimer's Disease Clinical Trials
Sayaka Machizawa [1], Erica Appleman [1], Jessica Stenclik [1], Andrei Iacob [2], Rujvi Kamat [1]
[1]Signant Health - Blue Bell (United States), [2]Signant Health - Bucharest (Romania)

P099 The Effect of Global Functioning on Participant and Study Partner Ratings of Quality of Life in Participants with Prodromal to Mild Alzheimer's Disease
Jessica Stenclik [1], Amanda Aedo [1], Sayaka Machizawa [1], Rujvi Kamat [1], Erica Appleman [1], Andrei Iacob [1]
[1]Signant Health - Blue Bell (United States)

P100 Blood pressure variability via ambulatory monitoring and risk for dementia in the SPRINT MIND trial
Isabel Sible [1], Daniel Nation [2]
[1]University of Southern California - Los Angeles (United States), [2]University of California Irvine - Irvine (United States)

P101 Longitudinal resting-state EEG along the Alzheimer's disease continuum: the road to successful clinical trial implementation
Elliz P. Scheijbeler [1], Willem De Haan [1], Cornelis J. Stam [1], Jos W. R. Twisk [1], Alida A. Gouw [1]
[1]Amsterdam UMC location VUmc - Amsterdam (Netherlands)

P102 The EEG as functional endpoint in AD trials
Willem De Haan [1,2], Elliz Scheijbeler [1,2], Alida Gouw [1,2,3], Cornelis Jan Stam [4,2]
[1]Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), [2]Amsterdam Neuroscience, Neurodegeneration, - Amsterdam (Netherlands), [3]Clinical Neurophysiology and MEG Center, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, - Amsterdam (Netherlands), [4]Clinical Neurophysiology and MEG Center, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands)

P103 Rates of Progression in Patients with Alzheimer's Disease Depending on Apolipoprotein E Genotype and Concomitant Medications
Carina Wattmo [1]
[1]Cognitive Disorders Research Unit, Department of Clinical Sciences, Malmö, Lund University - Malmö (Sweden)

P104 Effects of Melissa officinalis extract containing rosmarinic acid for Alzheimer's disease in human
Moeko Shinohara [1], Kenjiro Ono [1]
[1]Kanazawa University - Kanazawa (Japan)

P105 TRAILBLAZER-ALZ 2: Heterogeneity in performance of clinical outcome assessments across geo-cultural areas
Giulia Tronchin [1], Wendy Wenyu Ye [1], Xiaojuan Mi [2], Alette M. Wessels [1]
[1]Eli Lilly and Company - Indianapolis (United States), [2]TechData Services Company - King Of Prussia (United States)

P106 Assessing 'true' non-progression rate in early Alzheimer's disease accounting for within-subject variation
Menglan Pang [1], Willem Huijbers [1], Audrey Gabelle [1], Arie Gafson [1], Richard Hughes [1], Shibeshih Belachew [1], Shen Changyu [1]
[1]Biogen - Cambridge (United States)

P107 Video-based Assessment of Cognitive Frailty in Older Adults with Cognitive Impairment
Ram Kinker Mishra [1], Myeounggon Lee [2], Jaewon Beom [2], Mohammad Dehghan Rouzi [2], Ashkan Vaziri [1], Bijan Najafi [2]
[1]BioSensics LLC - Boston (United States), [2]Baylor College of Medicine - Houston (United States)

P108 Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies
Peter Høgh [1], Michael Fischer [1]
[1]Department of Neurology, Zealand University Hospital - Roskilde (Denmark)

P109 Timing the change in the Pre-clinical Alzheimer's Cognitive Composite score with Amyloid-β in pre-clinical Alzheimer's Disease
Timothy Cox [1], Rosita Shishegar [1], Christopher Fowler [2], Stephanie Rainey-Smith [3,4,5,6], Hamid Sohrabi [3,4], Shaun Markovic [3,4], Vincent Dore [1,7], Pierrick Bourgeat [8], Jurgen Fripp [8], Ralph Martins [6,9], Victor Villemagne [10], Colin Masters [2], Christopher Rowe [2,7], James Doecke [8]
[1]Australian E-Health Research Centre, CSIRO - Parkville (Australia), [2]The University of Melbourne, The Florey Institute - Melbourne (Australia), [3]Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), [4]Australian Alzheimer's Research Foundation - Perth (Australia), [5]University of Western Australia - Perth (Australia), [6]Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care - Perth (Australia), [7]Department of Molecular Imaging & Therapy Austin Health - Melbourne (Australia), [8]Australian E-Health Research Centre, CSIRO - Brisbane (Australia), [9]Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University - Sydney (Australia), [10]Department of Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh (United States)

P110 Impact of study partner type on primary endpoint variability in two phase 3 registration trials in mild-to-moderate Alzheimer's disease
Mary Ryan [1,2,3], Daniel Gillen [1,2], Joshua Grill [1,4,5]
[1]Institute for Memory Impairments and Neurological Disorders, UC Irvine - Irvine (United States), [2]Department of Statistics, UC Irvine - Irvine (United States), [3]Department of Biostatistics, Yale School of Public Health - New Haven (United States), [4]Department of Psychiatry and Human Behavior, UC Irvine - Irvine (United States), [5]Department of Neurobiology and Behavior, UC Irvine - Irvine (United States)

P111 Effects of phytoncide inhalation on Stroop task performance in patients with mild cognitive impairment: an fNIRS pilot study
Do Hoon Kim [1], Seungchan Park [1], Jiheon Kim [1]
[1]Chuncheon Sacred Heart Hospital Hallym University College of Medicine - Chuncheon (Korea, Republic of)

P112 The use of composite z-scores in place of normative-based scaling to improve signal detection in clinical trials involving neurodegenerative diseases
Erin Jacobs [1], Christopher Randolph [1,2], Danielle Digregorio [1], Selam Negash [1], Raymond Blattner [1]
[1]WCG Clinical - Princeton (United States), [2]Loyola University Medical Center - Chicago (United States)

POSTER PRESENTATIONS

P113 The Expanded Brief Assessment of Cognition (BAC) for the Assessment of Cognitive Impairment in Mild Alzheimer's Disease

Dorothee Schoemaker [1], Alexandra S. Atkins [1], Chelsea Abraham [1], Haley Evans [1], Matthew Welch [1], Brenda L. Plassman [2], Corrine Madsen [2], Nancy Sickel [2], Jan Sedway [1], Kathleen A. Welsh-Bohmer [1], Rich S.e. Keefe [1]
[1]WCG - Cary (United States), [2]Duke University - Durham (United States)

P114 Standardized Implementation of Personalized Endpoints Following FDA's Draft Guidance 4 on Patient-Focused Drug Development: Goal Attainment Scaling in a Phase 2 Study of Xpro in Patients with Early Alzheimer's Disease

Gunes Sevinc [1], Chere Chapman [1], Tara Lehner [2], Christopher Barnum [2], Judith Jaeger [2, 3, 4], Kenneth Rockwood [1, 5, 6]
[1]Ardea Outcomes - Nova Scotia (Canada), [2]INmune Bio, Inc - Florida (United States), [3]CognitionMetrics, LLC - Connecticut (United States), [4]Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine - New York (United States), [5]Division of Geriatric Medicine, Dalhousie University, - Nova Scotia (Canada), [6]Geriatric Medicine Research Unit, Nova Scotia Health Authority, - Nova Scotia (Canada)

P115 Verbal Learning Over Five Days: Learning Curves, Age-Independence, and Sleep Sensitivity

Alexander Kaula [1], Nicholas Taptiklis [1], Naim Sen [1], Francesca Cormack [1, 2], Nathan Cashdollar[1], Kenton Zavitz[1]
[1]Cambridge Cognition - Cambridge (United Kingdom), [2]University of Cambridge - Cambridge (United Kingdom)

P116 A Meta-Analysis to Demonstrate the Incidence of Placebo Effect in Alzheimer's Disease and Mild Cognitive Impairment Trials: Mitigating for Impacts on Trial Endpoints

Melissa Carbo [1], Madelyn Moberg [1], Rolana Avrumson [1]
[1]Worldwide Clinical Trials - Doylestown (United States)

P117 Capturing clinically meaningful change in Alzheimer's disease: the electronic Person Specific Outcome Measure approach

Álvaro Pascual-Leone [1, 8], Stina Saunders [1, 2], Joyce Gomes-Osman [1, 3], Ali Jannati [1, 4], Sean Tobyne [1], Jeff Pobst [1], Craig Ritchie [5, 6], Saturnino Luz [2], Graciela Muniz-Terrera [2, 7]
[1]Linus Health Inc - Boston (United States), [2]University of Edinburgh - Edinburgh (United Kingdom), [3]University of Miami Miller School of Medicine - Miami (United States), [4]Harvard Medical School - Boston (United States), [5]Scottish Brain Sciences - Edinburgh (United Kingdom), [6]University of Edinburgh - Edinburgh (United Kingdom) - Edinburgh (United Kingdom), [7]University of Ohio - Ohio (United States), [8]Hebrew SeniorLife - Boston (United States)

LP062 Tracking short-term cognitive changes among cognitively unimpaired older adults with different amyloid (A) and tau (T) profiles using The Boston Remote Assessment for Neurocognitive Health (BRANCH)

Roos Jutten [1], Daniel Soberanes [2], Emma Weizenbaum [1], Cassidy Molinare [1], Stephanie Hsieh [1], Michelle Farrell [1], Dorene Rentz [1, 2], Gad Marshall [1, 2], Keith Johnson [1], Reisa Sperling [1, 2], Rebecca Amariglio [1, 2], Kate Papp [1, 2]
[1]Massachusetts General Hospital, Harvard Medical School - Boston (United States), [2]Brigham and Women's Hospital, Harvard Medical School - Boston (United States)

LP063 Factors associated with floor and ceiling effects in the LatAm-FINGERS neuropsychological battery

Monica Yassuda [1], Claudia Suemoto [1], Lucia Crivelli [2], Ismael Calandri [2], Paulo Caramelli [3], Francisco Lopera [4], Sonia Brucki [1], Ricardo Nitrini [1], Ana Luisa Sosa [5], Rosa Salinas [5], Lina Velilla [4], Gustavo Sevlever [2], Miia Kivipelto [6], Maria Carrillo [7], Ricardo Allegri [2]
[1]University of São Paulo - São Paulo (Brazil), [2]Fleni - Buenos Aires (Argentina), [3]Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), [4]Antioquia Medical School - Antioquia (Colombia), [5]Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez - Ciudad De México (Mexico), [6]Karolinska Institutet - Stockholm (Sweden), [7]Alzheimer's Association - Chicago (United States)

LP064 Robustness and generalizability of a speech based composite score for measuring disease progression in AD

Michael Spilka [1], Mengdan Xu [1], Jessica Robin [1], William Simpson [1]
[1]Winterlight Labs - Toronto (Canada)

LP065 Cognitive Functional Composite detected time-dependent worsening of cognition and function during 18-month period in a phase II clinical trial with biomarker proven Alzheimer's disease patients

Sietske Sikkes [1], Merel Postema [1], Niels Prins [2], Pieter Van Bokhoven [3], Tomohiro Okuda [4], Philip Scheltens [5]
[1]Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location Vumc - Amsterdam (Netherlands), [2]Brain Research Center - Amsterdam (Netherlands), [3]IXA-Neuroscience, Amsterdam Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), [4]FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), [5]Amsterdam UMC - Amsterdam (Netherlands)

LP067 Measuring What Matters Most to People Living With Alzheimer's Disease and Care Partners: What Matters Most Qualitative Research

Carla Romano [1], Emily Bratlee-Whitaker [1], William L Herring [1, 2], Leigh F Callahan [3], Karina Raimundo [4], Jim Taylor [5], Geri Taylor [5], Ian Kremer [6], Debra Lappin [7], Terry Frangiosa [7], Kajan Gnanasakthy [1], Diana Goss [1], Russ Paulsen [8], Ann Hartry [9], Dana Dibenedetti [1]
[1]RTI Health Solutions - Research Triangle Park (United States), [2]Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), [3]University of North Carolina at Chapel Hill - Chapel Hill (United States), [4]Genentech - San Francisco (United States), [5]Memory Advocate Peers (MAP) - New York (United States), [6]LEAD Coalition (Leaders Engaged on Alzheimer's Disease) - Washington, D. C. (United States), [7]Faegre Drinker Consulting - Washington, D. C. (United States), [8]UsAgainstAlzheimer's - Washington, D. C. (United States), [9]Biogen Inc - Cambridge (United States)

LP068 The Down Syndrome – Clinical Global Impression of Change (DS-CGIC)

Julian Gray [1], Andre Strydom [2], Olivier Sol [1], Juan Fortea [3], Michael Rafii [4]
[1]AC Immune - Lousanne (Switzerland), [2]King's College - London (United Kingdom), [3]Hospital San Pau - Barcelona (Spain), [4]USC - San Diego (United States)

LP069 The Longitudinal Impact of COVID-19 Lockdown on Mild Cognitive Impairment and Alzheimer's Disease

Hahyun Lee [1, 2], Yoon-Soo Cho [3], Jun-Young Lee [1]
[1]Department of Psychiatry, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea - Seoul (Korea, Republic of), [2]Interdisciplinary Program in Cognitive Science, Seoul National University, Republic of Korea Interdisciplinary Program in Cognitive Science - Seoul (Korea, Republic of), [3]Keimyung University School of Medicine & Institute for Medical Science - Daegu (Korea, Republic of)

POSTER PRESENTATIONS

THEME: Cognitive assessment and clinical trials

P118 The ViewMind AI Solution (VIMAS) addresses inequities and disparities in the assessment of dementia risk

Mario A. Parra [1], Alfredis Gonzalez-Hernandez [2], Jasmin Bonilla-Santos [2], Rodrigo A. Gonzalez-Montealegre [2], Dorian Yisela-Cala [2], Gerardo Fernandez [3], Danilo Verge [4]
[1]University of Strathclyde - Glasgow (United Kingdom), [2]Universidad Surcolombiana - Huila (Colombia), [3]ViewMind - Bahia Blanca (Argentina), [4]ViewMind - West Chester (United States)

P119 Clinical Dementia Rating Scale (CDR®) domain scores differ by diagnosis in Hispanic and non-Hispanic White samples

Giovanna Pilonieta [1], David Geldmacher [1]
[1]The University of Alabama at Birmingham - Birmingham (United States)

P120 Sex bias and the association of dementia lifestyle risk factors with superager status

Matthew Mcphee [1], Larissa Mcketton [2], Annalise Laplume [3], Angela Troyer [1,4], Nicole Anderson [2,4,5]
[1]Neuropsychology and Cognitive Health, Baycrest - Toronto (Canada), [2]Rotman Research Institute, Baycrest Academy for Research and Education - Toronto (Canada), [3]Douglas Research Centre, McGill University and Centre for Research at the Geriatrics Institute of the University of Montreal - Montreal (Canada), [4]Department of Psychology, University of Toronto - Toronto (Canada), [5]Department of Psychiatry, University of Toronto - Toronto (Canada)

P121 Objective Monitoring of Instrumental Activities of Daily Living in Dementia

Ram Kinker Mishra [1], Myeounggon Lee [2], Adonay S. Nunes [1], Michele K. York [2], Mark E. Kunik [2], Ashkan Vaziri [1], Bijan Najafi [2]
[1]Biosensics - Boston (United States), [2]Baylor College of Medicine - Houston (United States)

P122 Errors in Clinical Dementia Rating administration and scoring: Identifying targets for intervention

Rujvi Kamat [1], Jacqueline Massa [1], Amanda Aedo [1], Gila Barbati [1], Sayaka Machizawa [1], Jessica Stenclik [1], Erica Appleman [1], Andrei Iacob [1]
[1]Signant Health - Blue Bell (United States)

P123 Leveraging AI methods to detect cognitive decline and dementia over the telephone: a promising new screening tool

Catherine Diaz-Asper [1], Chelsea Chandler [2], R. Scott Turner [3], Brigid Reynolds [3], Brita Elvevåg [4]
[1]Marymount University - Arlington (United States), [2]University of Colorado, Boulder - Boulder (United States), [3]Georgetown University - Washington Dc (United States), [4]University of Tromsø - the Arctic University of Norway - Tromsø (Norway)

P124 Influence of COVID-19 pandemic to self-perceived memory decline: contribution to cognitive change one-year later

Kenichiro Sato [1,2], Yoshiki Niimi [2], Ryoko Ihara [3], Kazushi Suzuki [4], Atsushi Iwata [3], Takeshi Iwatsubo [1,2]
[1]University of Tokyo - Tokyo (Japan), [2]University of Tokyo Hospital - Tokyo (Japan), [3]Tokyo Metropolitan Geriatric Medical Center Hospital - Tokyo (Japan), [4]National Defense Medical College - Saitama (Japan)

P125 Nili: Digital Health Solution for Dementia Care Coordination and Management

Ram Kinker Mishra [1], Myeounggon Lee [2,3], Michele K. York [3], Mark E. Kunik [4,5], Bijan Najafi [2,3], Ashkan Vaziri [1]
[1]BioSensics LLC - Newton (United States), [2]Department of Surgery, Baylor College of Medicine - Houston (United States), [3]Neurology and Psychiatry & Behavioral Sciences, Baylor College of Medicine - Houston (United States), [4]Menninger Department of Psychiatry and Behavioral Science, Baylor College of Medicine, - Houston (United States), [5]Michael E. DeBakey Veterans Affairs Medical Center - Houston (United States)

P126 Using Speech Biomarkers for Detection and Monitoring of Cognitive Decline

Adonay S. Nunes [1], Gozde Cay [2], Myeounggon Lee [2], Mohammad Dehghan Rouzi [2], Nesreen El-Refaei [2], Anmol Momin [2], Ram Kinker Mishra [1], Bijan Najafi [2], Ashkan Vaziri [1]
[1]BioSensics LLC - Boston (United States), [2]Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), Michael E. DeBakey Department of Surgery, Baylor College of Medicine - Houston (United States)

P127 Validation of a TICS-m cutoff score for identification of cognitive impairment during telephone pre-screening assessment

Eric Fischer [1], Abigail O'connell [2], Sarah Gaussoin [3], Samuel Lockhart [1], Suzanne Craft [1]
[1]Wake Forest School of Medicine, Department of Internal Medicine - Gerontology - Winston-Salem (United States), [2]Wake Forest School of Medicine, Department of Internal Medicine - Gerontology - Winston-Salem (United States) - Winston-Salem (United States), [3]Wake Forest School of Medicine, Department of Biostatistics and Data Science - Winston-Salem (United States)

P128 The Pre-Clinical Alzheimer's Cognitive Composite Score: Informing Clinical Meaningfulness through the Alzheimer's Disease Continuum

James David Doecke [1], Marcela Cespedes [1], Timothy Cox [2], Rosita Shishegar [3], Christopher James Fowler [4], Stephanie Rainey-Smith [5,6,7,8], Hamid Sohrabi [9,10], Shaun Markovic [9,10], Jurgen Fripp [1], Cai Gillis [11], Nancy Maserejian [11], Yen Ying Lim [12], Jason Hassenstab [13,14], Paul Maruff [15]
[1]Australian E-Health Research Centre, CSIRO - Herston (Australia), [2]Australian E-Health Research Centre, CSIRO - Canberra (Australia), [3]Australian E-Health Research Centre, CSIRO - Parkville (Australia), [4]The University of Melbourne, The Florey Institute - Parkville (Australia), [5]Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), [6]Australian Alzheimer's Research Foundation - Perth (Australia), [7]University of Western Australia - Perth (Australia), [8]Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care - Joondalup (Australia), [9]Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia), [10]Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia), [11]Biogen - Boston (United States), [12]Turner Institute for Brain and Mental Health, School of Psychological Sciences - Monash (Australia), [13]Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), [14]Department of Neurology, Washington University School of Medicine - St. Louis (United States), [15]Cogstate - Melbourne (Australia)

POSTER PRESENTATIONS

P129 Automated linguistic metrics from a novel, remote, smartphone-based self-assessment of cued narration and free recall correlate with brain atrophy in language and memory networks in early Alzheimer's disease

Irma T. Kurniawan [1], Michał K. Kosek [2], Raphael M. Ullmann [1], Arnaud M. Wolfer [1], Stefan Holiga [1], Eduardo A. Aponte [1], Thanneer M. Perumal [1], Kirsten I. Taylor [1]

[1]Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. - Basel (Switzerland), [2]Roche Global IT Solution Centre, Warsaw, Poland - Warsaw (Poland)

P130 Characterising progressive decline across multiple cognitive domains in preclinical Alzheimer's disease

Rosita Shishegar [1], Timothy Cox [2], Hamid R. Sohrabi [3], Shaun Markovic [3], Jurgen Fripp [4], Vincent Doré [1], Pierrick Bourgeat [4], Jason Hassenstab [5], Yen Ying Lim [6], Paul Maruff [7], Colin L. Masters [8], James D Doecke [8]

[1]Australian E-Health Research Centre, CSIRO - Melbourne (Australia), [2]Australian E-Health Research Centre, CSIRO - Canberra (Australia), [3]Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), [4]Australian E-Health Research Centre, CSIRO - Brisbane (Australia), [5]Department of Psychological and Brain Sciences, Washington University in Saint Louis - Saint Louis (United States), [6]Turner Institute of Brain and Mental Health, School of Psychological Sciences, Monash University - Clayton (Australia), [7]Cogstate Ltd. - Melbourne (Australia), [8]The University of Melbourne, The Florey Institute - Melbourne (Australia)

P131 Do Alzheimer's Risk Genes Also Predict Cognitive Decline?

Shane Fernandez [1,2], Rosita Shishegar [3], Paul Maruff [4,5], Colin Masters [4], Victor Villemagne [6,7], Timothy Cox [3], Vincent Doré [3,7], Tenielle Porter [1,2], Simon Laws [1,2]

[1]Centre for Precision Health, Edith Cowan University - Perth (Australia), [2]Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University - Perth (Australia), [3]Australian E-Health Research Centre, CSIRO - Melbourne (Australia), [4]Florey Institute of Neuroscience and Mental Health, The University of Melbourne - Melbourne (Australia), [5]Cogstate Ltd - Melbourne (Australia), [6]Department of Psychiatry, University of Pittsburgh, - Pittsburgh (United States), [7]Department of Molecular Imaging and Therapy and Centre for PET, Austin Health, - Melbourne (Australia)

P132 Forecasting Future Dementia Risk Using a Digital Clock Drawing Assessment in an African American Population

Jeff Pobst [1], Sean Tobyne [1], Ali Jannati [1,2], Russell Banks [1,3], David Libon [1,4], Rodney Swenson [1,5], Melissa Lamar [6,7], Lisa Barnes [6,7,8], David Bates [1], John Showalter [1], Alvaro Pascual-Leone [1,2,9]

[1]Linus Health, Inc. - Boston, Massachusetts (United States), [2]Department of Neurology, Harvard Medical School - Cambridge, Massachusetts (United States), [3]Michigan State University - East Lansing, Michigan (United States), [4]Rowan University - Stratford, New Jersey (United States), [5]University of North Dakota School of Medicine and Health Sciences - Fargo, North Dakota (United States), [6]Rush Alzheimer's Disease Center - Chicago, Illinois (United States), [7]Department of Psychiatry and Behavioral Sciences, Rush University Medical Center - Chicago, Illinois (United States), [8]Department of Neurological Sciences, Rush University Medical Center - Chicago, Illinois (United States), [9]Hinda and Arthur Marcus Institute for Aging Research, Deanna and Sidney Wolk Center of Memory Health, Hebrew Senior Life - Boston, Massachusetts (United States)

P133 Bridging the Assessment Gap: Newly Developed Neuropsychiatric Cognitive Assessments on the Cognivue® Platform Show Strong Correlation with Traditional Gold Standard Tests

James Galvin [1]

[1]University of Miami Comprehensive Center for Brain Health - Miami (United States)

P134 Efficient and Automated Cognitive Pre-Screening for Clinical Trials using the Montreal Cognitive Assessment (MoCA) XpressO Tool and Automated Report

Sivan Klil-Drori [1], Katie Bodenstein [2], Lara Kojok [2], Shuo Mila Sun [3], Youssef Ghantous [2], Ziad Nasreddine [2]

[1]McGill University - Montreal, Qc (Canada), [2]MoCA Cognition Clinic and Institute - Montreal, Qc (Canada), [3]Harvard University - Cambridge, Ma (United States)

P135 Attaching clinical meaningfulness to CDR-SB score

Danielle Digregorio [1], Christopher Randolph [1,2], Dorothee Shoemaker[1], Selam Negash [1], Erin Jacobs [1], Raymond Blattner [1]

[1]WCG - Princeton (United States), [2]Loyola University Medical Center - Chicago (United States)

P136 Analysis of Aβ(1-42) Oligomers by Cyclic Ion Mobility SPECTROMETRY in spiked HUMAN cerebrospinal fluid

Mikuláš Vlk [1], John Hey [2], Walter Korfmacher [2], Alexander Muck [3], Martin Hubálek [1], Josef Cvačka [1]

[1]Institute of Organic Chemistry and Biochemistry of the CAS, Mass Spectrometry Group - Prague (Czech Republic), [2]Alzheon - Framingham (United States), [3]Waters Corporation, Analytical Professional Services EMEA - Wilmslow (United Kingdom)

P137 Sex Differences in Predicting Progression in Cognitively Unimpaired ADNI Participants Using Cognitive Test Performance

Adam Diaz [1,2], Melanie J. Miller [1,2], Marta Mila Aloma [1,3], Zack Hausle [1,3], Pamela Zobel-Thropp [1,3], Duygu Tosun [3], Rachel Nosheny [4], Leslie M. Shaw [5], Michael W. Weiner [1,2]

[1]Northern California Institute for Research and Education (NCIRE) - San Francisco (United States), [2]Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases - San Francisco (United States), [3]University of California, San Francisco, Department of Radiology and Biomedical Imaging - San Francisco (United States), [4]University of California, San Francisco, Department of Psychiatry and Behavioral Sciences - San Francisco (United States), [5]University of Pennsylvania, Perelman School of Medicine - Pennsylvania (United States)

LP070 Association of Speech and Language features with Biomarkers in Early Stage Alzheimer patients

Alexandra König [1,2], Stefanie Köhler [3], Johannes Tröger [1], Elisa Mallick [1], Nicklas Linz [1], Josef Priller [4,5,6,7], Markus Donix [8,9], Jens Wiltfang [10,11,12], Inga Zerr [10,13], Düzel Düzel [14,15,16], Annika Spottke [17,18], Frederic Brosseron [19], Michael Wagner [19,20], Alfredo Ramirez [19,20,21,22], Stefan Teipel [3,23]

[1]ki:elements GmbH - Saarbrücken (Germany), [2]Cobtek (Cognition-Behaviour-Technology), Université Côte d'Azur,e - Nice (France), [3]Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Standort Rostock/Greifswald, - Rostock/greifswald (Germany), [4]Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) - Berlin (Germany), [5]Department of Psychiatry and Psychotherapy, Charité - Berlin (Germany), [6]School of Medicine, Technical University of Munich; Department of Psychiatry and Psychotherapy, - Munich (Germany), [7]University of Edinburgh and UK DRI, - Edinburgh (United Kingdom), [8]Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) - Dresden (Germany), [9]Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden,y. - Dresden (Germany), [10]German Center for Neurodegenerative Diseases (DZNE) - Goettingen (Germany), [11]Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen y - Goettingn (Germany), [12]Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveirol - aveiro (Portugal), [13]Department of Neurology, University Medical Center, Georg August University,. - Goettingen (Germany), [14]German Center for Neurodegenerative Diseases (DZNE) - Magdeburg (Germany), [15]Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University - Magdeburg (Germany), [16]Institute of Cognitive Neuroscience, University College London. - London (United Kingdom), [17]German Center for Neurodegenerative Diseases (DZNE) - Bonn (Germany), [18]Department of Neurology, University of Bonn, - Bonn (Germany), [19]German Center for Neurodegenerative Diseases (DZNE) - Bonn (Germany) - Bonn (Germany), [20]Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, - Bonn (Germany), [21]Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) University of Cologne - Cologne (Germany), [22]Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry, University of Cologne, Medical Faculty, - Cologne (Germany), [23]University Medical Center Rostock, - Rostock (Germany)

LP071 A Blueprint for Early Detection of Cognitive Impairment in Primary Care Settings

Tim Macleod [1], Jim Murray [1], Chantale Bielak [2], Katherine Selzler [1]

[1]Davos Alzheimer's Collaborative Health System Preparedness - Wayne (United States), [2]Bridgeable - Toronto (Canada)

LP072 Implementing cognitive assessment and RetiSpec retinal screening in community-based settings: Enhancing early detection of Alzheimer's disease

Sharon Cohen [1], Alissa Kurzman [2,3,4], Jennifer Giordano [2], Rozana Naureen [2], Amelia Hansen [1], Michelle Martinez [1], Mailis Bietenhader [2], Negar Sohbati [5], Naeem Abdulla [6], Colette Cameron [7], Shmuel Estreicher [7], Sangeeta Semwel [7], Catherine Bornbaum [2]

[1]Toronto Memory Program - Toronto (Canada), [2]RetiSpec, Inc. - Toronto (Canada), [3]University of California, Irvine - Irvine (United States), [4]Davos Alzheimers Collaborative - Philadelphia (United States), [5]Victoria Village Optometry - Toronto (Canada), [6]Summerhill Optometry - Toronto (Canada), [7]Alzheimer Society of Toronto - Toronto (Canada)

LP073 Concurrent Detection of Cognitive Impairment and Aβ PET Status with a Short AI-enabled Digital Cognitive Assessment

David Bates [1], Ali Jannati [1,2], Karl Thompson [1], Claudio Toro-Serey [1], Joyce Gomes-Osman [1,3], Russell Banks [1], Jeff Pobst [1], Connor Higgins [1], John Showalter [1], Sean Tobyne [1], Alvaro Pascual-Leone [1,2,4]

[1]Linus Health, Inc. - Boston (United States), [2]Department of Neurology, Harvard Medical School - Boston (United States), [3]Department of Neurology, University of Miami Miller School of Medicine - Miami (United States), [4]Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife - Boston (United States)

LP075 A pilot test to examine the utility of the Montreal Cognitive Assessment (MoCA) in predicting Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score for eligibility in Alzheimer's Disease (AD) trials

Elizabeth Sosa [1], Jennifer Mitolo [1], Tara Parnitvithikul [1], Jade Serrano-Sanchez [1], Corinne Karmar [1]

[1]Irvine Clinical Research - Irvine (United States)

LP076 Identifying the Severity of Dementia Based on Cognitive Performance and Index of Independence in Basic Activities of Daily Living

Duong Huynh [1], Bin Huang [1], Reza Hosseini Ghomi [1,2]

[1]BrainCheck Inc. - Austin (United States), [2]Frontier Psychiatry - Billings (United States)

LP077 Comparing Psychometric Characteristics of a Computerized Cognitive Test (BrainCheck-Assess) against the Montreal Cognitive Assessment (MoCA)

Duong Huynh [1], Bin Huang [1], Reza Hosseini Ghomi [1,2]

[1]BrainCheck Inc. - Austin (United States), [2]Frontier Psychiatry - Billings (United States)

LP078 Cognitive effects of a randomized, double-blind, placebo-controlled, 36-week clinical trial of citrus phytochemicals in subjective cognitive decline

Elena Gatti[1], Giovanni Sgro[2,3], Natale Salvatore Bonfiglio[4], Andrea Geviti[4], Salvatore Genovese[5], Serena Fiorito[5], Lucia Palumbo[5], Giovanni B. Frisoni[6], Michela Pievani[1], Francesco Epifano[5], Samantha Galluzzi[1]

[1]Laboratory Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia (Italy) [2]Molecular Markers Laboratory and [3]Clinical Trial Service, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia (Italy) [4]Service of Statistics, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, (Italy) [5]Laboratory of Phytochemistry and Chemistry of Natural Products, Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Chieti, (Italy) [6]University Hospitals and University of Geneva, Geneva (Switzerland)

LP080 Eco-Exposome and Mild Cognitive Impairment: Linking Environmental and Social Vulnerability Indices to the COG-IT Clinical Trial

Alisa Adhikari [1], Adaora Nwosu [1], Caroline Hellegers [1], Julia Phillips [2], Jeffery Petrella [3], Davangere Devanand [4], Murali Doraiswamy [1]

[1]Neurocognitive Disorders Program, Department of Psychiatry, Duke University School of Medicine - Durham (United States), [2]Department of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute - New York City (United States), [3]Department of Radiology, Duke University School of Medicine - Durham (United States), [4]b Department of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute - New York City (United States)

POSTER PRESENTATIONS

LP121 memTEST, a direct-to-consumer self-administered digital cognitive test SELF completed in under 10 minutes on mobile (Android or iPhone), PC, or tablet to increase clinical trial participation and decrease screen fails for verbal screening tests and fluid biomarkers in Alzheimer's Disease clinical trials

David Watson [1], Sean Stanton [2], Robert Guilfoyle [3], Thomas Mareck [3], Brandon Lenox [1]
[1]K2 Medical Research - Maitland (United States), [2]K2 Medical Research - Winter Park (United States), [3]Recall Technologies - Orlando (United States)

LP122 Validating Enhanced Behavioral Measures of Word Recall Based on Underlying Cognitive Processes

Jason Bock [1, 2], Junko Hara [1, 3], Dennis Fortier [1], Tushar Mangrola [1], Michael Lee [2]
[1]Embic Corporation - Newport Beach (United States), [2]Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), [3]Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)

LP123 ARC-DS: A Digital Cognitive Outcome Measure for Down Syndrome-Associated AD Prevention Trials

Jason Hassenstab [1], Laura Del Hoyo Soriano [2], Olivia Wagemann [3], Asaad Baksh [4], Andrew Aschenbrenner [1], Beau Ances [1], Juan Fortea [2], Johannes Levin [3], Michael Schöll [5], Ezequiel Surace [6], Andre Strydom [4]
[1]Washington University in St. Louis - St. Louis (United States), [2]Sant Pau Hospital - Barcelona (Spain), [3]Ludwig-Maximilian-University - Munich (Germany), [4]King's College London - London (United Kingdom), [5]University of Gothenburg - Gothenburg (Sweden), [6]FLENI Institute - Buenos Aires (Argentina)

THEME: Behavioral disorders and clinical trials

P138 Effects of brexpiprazole on agitation associated with dementia due to Alzheimer's disease: analysis of pooled efficacy data from two Phase 3 fixed-dose trials by baseline agitation frequency

Jyoti Aggarwal [1], Daniel Lee [1], Nanco Hefting [2], Dalei Chen [1], Denise Chang [1], Zhen Zhang [1], Maia Miguelez [1], Saloni Behl [1]
[1]Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), [2]H. Lundbeck A/S - Valby, Copenhagen (Denmark)

P139 Effects of brexpiprazole on agitation associated with dementia due to Alzheimer's disease: analysis of pooled response data from two Phase 3 fixed-dose trials

Daniel Lee [1], Jyoti Aggarwal [1], Nanco Hefting [2], Dalei Chen [1], Denise Chang [1], Saloni Behl [1]
[1]Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), [2]H. Lundbeck A/S - Valby, Copenhagen (Denmark)

P140 Design of ADEPT-2, a phase 3, parallel group study to evaluate KarXT (xanomeline–trospium) as a treatment for psychosis associated with Alzheimer's disease

Minsu Kang [1], Carolyn Watson [1], Jeffrey Cummings [2], George Grossberg [3], Ronald Marcus [1], Paul Yeung [1]
[1]Karuna Therapeutics - Boston (United States), [2]Chambers-Grundy Center for Transformative Neuroscience, University of Nevada, Las Vegas - Las Vegas (United States), [3]Department of Psychiatry & Behavioral Neuroscience, Saint Louis University School of Medicine - Saint Louis (United States)

LP124 A review of meaningful change in agitation behaviors associated with Alzheimer's disease and the potential impact of brexpiprazole

Jyoti Aggarwal [1], Brian Talon [2], Pedro Such [3], Malaak Brubaker [1], David Wang [3], Alireza Atri [4, 5, 6, 7]
[1]Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton (United States), [2]H. Lundbeck A/S - Deerfield (Denmark), [3]H. Lundbeck A/S - Valby, Copenhagen (Denmark), [4]Banner Sun Health Research Institute - Sun City (United States), [5]Banner Alzheimer's Institute - Phoenix (United States), [6]Brigham and Women's Hospital - Boston (United States), [7]Harvard Medical School - Boston (United States)

LP125 Longitudinal Effects of Caregiving Burden on Inflammatory Biomarkers in Spousal Caregivers of Individuals with Cognitive Impairments

So Yeon Jeon [1]
[1]Department of psychiatry, Chungnam National University College of Medicine - Daejeon (Korea, Republic of)

LP126 Feasibility and acceptability of using technology in caregivers and Alzheimer's disease patients with agitation

H Okhravi [1], A Gupta [2], S Jain [3], K Maly [2], C Nesbitt [2], I El Moudden [1], S Alyaan [2]
[1]Eastern Virginia Medical School - Norfolk (United States), [2]Old Dominion Univiersity - Norfolk (United States), [3]Stony Brook University - New York (United States)

THEME: Health economics and clinical trials

P141 Implications of Treatment Duration and Intensity on the Value of Alzheimer's Treatments

Soeren Mattke [1], Tabasa Ozawa [1], Mark Hanson [1]
[1]USC - Los Angeles (United States)

P142 Amyloid PET: The Case for Quantification in Clinical Routine

Phillip Kuo [1], William Jagust [2], Gill Farrar [3]
[1]U Arizona - Tuscon (United States), [2]UC Berkeley - Berkeley (United States), [3]GE Healthcare - Amersham (United Kingdom)

P143 Assessing health system capacity for delivery of a disease-modifying therapy for Alzheimer's disease: a multi-country analysis

Ilke Mirik Danaci [1], Valerie Crowell [1], Nathalie Budd [2], Haakon B Nygaard [3]
[1]F. Hoffmann-La Roche Ltd - Basel (Switzerland), [2]F. Hoffmann-La Roche Ltd - Mississauga (Canada), [3]Division of Neurology and Djavad Mowafaghian Centre for Brain Health - Vancouver (Canada)

THEME: Epidemiology and clinical trials

P144   **State Department of Motor Vehicles clinician reporting mandates of dementia diagnoses: Evidence for risks and benefits**

Hankyung Jun [1], Ying Liu [2], Emily Chen [2], Andrew Becker [2], Soeren Mattke [2]
[1]Harvard Medical School - Boston (United States), [2]University of Southern California - Los Angeles (United States)

P145   **Age-specific relative comorbidity burden of mild cognitive impairment: A US database study**

Gang Li [1], Nicola Toschi [2], Viswanath Devanarayan [1], Richard Batrla [1], Tommaso Boccato [2], Min Cho [1], Matteo Ferrante [2], Feride Frech [1], James Galvin [3], David Henley [4], Soeren Mattke [5], Susan De Santi [1], Harald Hampel [1]
[1]Eisai Inc - Nutley (United States), [2]University of Rome Tor Vergata - Rome (Italy), [3]University of Miami - Miami (United States), [4]Janssen Research & Development - New Brunswick (United States), [5]University of Southern California - Los Angeles (United States)

P146   **Comorbidities Occurring Before and After Diagnosis of Mild Cognitive Impairment or Alzheimer's Disease: A Large US Nationwide Electronic Health Record Cohort Study**

Lisa Vinikoor-Imler [1], Olga Sanchez-Solino [1], Emma Xiaomeng Yue [1], Isabella Boroje [1]
[1]AbbVie Inc. - Chicago (United States)

P147   **Biomarker and clinical correlations for amyloid targeting monoclonal antibody (mAb) treatment responses**

Jonathan Wagg [1], Nicolas Fournier [1], Garance Lucken [1], Clarisse Schumer [2], Olivier Sol [1], Julian Gray [1], Marija Vukicevic [1], Marie Kosco-Vilbois [1], Andrea Pfeifer [1], Johannes Streffer [1]
[1]AC Immune SA - Lausanne (Switzerland), [2]EPFL - Lausanne (Switzerland)

P148   **High prevalence of amyloid cerebral pathology in older adults with cognitive frailty - an indication for anti-amyloid therapies?**

Sandrine Sourdet [1], Gaëlle Soriano [1], Bruno Vellas [1]
[1]Gerontopôle - Toulouse (France)

P149   **Acculturation-related characteristics associated with research attitudes among underrepresented populations recruited to an Alzheimer's disease preclinical trial**

Christian Salazar [1], Hye-Won Shin [1], Melanie Tallakson [1], Edwin Duran [1], Russ Eunji [1], Maria Corona [1], Romina Romero [1]
[1]UC Irvine Institute for Memory Impairments and Neurological Disorders - Irvine (United States)

P150   **Sildenafil is a candidate drug for Alzheimer's disease: Real-world patient data observation**

Cheng Feixiong [1], Zhang Pengyue [2], Jeffrey Cummings [3]
[1]Cleveland Clinic - Cleveland (United States), [2]Indiana University - Bloomington (United States), [3]University of Nevada Las Vegas - Las Vegas (United States)

LP081   **Bridging the Gap: Enhancing Representation in Alzheimer's Clinical Trials Through Strategic Collaboration with Primary Care Clinics in Diverse Communities**

Brina Quaning [1], Santiago Santeli [2], Sandra Carmona Torres [2], Lucy Lenox [2], Bryce Warner [2], Sheila Baez-Torres [2]
[1]Metro Health Inc. - Orlando (United States), [2]K2 Medical Research - Orlando (United States)

LP082   **Predictors of Response Rate to a Mailed Invitation to Participate in a Dementia Prevention Lifestyle Intervention Trial (U.S. POINTER): Houston Site Experience**

Valory Pavlik [1], Melissa Yu [1], Hannah Shields [1], Ashley Alexander [2], Rose Trevino-Whitaker [2], John Valenta [2], Richard ELPein [3], Ann Marie Mcdonald [3]
[1]Baylor College Of Medicine - Houston (United States), [2]Kelsey Research Foundation - Houston (United States), [3]Alzheimer's Association - Houston (United States)

LP083   **Alzheimer's disease linkage to evidence (AD-LINE) study: An analysis of concordance between clinical diagnosis and evidence of AD diagnosis in real-world US claims data**

Howard Fillit [1,2], Sheila Seleri Assunção [3], Chris Wallick [3], Ibrahim M. Abbass [3], Carmen Ng [3], Tu My To [3], Karina Raimundo [3], Thomas Majda [3], Desilu Glazebrook [3], Oleg V. Tcheremissine [4]
[1]Alzheimer's Drug Discovery Foundation, - New York City (United States), [2]Departments of Geriatric Medicine, Medicine, and Neuroscience, Icahn School of Medicine at Mount Sinai - New York City (United States), [3]Genentech, Inc., a member of the Roche Group - South San Francisco (United States), [4]Department of Psychiatry, Atrium Health Behavioral Health Charlotte - Charlotte (United States)

LP127   **Characteristics of adults with incident cognitive impairment in a population-based study of cognitive aging**

Khaled Ghoniem [1], Jeremiah A. Aakre [2], Anna M. Castillo [2], Mohamed Elminawy [1], Emma A. Brauer [1], Prashanthi Vemuri [3], Clifford R. Jack Jr. [3], Jonathan Graff-Radford [1], David S. Knopman [1], Ronald C. Petersen [1], Maria Vassilaki [1]
[1]Department of Neurology, Mayo Clinic - Rochester (United States), [2]Department of Quantitative Health Sciences, Mayo Clinic - Rochester (United States), [3]Department of Radiology, Mayo Clinic - Rochester (United States)

LP128   **Study Partner Effect on Retention in Alzheimer's Disease Trials**

Michelle Nuño [1], Daniel Gillen [2], Joshua Grill [2]
[1]University of Southern California - Los Angeles (United States), [2]University of California, Irvine - Irvine (United States)

POSTER PRESENTATIONS

THEME: Animal model

P151   Deciphering the mechanisms of action of cognitive gain using the multidomain lifestyle intervention protocol – from human RCTs to mice

Vilma Alanko [1,2], Francesca Eroli [2], Alina Solomon [3,4], Krister Håkansson [1], Tiia Ngandu [5], Tobias Hartmann [6,7], Per Nilsson [2], Miia Kivipelto [1,4,8], Silvia Maioli [2], Anna Matton [1,2,4]

[1]Division of Clinical Geriatrics, Department of NVS, Karolinska Institutet - Solna (Sweden), [2]Division of Neurogeriatrics, Department of NVS, Karolinska Institutet - Solna (Sweden), [3]Institute of Clinical Medicine/Neurology, University of Eastern Finland - Kuopio (Finland), [4]Ageing Epidemiology (AGE) Research Unit, Imperial College London - London (United Kingdom), [5]Population Health Unit, Finnish Institute for Health and Welfare - Helsinki (Finland), [6]Deutsches Institut für Demenz Prävention (DIDP), Saarland University - Homburg (Germany), [7]Department of Experimental Neurology, Medical Faculty, Saarland University - Homburg (Germany), [8]Theme Inflammation and Aging, Karolinska University Hospital - Solna (Sweden)

P152   Subcellular and secretory effects of the App^{NL-F} knock-in in mice neurons

Sophia Schediin-Weiss [1], Yang Yu [1], Robin Z. Zhou [1], Lars O. Tjernberg [1]

[1]Karolinska Institutet - Solna (Sweden)

LP084   TREM2 Agonism Affects Human Microglia Response in the Presence of Amyloid Pathology In Vivo

Peter Flagstad [1], Ivana Geric [1,2,3], Manuela Polydoro [1], Leen Wolfs [2,3], Anke Misbaer [1,2,3], Arya Nair [2,3], Laura Sans [1], Maria DaLPy [1], Jin Zheng [1], Tina Sommer Bisgaard [1], Lars Christian Roenn [1], Rita Balice-Gordon [1], Bart De Strooper [2,3,4], Niels Plath [1]

[1]Muna Therapeutics - Copenhagen (Denmark), [2]Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB) - Leuven (Belgium), [3]Department of Neurosciences and Leuven Brain Institute, KU Leuven - Leuven (Belgium), [4]UK Dementia Research Institute at UCL, University College London - London (United Kingdom)

LP085   KIT-13, an Innovative Plasmalogen Derivative, Improved Memory and Cognition through Suppression of Neuroinflammation in Murine Models

Md Shamim Hossain [1], Shiro Mawatari [1], Masanori Honsho [2], Takehiko Fujino [3]

[1]Institute of Rheological Functions of Food - Fukuoka (Japan), [2]Kyushu University - Fukuoka (Japan), [3]Neurocores - Boston (United States)

LP086   Protective Effects of New Combination Drug FPT-03 in Oxidative Damages and Cognitive Impairments against Traumatic Brain Injury

William Chao [1], Bert Chen [1], Chia-Yi Tseng [2]

[1]Future PharmTech - Taipei (Taiwan, Republic of China), [2]Chung Yuan Christian University - Taoyuan (Taiwan, Republic of China)

LP087   Nonfibrillar Dutch mutant amyloid beta (Aβ) aggregates (oligomers) revealed by anti-prefibrillar oligomer antibody A11 and FITC-peptide imaging are associated with aging-related synaptic dysfunction but cause no detectable inflammation

Sam Gandy [1], Emilie Castranio [1], Merina Varghese [1], Elentina Argyrousi [2], Kuldeep Tripathi [3], Charles Glabe [4], Efrat Levy [5], Minghui Wang [1], Bin Zhang [1], William Lubell [6], Brigitte Guerin [7], Shai Rahimipour [8], Dara Dickstein [9], Ottavio Arancio [2], Michelle Ehrlich [1]

[1]Icahn School of Medicine - New York (United States), [2]Columbia U - New York (United States), [3]Bar Ilan U - Raman Gat (Israel), [4]U Calif Irvine - Irvine (United States), [5]NYU & NKI - New York (United States), [6]U Montreal - Montreal (Canada), [7]U Sherbrooke - Sherbrooke (Canada), [8]Bar Ilan U - Raman Gat (Canada), [9]Uniformed Health Sci U - Bethesda (United States)

LP088   Humanized model to study the role of Kv1.3 blockade on microglia in neuroinflammation

Ivana Geric [1], Lucas Baltussen [2], Leen Wolfs [2], Anke Misbaer [1], Negin Afrang [2], Laura Sans [1], Maria DaLPy [1], Anja Koustrup [1], Dorota Kuczek [1], Jorge Valadas [1], Lars Christian Roenn [1], Marianne Terndrup Pedersen [1], Rita Balice-Gordon [1], Bart De Strooper [2,3,4], Niels Plath [1]

[1]Muna Therapeutics - Copenhagen (Denmark), [2]Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB) - Leuven (Belgium), [3]UK Dementia Research Institute at UCL - London (United Kingdom), [4]Department of Neurosciences and Leuven Brain Institute, KU Leuven - Leuven (Belgium)

LP089   Impact of 'Masked' 40 Hz Light Therapy on Cognitive Decline and Associated Neuropathology in a Mouse Model of Alzheimer's Disease

Madison Browne [1], Olive Curreri [1], Stephanie Ancheta [1], Lucy Jiwu [1], Stephanie Wu [1], Lynn Yang [1], Yuanyuan Yao [1], Marcus Carstensen [2,3], Mai Nguyen [2], Daniela Kaufer [1], Lance Kriegsfeld [1]

[1]University of California, Berkeley - Berkeley (United States), [2]Optoceutics ApS - Copenhagen (Denmark), [3]Technical University of Denmark - Lyngby (Denmark)

THEME: New therapies and clinical trials

P153   Impact of adherence on cognitive outcomes in a pilot study of the Cogstim model

Raymond L Ownby [1]

[1]Nova Southeastern University - Fort Lauderdale (United States)

P154   Pivotal trial of low-intensity pulsed ultrasound therapy for early stage of Alzheimer's disease (LIPUS-AD) –Rationale and design-

Hiroaki Shimokawa [1,2], Masanori Akishita [3], Masafumi Ihara [4], Satoshi Teramukai [5], Aiko Ishiki [6], Yoji Nagai [7], Hajimu Kato [2], Masanori Fukushima [8]

[1]International University of Health and Welfare - Narita (Japan), [2]Sound Wave Innovation Inc. - Tokyo (Japan), [3]University of Tokyo - Tokyo (Japan), [4]National Cerebrovascular and Cardiovascular Center - Suita (Japan), [5]National Cerebrovascular and Cardiovascular Center - Kyoto (Japan), [6]Tohoku Medical and Pharmaceutical University - Sendai (Japan), [7]Kyoto University - Kyoto (Japan), [8]Learning Health Society Institute - Nagoya (Japan)

P155   Masupirdine (A Pure 5-HT6 Receptor Antagonist) for the Treatment of Agitation in Patients with Dementia of Alzheimer's Type - Rationale and Phase-3 Study Design

Ramakrishna Nirogi [1], Jyothsna Ravula [1], Satish Jetta [1], Vinod Kumar Goyal [1], Pradeep Jayarajan [1], Vijay Benade [1], Anil Shinde [1], Santosh Kumar Pandey [1], Ramkumar Subramanian [1], Abdul Rasheed Mohammed [1], Venkat Jasti [1]

[1]Suven Life Sciences Ltd - Hyderabad (India)

P157 Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate

Linda Van Eldik [1], Wendy Ziai [2], Lauren Sansing [3], Daniel Hanley [2]
[1]University of Kentucky - Lexington (United States), [2]Johns Hopkins University - Baltimore (United States), [3]Yale University - New Haven (United States)

P158 Treatment of early symptomatic Alzheimer's disease with nasal Protollin to activate monocytes and clear amyloid beta

Panayota Kolypetri [1], Patrick Da Silva [1], Lei Liu [1], Christian D. Gauthier [1], Taylor J. Saraceno [1], Tarun Singhal [1], Seth A. Gale [1], Tanuja Chitnis [1], Dennis J. Selkoe [1], Howard L. Weiner [1]
[1]Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School - Boston (United States)

LP090 The purely thermodynamic anti-prionic mode of action for the treatment of neurodegenerative diseases

Dieter WilLPold [1]
[1]Forschungszentrum Jülich - Jülich (Germany)

LP091 Rationale for a trial in type 2 diabetes and/or coronary artery disease: Combined intervention with exercise and a soluble epoxide hydrolase inhibitor

Myuri Ruthirakuhan [1,2], Natasha Anita [1,2,3], Jennifer S. Rabin [2,3,4], Maged Goubran [2], Nathan Herrmann [2], Paul I. Oh [5], Ameer Y. Taha [6], Sandra E. Black [2,5], Carmela Tartaglia [7], Ana C. Andreazza [1], Hugo Cogo-Moreira [8], Jodi Edwards [9], Krista Lanctot [1,2,3,10], Walter Swardfager [1,2,3]
[1]Department of Pharmacology & Toxicology – University of Toronto - Toronto (Canada), [2]Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute - Toronto (Canada), [3]KITE Research Institute, Toronto Rehabilitation Institute-University Health Network - Toronto (Canada), [4]Rehabilitation Sciences Institute, Temerty Faculty of Medicine, University of Toronto - Toronto (Canada), [5]Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto - Toronto (Canada), [6]Department of Food Science and Technology, College of Agriculture and Environmental Sciences, University of California, Davis; West Coast Metabolomics Center, Genome Center, University of California - Davis; Center for Neuroscience, One Shields Avenue, University of California - Davis, Ca (United States), [7]Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto - Toronto (Canada), [8]Department of Education, ICT and Learning, Østfold University College - Østfold (Norway), [9]School of Epidemiology and Public Health-University of Ottawa - Ottawa (Canada), [10]Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto - Toronto (Canada)

LP092 Personalized hippocampal network-targeted stimulation for Alzheimer's disease: A randomized controlled trial

Young Hee Jung [1], Hyemin Jang [2], Sungbeen Park [3], Hee Jin Kim [2], Sang Won Seo [2], Guk Bae Kim [4], Duk Lyul Na [5]
[1]Myongji Hospital, College of Medicine, Hanyang University - Goyang (Korea, Republic of), [2]Samsung Medical Center - Seoul (Korea, Republic of), [3]Hanyang University - Seoul (Korea, Republic of), [4]anymed - Seoul (Korea, Republic of), [5]sungkyunkwan University - Seoul (Korea, Republic of)

LP093 Efficacy and Safety Of AXS-05 in Agitation Associated With Alzheimer's Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial

Jeffrey Cummings [1], George Grossberg [2], Candace Andersson [3], Graham Eglit [3], Caroline Streicher [3], Herriot Tabuteau [3]
[1]University of Nevada, Las Vegas - Las Vegas, Nv (United States), [2]Saint Louis University School of Medicine - St. Louis, Mo (United States), [3]Axsome Therapeutics - New York, Ny (United States)

LP094 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Escalating Single and Multiple Doses of DGX-001 in Healthy Volunteers Followed by a Stress Exposure Resilience Panel (SERP)

Tom Polasek [1], Titus Plattel [2], Richard Kim [2], Steve Smith [2], Igor Grachev [2], Neil Schwartz [2], Dirk Smith [2]
[1]Monash University - MeLPourne (Australia), [2]Viage - Palo Alto (United States)

LP095 NeuroRestore ACD856, a Trk-PAM in clinical development for Alzheimer's disease shows neuroprotective and neurorestorative effects

Pontus Forsell [1,2], Veronica Lidell [1,2], Azita Rasti [1,2], Gunnar Nordvall [1,2], Johan Sandin [1,2], Martin Jönsson [1,2]
[1]AlzeCure Pharma AB, Hälsovägen 7, Sweden - Huddinge (Sweden), [2]Division of Neuroscience, Care and Society, Karolinska Institutet, Sweden - Solna (Sweden)

LP096 Phase 1 SAD/MAD data and Phase 2 study design for LHP588, a second-generation gingipain inhibitor for the treatment of P. gingivalis-positive Alzheimer's dementia

Michael Detke [1], Marwan Sabbagh [2], Joanna Bolger [1], Jianhong Wang [1], Mark Ryder [3], Suzanne Hendrix [4], Sam Dickson [4], Craig Mallinckrodt [4], Leslie Holsinger [1], Casey Lynch [1], Stephen Dominy [1]
[1]Lighthouse Pharmaceuticals - San Francisco (United States), [2]Barrow Neurological Institute - Phoenix (United States), [3]University of California, San Francisco, CA - San Francisco (United States), [4]Pentara Corp - Millcreek (United States)

LP097 Alzheimer's Disease Research Recruitment in a World with Disease Modifying Treatments on Market

Ira Goodman [1], Daniel Gautieri [1], Erin Beck [1], Michael Stalder [1]
[1]SiteRx - New York (United States)

LP129 Treatment of Alzheimer's Disease Subjects With Expanded Non-genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity — Final Report of a Phase I Dose Escalation Study

Clemente Humberto Zuniga Gil [1], Blanca Isaura Acosta Gallo [1], Rufino Menchaca Diaz [1], Cesar Alejandro Amescua [1], Sean Hong [2], Lucia Hui [2], Hank Lee [2], Juan Mata [2], Paul Y. Chang [2], Katia Betito [2], Paul Y. Song [2]
[1]Hospital Angeles - Tijuana (Mexico), [2]NKGen Biotech - Santa Ana (United States)

LP130 Anti-Abeta liposomal vaccine, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies

Emma Fiorini [1], Chiara Babolin [1], Rakel Carpintero [1], Stefania Rigotti [1], Stefanie Siegert [1], Catherine Morici [1], Maelle Verardo [1], Jonathan Wagg [1], Piergiorgio Donati [1], Saskia Delpretti [1], Johannes Streffer [1,2], Andrea Pfeifer [1], Marie Kosco-Vilbois [1], Marija Vukicevic [1]
[1]AC Immune SA - Lausanne (Switzerland), [2]University of Antwerp - Antwerp (Belgium)

POSTER PRESENTATIONS

THEME: Proof of concept/Translational research for Alzheimer Drug Development interventions

P159 D-peptide-magnetic nanoparticles disaggregate tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease
Ke Hou [1], Hope Pan [1], David Eisenberg [1]
[1]UCLA - Los Angeles (United States)

P160 Structural dynamics of amyloid-β protofibrils and action of lecanemab as observed by high-speed atomic force microscopy
Kenjiro Ono [1], Takahiro Nakayama [2], Mayumi Tsuji [3], Kenichi Umeda [2], Tatsunori Oguchi [3], Hiroki Konno [2], Moeko Shinohara [1], Yuji Kiuchi [3], Noriyuki Kodera [2], David B. Teplow [4]
[1]Kanazawa University Graduate School of Medical Sciences - Kanazawa (Japan), [2]Nano Life Science Institute, Kanazawa University - Kanazawa (Japan), [3]Showa University School of Medicine - Tokyo (Japan), [4]David Geffen School of Medicine at UCLA - Los Angeles (United States)

P161 APOE-Targeted Epigenome Therapy for Alzheimer's Disease: Pre-Clinical Studies
Ornit Chiba-Falek [1,2], Boris Kantor [1,2]
[1]Duke University - Durham (United States), [2]CLAIRIgene, LLC - Durham (United States)

P162 A Possible Pathogenic PSEN2 Gly56Ser Mutation in a Korean Patient with Early-Onset Alzheimer's Disease
Da-Eun Jeong [1], Min Ju Kang [1]
[1]Department of Neurology, Veterans Health Service Medical Center - Seoul (Korea, Republic of)

P163 Effect of spectral binning in x-ray scattering method for non-invasively characterizing amyloids
Eshan Dahal [1], Sabri Amer [1], Karthika Suresh [1], Olivia Sandvold [2], Peter Noël [2], Aldo Badano [1]
[1]U.S. Food and Drug Administration - Silver Spring (United States), [2]University of Pennsylvania - Philadelphia (United States)

P164 Novel brain shuttle platform for precision delivery of Alzheimer's disease therapeutics
Liqun Wang [1], João Santos [2], Amy England [1], Yife Lu [1], Amanda Graveline [1], Melinda Sanchez [1], Teresa Barata [2], Daniela Teixeira [2], Donald Ingber [1], James Gorman [1]
[1]Wyss Institute at Harvard University - Boston (United States), [2]FairJourney Biologics - Porto (Portugal)

P165 Equilibrative nucleoside transporter 1 (ENT1) as a promising therapeutic target to rescue pathological features and alleviate cognitive impairment in Alzheimer's disease
Chien-Yu Lin [1,2], Ching-Pang Chang [1,2], Kuo-Chen Wu [2,3], Ching-Wen Wu [1,2], Chun-Jung Lin [2,3], Yijuang Chern [1,2]
[1]Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Republic of China), [2]Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Republic of China), [3]School of Pharmacy, National Taiwan University - Taipei (Taiwan, Republic of China)

P166 Study of novel copper and zinc binding analogue of GMP-1 in Tg4510 tauopathy mouse model
Bengt Winblad [1], Zhe Zhao [1], Pavel Pavlov [1]
[1]Karolinska Institutet - Solna (Sweden)

P167 Novel small molecule poly-disaggregator therapeutics for AD, ALS and FTD reduce TDP-43 oligomerization, aggregation, and pathology
Marcela Kokes [1], Vidhu Mathur [1], Eric Shao [1], Shruti Arya [1], Catherine Planey [1]
[1]Acelot - Palo Alto (United States)

P168 Differences in Glutaminyl Cyclase protein levels in Mild Cognitive Impairment subjects
Xavier Morato [1], Amanda Cano [1], Sergi Valero [1], Raul Nuñez [1], Raquel Puerta [1], Jose Antonio Allué [1], Leticia Sarasa [1], Agustín Ruiz [1], Mercè Boada [1]
[1]FUNDACIO ACE - Barcelona (Spain)

P169 White matter hyperintensity accumulation is related to cerebral amyloid angiopathy and neurodegeneration in autosomal dominant and sporadic AD
Zahra Shirzadi [1], Stephanie Schultz [1], Wai-Ying Yau [1], Nelly Friedrichsen [2], Kejal Kantarci [3], Gregory Preboske [3], Clifford Jack Jr [3], Brian Gordon [2], Eric Mcdade [2], Tammie Benzinger [2], Randall Bateman [2], Steven Greenberg [1], Reisa Sperling [1], Aaron Schultz [1], Jasmeer Chhatwal [1]
[1]Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), [2]Washington University in St. Louis School of Medicine - St. Louis (United States), [3]Mayo Clinic, Radiology - Rochester (United States)

P170 Systematic in silico analysis of clinically tested drugs for reducing amyloid beta plaque accumulation in Alzheimer's disease
Sarah Head [1], Raibatak Das [1], Brian Campbell [2], Dan Zweifel [2], John Burke [1], Joshua Apgar [1], Fei Hua [1]
[1]Applied BioMath - Concord, Massachusetts (United States), [2]Prothena Biosciences Inc. - South San Francisco, California (United States)

P171 In Silico Simulation of Dementia-Alzheimer-Syndrome: Application of hybrid computing approach to the study of emergent behavior
Ara Khachaturian [1], Zaven Khachaturian [1], Jeanmarie Bouteiller [2], Eva Troppová [3], Vaclav Snášel [4], Vit Vondrák [4], Jiri Damborský [5], Stanislav Mazurenko [5], Josef Šivic [3], Vit Dočkal [3]
[1]Campaign to Prevent Alzheimer's Disease - Rockville (United States), [2]University of Southern California - Los Angeles (United States), [3]Czech Institute of Informatics, Robotics and Cybernetics, Czech Technical University - Prague (Czech Republic), [4]Technical University of Ostrava - Ostrava (Czech Republic), [5]International Clinical Research Center of St. Anne's University Hospital - Brno (Czech Republic)

P172 Neuroprotective and mnesic-improving effects of Fluoroethylnormemantine (FENM) in the Aß25-35 mouse model of Alzheimer's disease
Allison Carles [1], Aline Freyssin [2], Florent Perin-Dureau [2], Gilles Rubinstenn [2], Tangui Maurice [1]
[1]MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France, [2]ReST Therapeutics - Paris (France)

P173   Nanolithium has a dual potential in Alzheimer's disease: to treat Neuropsychiatric Symptoms and modify disease course

Maria Eugenia Soto-Martin [1], Solene Guilliot [2], Pierre-Jean Ousset [1], Karim Bennys [3], Claire Paquet [4], Jacques Touchon [5], Edward N Wilson [6]

[1]Alzheimer's disease Memory Research & Clinical center, Department of Geriatrics, Gerontopole, Hôpital Lagrave - Toulouse (France), [2]Medesis Pharma - Baillargues (France), [3]Alzheimer's disease Memory Research & Clinical center, Department of Neurology, University Hospital Gui de Chauliac - Montpellier (France), [4]Cognitive Neurology Center, Lariboisière Fernand-Widal Hospital APHP Université de Paris Cité - Paris (France), [5]University of Montpellier - Montpellier (France), [6]Neurology & Neurological Sciences, Stanford School of Medicine - Stanford (United States)

P174   Advancing Diverse Recruitment by Assessing Facilitators and Barriers to Participation in Alzheimer's and Dementia-Related Research

John Lucas [1], Shawna Green [1], Maisha Robinson [1], Aaron Spaulding [1]

[1]Mayo Clinic - Jacksonville (United States)

P175   Fosgonimeton, a small-molecule positive modulator of the HGF/MET system, attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease

Sherif Reda [1], Sharay Setti [1], Andrée-Anne Berthiaume [1], Wei Wu [1], Jewel Johnston [1], Robert Taylor [1], Kevin Church [1]

[1]Athira Pharma, Inc. - Bothell (United States)

P176   Designed peptide targeting α-sheet Amyloid-β oligomers decreases toxic oligomer burden and improves behavior in AD mouse models

Carolyn Tallon [1], Chandresh Gajera [1], Jeff Posakony [1], GiLPert Block [1], Valerie Daggett [1]

[1]AltPep Corporation - Seattle (United States)

P177   Unraveling the therapeutic potential of novel hyaluronic acid estradiol conjugate ND108E in Alzheimer's Disease: Mechanistic insights and future directions

Chia-Lung Hou [1], Szu-Yuan (viola) Lee [1], Jia-Chi Wang [1], Ting-An Chen [1], Kai-Ting Chang [1], Mu-Hsuan Chen [2], Hsiao-Chun Lin [2], Tzu Chao [2], Tsyr-Jiuan Wang [3], Jeng-Rung Chen [2]

[1]Holy Stone HealthCare - Taipei (Taiwan, Republic of China), [2]National Chung-Hsing University - Taichung (Taiwan, Republic of China), [3]National Taichung University of Science and Technology - Taichung (Taiwan, Republic of China)

P178   Structural and biochemical similarities of protofibrils and plaque fibrils: implications for anti-amyloid immunotherapy

Andrew Stern [1], Yang Yang [2], Shanxue Jin [1], Keitaro Yamashita [2], Angela Meunier [1], Wen Liu [1], Yuqi Cai [1], Maria Ericsson [3], Lei Liu [1], Michel Goedert [2], Sjors Scheres [2], Dennis Selkoe [1]

[1]Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston (United States), [2]MRC Laboratory for Molecular Biology - Cambridge (United Kingdom), [3]Harvard Medical School - Boston (United States)

LP098   Human specific α7nAChR-dependent adaptation to mechanical properties of the extracellular environment

Ivanna Ihnatovych [1], Ryu P. Dorn [1], Erik Nimmer [1], Yuna Heo [1], Yongho Bae [1], Kinga Szigeti [1]

[1]University at Buffalo - Buffalo (United States)

LP099   Mechanistic insights into the translational gap for cholinergic therapies in Alzheimer's Disease

Kinga Szigeti [1], Ivanna Ihnatovych [1], Nicolás Rosas [2,1], Ryu P. Dorn [1], Emily Notari [1], Ziquiang Chen [1], Eduardo Cortes Gomez [3], Muye He [1], Megan Del Regno [1], David A. Bennett [4], Arnd Pralle [1], Yongho Bae [1], Jianmin Wang [3], Gregory Wilding [1]

[1]University at Buffalo - Buffalo (United States), [2]Universidad Nacional de San Martin - Buenos Aires (Argentina), [3]Roswell Park Comprehensive Cancer Center - Buffalo (United States), [4]Rush Alzheimer's Disease Center - Chicago (United States)

LP100   Human restricted CHRFAM7A gene may enhance brain efficiency

Kinga Szigeti [1], Ryu P. Dorn [1], Megan Del Regno [1], Jakimovski Dejan [2], Niels Bergsland [2], Murali Ramanathan [1], Michael G. Dwyer [2], Ralph H. Benedict [1], Robert Zivadinov [1]

[1]University at Buffalo - Buffalo (United States), [2]Buffalo Neuroimaging Analysis Center - Buffalo (United States)

LP101   Combined E2 and Christchurch Gain-of-Function Variants of the Human APOE Gene Delivered by AAVrh.10 Effectively Suppresses Both Amyloid and Tau Pathology in the CNS of Murine Models of APOE4 Homozygous Alzheimer's Disease

Cancer Günaydın [1], Dolan Sondhi [1], Stephen Kaminsky [1], Hailey Lephart [1], Philip Leopold [1], Richie Khanna [2], Ronald Crystal [1]

[1]Weill Cornell Medical College - New York (United States), [2]LEXEO Therapeutics - New York (United States)

LP102   New Approach to Alzheimer's Disease - Novel Chimeric GAS6 Fusion Protein

Soomin Ji [1], Haejung Han [1], Jaekeun Lee [1], Sanghoon Park [1], Won-Suk Chung [1,2], Chan Hyuk Kim [1,2]

[1]Illimis Therapeutics., Inc. - Seoul (Korea, Republic of), [2]Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST) - Daejeon (Korea, Republic of)

LP104   Microglia-Specific APOE-Targeted Epigenome Therapy for Alzheimer's Disease

Ornit Chiba-Falek [1], Elena Korsakova [2], Kantor Boris [1]

[1]Duke University - Durham (United States), [2]CLAIRIgene - Durham (United States)

LP105   ABvac40 induces anti-Aβx-40 plasma specific antibodies that bind with Aβ vascular deposits in brain slices from humans with cerebal amyloid angiopathy

María Montañes [1], Jesús Canudas [1], Ignacio Martinez [1], Ana María Lacosta [1], María Pascual-Lucas [1], Jose Terencio [2,1]

[1]Araclon Biotech-Grifols - Zaragoza (Spain), [2]Grifols - Barcelona (Spain)

POSTER PRESENTATIONS

LP106 Centiloid scale expression using Neurophet SCALE PET with diverse tracer comparison
Choe Yeong Sim [1], Lee Min-Woo [1], Kim Hajin [1], Lee Jiyeon [1], Moon Youngjoon [1], Lee Minho [1], Kim Donghyeon [1], Kim Regina Ey [1]
[1]*Research Institute, Neurophet Inc. - Seoul (Korea, Republic of)*

LP107 Simufilam's primary mechanism of action confirmed by time-resolved FRET
Erika Cecon [1], Julie Dam [1], Lindsay Burns [2], Ralf Jockers [1]
[1]*. Université Paris Cité, Institut Cochin, INSERM, CNRS - Paris (France), [2]Cassava Sciences, Inc. - Austin, Tx (United States)*

LP108 Prediction of global standardized uptake value ratio and amyloid status with both T1-weighted and T2-FLAIR image using deep learning
Min-Woo Lee [1], Hyeon Sik Yang [1], Hye Weon Kim [1], Yeong Sim Choe [1], Ji Min Kang [1], Soo Hyun Jeon [1], Young Joon Moon [1], Dong Hyeon Kim [1], Min Ho Lee [1], Dong Woo Kang [2], So Yeon Jeon [3], Sang Joon Son [4], Young-Min Lee [5], Regina Kim [1], Hyun Kook Lim [6]
[1]*Research Institute, Neurophet Inc. - Seoul (Korea, Republic of), [2]Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), [3]Department of Psychiatry, Chungnam National University Hospital - Daejeon (Korea, Republic of), [4]Department of Psychiatry, Ajou University School of Medicine - Suwon (Korea, Republic of), [5]Department of Psychiatry, Medical Research Institute, Pusan National University Hospital - Busan (Korea, Republic of), [6]Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)*

THEME: Digital health/E-trials

P179 Development of a mild cognitive impairment risk prediction model using electronic health record data
Gang Li [1], Viswanath Devanarayan [1], Rachel Halpern [2], Richard Batrla [1], Susan De Santi [1], Feride Frech [1], Jo Vandercappellen [1], Ara S. Khachaturian [3], Richard Crislip [4], Soeren Mattke [5], Harald Hampel [1]
[1]*Eisai - Nutley (United States), [2]Optum - Eden Prairie (United States), [3]Prevent Alzheimer's Disease 2020, Inc. - Rockville (United States), [4]OptumCare - Phoenix (United States), [5]University of Southern California - Los Angeles (United States)*

P180 Validating a novel digital cognitive platform: sensitivity to change following an alcohol challenge
John Dyer [1], Florentine Barbey [2], Md Nurul Islam [2], Judith Jaeger [3,4], Brian Murphy [2], Niamh Kennedy [5]
[1]*Cumulus Neuroscience - Belfast (United Kingdom), [2]Cumulus Neuroscience - Dublin (Ireland), [3]CognitionMetrics - Stamford, Ct (United States), [4]Albert Einstein College of Medicine - Bronx, Ny (United States), [5]University of Ulster - Coleraine (United Kingdom)*

P181 The effects of home-based, semi-computerized cognitive training on cognitive function in community dwelling older adults
Geon Ha Kim [1], Bori R. Kim [2], Haeun Kim [3], Jee Hyang Jeong [4]
[1]*Department of Neurology, Ewha Womans University,College of Medicine - Seoul (Korea, Republic of), [2]Ewha Medical Research,InstituteEwha Womans University - Seoul (Korea, Republic of), [3]Department of Artificial Intelligence Convergence, Ewha Womans University - Seoul (Korea, Republic of), [4]Ewha Womans University - Seoul (Korea, Republic of)*

P182 Comparing the Effects of Combined Cognitive and Functional Skills Training to Skills Training Alone: Burst Training Increases Training Gains without Increasing Drop-outs
Philip Harvey [1], Peter Kallestrup [2], Sara Czaja [3]
[1]*University of Miami Miller School of Medicine - Miami (United States), [2]i-Function - Miami (United States), [3]Weill Cornell Medical Center - New York (United States)*

P183 A real-world, longitudinal observational study in patients with Alzheimer's Disease dementia and healthy controls, using frequent repeated digital measurements performed at-home on the Cumulus Platform: a preliminary report
Alison Buick [1], Azar Alexander-Sefre [1], Shannon Diggin [1], John Dyer [1], Brian Murphy [2], Hugh Nolan [2], Laura Rueda-Delgado [2], James Rowe [3], Kinan Muhammed [4]
[1]*Cumulus Neuroscience Ltd - Belfast (United Kingdom), [2]Cumulus Neuroscience Ltd - Dublin (United Kingdom), [3]Department of Clinical Neurosciences, University of Cambridge - Cambridge (United Kingdom), [4]Nuffield Department of Clinical Neurosciences, University of Oxford - Oxford (United Kingdom)*

P184 Enhancing Automated Transcription for Speech-Based Screening in Alzheimer's Disease
Udeepa Meepegama [1], Caroline Skirrow [1], Michael Ropacki [2], Emil Fristed [1], Jack Weston [1]
[1]*Novoic - London (United Kingdom), [2]Strategic Global Research & Development - Temecula (United States)*

P185 A Hybrid Deep Learning Audio-Visual Approach for Mild Cognitive Impairment Prediction: I-CONECT Study
Farida Far Poor [1], Muath Alsuhaibani [1], Mohammad H Mahoor [1], Liu Chen [2], Hiroko H Dodge [2]
[1]*Department of Electrical and Computer Engineering, University of Denver - Denver (United States), [2]Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)*

P186 Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralised trials in Alzheimer's Disease
Florentine Marie Barbey [1], Christopher J Barnum [2], Alison R Buick [3], John Frederick Dyer [3], Md Nurul Islam [1], Jack Fogarty [4], Hugh Nolan [1], Brian Murphy [1]
[1]*Cumulus Neuroscience Ltd. - Dublin (Ireland), [2]INmune Bio Inc. - Boca Raton (United States), [3]Cumulus Neuroscience Ltd. - Belfast (United Kingdom), [4]Nanyang Technological University - Singapore (Singapore)*

P187 Accelerating Sustainable Adoption and Justification of Digital Clinical Detection Applications for Cognitive Impairment and Dementia into Established Healthcare Systems
Ara Khachaturian [1], Brittany Cassin [2], Glen Finney [3], Phyllis Barkman Ferrell [4], Eric Klein [4], Malaz Boustani [5], Zaven Khachaturian [1]
[1]*Campaign to Prevent Alzheimer's disease - Rockville (United States), [2]DigiCARE Realized Inc. - Old Bridge (United States), [3]Geisinger Health - Danville (United States), [4]Eli Lilly and Company - Indianapolis (United States), [5]Indiana University - Indianapolis (United States)*

P189   Correlation between Altoida's digital cognitive assessment and standard neuropsychological tests in individuals with mild cognitive impairment and cognitively healthy volunteers

Emmanuel Streel [1], Adria Tort Merino [2], Alberto Ferrari [3], Gonzalo Sanchez-Benavides [4,5,6,7], Carolina Minguillon [4,5], Silvia Fallone Fallone [8], Robbert Harms [9], Ioannis Tarnanas [10], Mircea Balasa [2], M. Florencia Iulita [11]

[1]Altoida Inc. - Washington (United States), [2]Hospital Clinic, IDIBAPS - Barcelona (Spain), [3]Altoida Inc. - Rome (Italy), [4]Barcelonaβeta Brain Research Center (BBRC) - Barcelona (Spain), [5]Pasqual Maragall Foundation - Barcelona (Spain), [6]Hospital del Mar Medical Research Institute - Barcelona (Spain), [7](CIBERFES), Instituto de Salud Carlos III - Madrid (Spain), [8]Altoida Inc. - Maastricht (Netherlands), [9]Altoida Inc. - Nijmegen (Netherlands), [10]Altoida Inc. - Thessaloniki (Greece), [11]Altoida Inc. - Barcelona (Spain)

P190   Building an Evidence Catalog of Digital Measurement Technologies to Accelerate Endpoint Development in Alzheimer's Disease and Related Dementias Clinical Trials

Sarah Averill Lott [1], Emmanuel Streel [2], Piper Fromy [3], Jennifer Goldsack [4], On Behalf of The Dime Core Digital Measures Of ADRD Project Team [4]

[1]The Digital Medicine Society - Johnstown (United States), [2]Altoida - Washington, DC (United States), [3]The Digital Medicine Society - Saumur (France), [4]The Digital Medicine Society - Boston (United States)

P191   Advancing Computerized Cognitive Assessment: Cognivue's® Enhanced Normative Range Data Sets the New Gold Standard for Sensitivity and Patient Profiling

James Galvin [1]

[1]University of Miami Comprehensive Center for Brain Health - Boca Raton (United States)

P192   The Brain Health Champion Study: A Health Coaching Intervention with Mobile Technology in Older Adults with Mild Cognitive Impairment or Risk Factors for Dementia- An Update

Kayla Riera [1], Ashley Park [1], Brittany Mcfeeley [1], Demsina Babazadeh [1], Abby Altman [1], Kirk Daffner [1], Seth Gale [1]

[1]Brigham and Women's Hospital - Boston (United States)

LP109   Development and clinical validation of icobrain aria – an AI-based assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities

Diana M. Sima [1], Thanh Vân Phan [1], Simon Van Eyndhoven [1], Sophie Vercruyssen [1], Ricardo Magalhães [1], Celine Maes [1], Joshua Guo [2], Richard Hughes [2], Refaat Gabr [2], Paramita Saha-Chaudhuri [2], Gioacchino G Curiale [3], Shibeshih Belachew [2], Wim Van Hecke [1], Annemie Ribbens [1], Dirk Smeets [1]

[1]icometrix - Leuven (Belgium), [2]Biogen Digital Health - Cambridge, Massachusetts (United States), [3]Biogen - Cambridge, Massachusetts (United States)

LP110   The Mobile ToolBox (MTB) as a novel outcome measure for assessing cognition remotely in Alzheimer's disease clinical trials: Validation with in-clinic cognitive assessments and AD biomarkers

Jessa Burling [1], Roos Jutten [1], Michael Properzi [1], Rebecca Amariglio [2], Gad Marshall [2], Kathryn Papp [2], Keith Johnson [3], Reisa Sperling [2], Dorene Rentz [2]

[1]Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA - Boston (United States), [2]Department of Neurology, Massachusetts General Hospital, Harvard Medical School & Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), [3]Department of Neurology/Radiology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)

LP111   Improving cognitive testing and care processes for older adults at risk of cognitive decline in a large health care system

Darren Gitelman [1,2,3], Jennifer Mishos [1], Cristybelle-Marie Canda [1], Patti Pagel [1,4], Lisa Dimitris [1], Michael Malone [1,4,5]

[1]Advocate Health, Neuroscience Service Line – Midwest Region - Downers Grove, Il (United States), [2]Rosalind Franklin University of Medicine and Science, Department of Medicine - North Chicago, Il (United States), [3]Northwestern University / Feinberg School of Medicine, Department of Neurology - Chicago, Il (United States), [4]Aurora Health Care, Department of Senior Services - Milwaukee, Wi (United States), [5]University of Wisconsin School of Medicine & Public Health - Madison, Wi (United States)

LP112   Feasibility and acceptability of a remote and fully-automated phone screening for cognitive impairment in the Autonomy Phase II study

Simona Schäfer [1], Stephen Ruhmel [2], Johannes Tröger [1], David Henley [2], Felix Dörr [1], Jannic Warken [1], Nicklas Linz [1], Janna Herrmann [1], Kai Langel [2], Alexandra König [1]

[1]ki elements GmbH - Saarbrücken (Germany), [2]Janssen Research & Development, LLC - Raritan (United States)

LP113   Older people with mild cognitive impairment exhibit lower semantic noise after six months of frequent social conversations

Liu Chen [1], Meysam Asgari [1], Hiroko Dodge [2]

[1]Department of Pediatrics, Oregon Health & Science University - Portland (United States), [2]Massachusetts General Hospital, Harvard Medical School - Boston (United States)

LP114   Development and Preliminary Validation of a Virtual Reality Memory Test for Assessing Visuospatial Memory

Ko Woon Kim [1], Jong Doo Choi [2], Juhee Chin [3], Byung Hwa Lee [3], Choi Jee Hyun [4]

[1]Jeonbuk National University Medical School and Hospita - Jeonju (Korea, Republic of), [2]Seers Technology Company Ltd - Seongnam (Korea, Republic of), [3]Samsung Medical Center - Seoul (Korea, Republic of), [4]Korea Institute of Science and Technology - Seoul (Korea, Republic of)

LP115   Assessing the Impact of Donepezil on Visuospatial Abilities in Individuals with Mild Cognitive Impairment: A Preliminary Study Utilizing Eye-Tracking Metrics

Ko Woon Kim [1], Qi Wang [1], Byoung-Soo Shin [1]

[1]Kim - Jeonju (Korea, Republic of)

POSTER PRESENTATIONS

LP116 The Effect of Robot-Based Digital Cognitive Training on Cognitive Performance of Dementia Patients

Jae Won Oh [1,2], Ji Hyun Lee [3], Myeong Hun Hong [4], Won Sub Kang [5], Jong Woo Kim [5,3]
[1]Department of Neurology, Brigham and Women's Hospital - Boston, Massachusetts (United States), [2]Whydots Inc. - Bucheon (Korea, Republic of), [3]Department of Psychiatry, Kyung Hee University Hospital - Seoul (Korea, Republic of), [4]Seodaemun-gu Center for Dementia - Seoul (Korea, Republic of), [5]Department of Psychiatry, Kyung Hee University College of Medicine - Seoul (Korea, Republic of)

LP117 The digital literacy predicts the quality of life in normal old age group but not in dementia group

Lee So-Yeong [1], Lim Jung-In [1], Lee Jun-Young [1,2]
[1]SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), [2]Department of Psychiatry, Seoul National University College of Medicine - Seoul (Korea, Republic of)

LP131 Observer-reported outcome of functional decline using continuous experience sampling: Findings from the RADAR-AD Study

Sietske Sikkes [1,2], Merel Postema [1], Mukrabe Tewolde [1], Merike Verrijp [3], Marijn Muurling [1], Casper De Boer [1], Srinivasan Vairavan [4], Dag Aarsland [5], Anna-Katharine Brem [5], Gayle Wittenberg [4], Mark Dubbelman [6], Roos Jutten [7], Philip Scheltens [1], Pieter Jelle Visser [1], Wiesje Van Der Flier [1]
[1]Amsterdam UMC - Amsterdam (Netherlands), [2]VU University - Amsterdam (Netherlands), [3]Brain Research Center - Amsterdam (Netherlands), [4]Janssen Neuroscience R&D - Titusville, Nj (United States), [5]Kings College London - London (United Kingdom), [6]Brigham and Womens Hospital - Boston, Ma (United States), [7]Harvard Medical School - Boston, Ma (United States)

LP133 A One-Stop-Shop for Telehealth Guided APOE Testing, Blood Based Biomarkers, and Multi-Domain Lifestyle Intervention: Early Learnings From a Proof-of-Concept

Anitha Rao [1], Leyla Anderson [1], Travis Wilkes [1], Steven Verdooner [1]
[1]Neurovision Inc - Sacramento (United States)

THEME: Beyond Amyloid and Tau

P193 Angiogenic Mechanisms in Alzheimer's Disease: A Systematic Review of Neuropathological Evidence

Arunima Kapoor [1], Daniel Nation [1]
[1]University of California, Irvine - Irvine (United States)

P194 Do Mouse Data Lie? For Buntanetap They Totally Predict Human Outcomes All the Way to Clinical Efficacy

Maria Maccecchini [1], Cheng Fang [1]
[1]Annovis Bio - Berwyn (United States)

P195 Fluid Biomarker Results from an Open-Label Pilot Study of Senolytic Therapy for Alzheimer's Disease, SToMP-AD

Miranda E. Orr [1,2,3], Valentina R Garbarino [4,5], Juan Pablo Palavicini [4], Tiffany F. Kautz [4,5], Shiva K Dehkordi [6,5], Habil Zare [6,5], Peng Xu [7,8], Bin Zhang [7,8], Justin Melendez [9,10], Nicolas Barthelemy [9,10], Randall J Bateman [9,10], Mitzi M Gonzales [11,5]
[1]Wake Forest University School of Medicine, Gerontology and Geriatric Medicine, - Winston-Salem (United States), [2]Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States), [3]Salisbury VA Medical Center - Salisbury (United States), [4]University of Texas Health Science Center at San Antonio, Department of Medicine, - San Antonio (United States), [5]Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases - San Antonio (United States), [6]University of Texas Health Science Center at San Antonio Department of Cell Systems and Anatomy, - San Antonio (United States), [7]Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, - New York (United States), [8]Mount Sinai Center for Transformative Disease Modeling - New York (United States), [9]Washington University School of Medicine, Department of Neurology - St Louis (United States) - St Louis (United States), [10]The Tracy Family SILQ Center - St Louis (United States), [11]University of Texas Health Science Center at San Antonio, Department of Neurology - San Antonio (United States)

P196 Plasma and cerebrospinal fluid proteomic association during Alzheimer's disease (AD) progression suggests possible new targets for treating AD patients

Ying Wang [1], Ricardo Gonzalo [2], Carla Minguet [2], Ana Maria Ortiz [2], Scott Lohr [1], Mercè Boada [3], Oscar López [4], Antonio Paez [2], Jorge Loscos [5], Jesús Canudas [5], María Pascual [5], Jose Terencio [2], Montserrat Costa [2], Chunmiao (mia) Feng [1], Benoit Lehallier [1]
[1]Alkahest, a Grifols company - San Carlos (United States), [2]Grifols - Barcelona (Spain), [3]Universitat Internacional de Catalunya - Barcelona (Spain), [4]University of Pittsburgh - Pittsburgh (United States), [5]Araclon, a Grifols company - Zaragoza (Spain)

P197 Whole transcriptomic cell free messenger RNA characterization of Alzheimer's disease in cerebrospinal fluid compared to plasma from human subjects

Rhys De Sota [1], Robert Rissman [2], James Brewer [2], Samantha Khoury [1], Shusuke Toden [1], John Sninsky [1]
[1]Molecular Stethoscope - South San Francisco (United States), [2]University of California, San Diego - San Diego (United States)

P198   **CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease**

Charlotte Teunissen [1], Emma L. Van Der Ende [2], Sjors In 't Veld [2], Iris Hanskamp [2], Sven Van Der Lee [3, 4], Janna Dijkstra [5], John C. Van Swieten [6], David J. Irwin [7], Alice Chen-Plotkin [7], William T. Hu [8], Afina Lemstra [9], Yolande A.L. Pijnenburg [9], Wiesje M. Van Der Flier [9, 10], Marta Del Campo [9, 11], Lisa Vermunt [2, 9]

[1]Amsterdam UMC - Amsterdam (Netherlands), [2]Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [3]lzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [4]Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Pays-Bas) - Amsterdam (Netherlands), [5]Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [6]Alzheimer Center and Department of Neurology, Erasmus University Medical Center - Rotterdam (Netherlands), [7]Department of Neurology, Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States), [8]Department of Neurology, Emory University School of Medicine - Atlanta (United States), [9]Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [10]Department of Epidemiology and Data Science, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [11]Barcelonabeta Brain Research Center (BBRC) - Barcelona (Spain)

P199   **Lipid Dicarbonyl Scavengers for the Prevention of Alzheimer's Disease**

John A. Rathmacher [1], Naji N. Abumrad [2], Paul A. Newhouse [2]

[1]MTI BioTech Inc - Ames (United States), [2]Vanderbilt University Medical Center - Nashville (United States)

P200   **Translation Studies and Clinical Development of THN391, a Novel Anti-Fibrin Antibody for the Treatment of Dementia**

Jeffrey Stavenhagen [1], Mathias Rickert [1], Kenneth Flanagan [1], Hank Cheng [1], Anjana Suppahia [1], Vasudha Salgotra [1], Jae Kyu Ryu [2], Katerina Akassoglou [2]

[1]Therini Bio - San Francisco (United States), [2]Gladstone Institute - San Francisco (United States)

P201   **The temporal relationship between neuropsychiatric symptoms, physical activity, and sleep: A three cohort-study**

Adrian Noriega De La Colina [1], Meishan Ai [2], Nikolaos Scarmeas [3], Arthur F. Kramer [2], Maiya R. Geddes [1]

[1]Department of Neurology and Neurosurgery, The Montreal Neurological Institute-Hospital, McGill University - Montreal (Canada), [2]Center for Cognitive and Brain Health, Department of Psychology, Northeastern University - Boston (United States), [3]1st Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens - Athens (Greece)

P202   **Cerebrospinal Fluid Proteomic Analysis Reveals Reversal Effects on Glucose Dysmetabolism in Alzheimer's Disease after Treatment with Atomoxetine**

Eric Dammer [1], Lingyan Ping [1], Duc Duong [1], Erica Modeste [1], Nicholas Seyfried [1], James Lah [1], Allan Levey [1], Erik Johnson [1]

[1]Emory University - Atlanta (United States)

P203   **Blood-Based small RNA Biomarkers and the ATN(V) Framework: Predicting Neurodegeneration and Vascular Profiles in the EPAD Cohort**

Bruno Steinkraus [1], Marco Heuvelman [1], Luigi Lorenzini [2], Julia Jehn [1], Tobias Sikosek [1], Rastislav Horos [1], Kaja Tikk [1], Jeffrey Cummings [3], Jean Manson [4], Craig Ritchie [4]

[1]Hummingbird Diagnostics GmbH - Heidelberg (Germany), [2]Amsterdam University Medical Center - Amsterdam (Netherlands), [3]Department of Brain Health, Chambers-Grundy Center for Transformative Neuroscience, University of Nevada Las Vegas - Las Vegas (United States), [4]Centre for Clinical Brain Sciences, The University of Edinburgh - Edinburgh (United Kingdom)

P204   **Evaluation of GLP-1 analogue, Liraglutide in the treatment of Alzheimer's disease**

Paul Edison [1]

[1]Imperial College London - London (United Kingdom)

LP118   **An open-label, pilot study of daratumumab SC in patients with mild to moderate Alzheimer's disease (DARZAD)**

Marc Gordon [1,2], Erica Christen [1], Lynda Keehlisen [1], Michelle Gong [1], Fung Lam [3], Luca Giliberto [1,4], Jesus Gomar [1], Jeremy Koppel [1,5]

[1]Litwin-Zucker Research Center, Feinstein Institutes for Medical Research, Northwell Health - Manhasset, New York (United States), [2]Departments of Neurology and Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell - Hempstead, New York (United States), [3]Feinstein Institutes for Medical Research, Northwell Health - Manhasset, New York (United States), [4]Institute for Neurology and Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell - Great Neck, New York (United States), [5]Department of Psychiatry, Zucker Hillside Hospital, Northwell Health - Glen Oaks, New York (United States)

LP119   **Association of Serum Leptin with in vivo brain Alzheimer's disease pathologies in cognitively normal older adults**

Seunghoon Lee [1], Min Soo Byun [2,3], Dahyun Yi [4], Dongyoung Lee [2,3,4]

[1]Department of Psychiatry, Myongji hospital, Hanyang University College of Medicine - Goyang (Korea, Republic of), [2]Department of Neuropsychiatry, Seoul National University Hospital - Seoul (Korea, Republic of), [3]Department of Psychiatry, Seoul National University College of Medicine, - Seoul (Korea, Republic of), [4]Institute of Human Behavioral Medicine, Medical Research Center Seoul National University - Seoul (Korea, Republic of)

LP120   **Misfolding Of Biomarkers Stratifies Proteinopathies**

Klaus Gerwert [1]

[1]Ruhr-University Bochum - Bochum (Germany)

Practical Details

Conference Venue

BOSTON PARK PLAZA

50 Park Plaza at Arlington

Boston, MA 02116

> Meeting Rooms

> Conference Room

All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)

> Overflow room

Due to space constraints in the ballroom, a livefeed is available
in Avenue 34 at Lobby Level (Floor 1)

> Posters Sessions and Coffee Breaks

Meet our poster presenters during the coffee breaks. A poster assistance desk will be available to locate the posters.

POSTER WALKING TOUR

Enjoy a morning coffee while touring the posters from
7:30 a.m. to 8:30 a.m. on Wednesday, Thursday and Friday.

Free WiFi available at CTAD

Network: CTAD2023 - Password: CTAD2023

> Mobile App

Download the VFairs mobile app on
the Apple Store or Google Play. Login with the email address used to register, then click on CTAD2023 and enjoy the conference at your fingertips, you can watch the livestream from the Ballroom, access the virtual poster hall and connect with your colleagues!

> CTAD23 digital platform

To access our digital platform simply go to www.ctad23.com and enter with your email address.

> Lunch on your own at CTAD23

Several restaurants and take out options are available close to the Boston Park Plaza!

> CTAD Welcome Reception with the Support of the Alzheimer's Association

Tuesday, October 24 from 6:50 p.m. to 7:50 p.m.

CTAD Level - Floor 2 - Mezzanine

CTAD would like to thank its 2023 privileged partners for their continued support.

Ultimate Sponsor

Alzheimer's **Drug Discovery** Foundation

Platinum Sponsors

Eisai

Lilly

Gold Sponsors

ALZHEIMER'S ASSOCIATION

Biogen

GSK

LANTHEUS CERVEAU

Lundbeck

novo nordisk

Otsuka

Notes

CTAD 2023
Clinical Trials on Alzheimer's Disease

Graphic designer: Mélanie Vaissette - Photograph: Romanslavik.com

Follow us on social media!

@CTADConference
#CTAD23

CTAD Conference

CTAD Alzheimer

Contact us: ctad@ant-congres.com
www.ctad-alzheimer.com

CTAD 2024

Alzheimer

Clinical Trials on Alzheimer's Disease

© Designpics

October 29 - November 1, 2024
Madrid, Spain

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11 / Monte Carlo '12
San Diego '13 / Philadelphia '14 / Barcelona '15 / San Diego '16 / Boston '17 / Barcelona '18
San Diego '19 / Virtual '20 / Boston '21 / San Francisco '22 / Boston '23

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

JPAD